Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No ☐

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes☒No ☐

Indicate by check mark whether the ~~Registrant~~registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated ~~filer”,~~filer,” “accelerated ~~filer”,~~filer,” “smaller reporting ~~company”,~~company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ~~(Check one):~~

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the ~~Registrant~~registrant is a shell company (as defined byin Rule 12b-2 of the Exchange Act). Yes ☐No ☒

The ~~Registrant~~registrant had ~~185,163,064~~148,438,276 shares of common stock, $0.01 par value, outstanding at October ~~31, 2017.~~23, 2023.

~~Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our Company”, “we”, “us” and “our” refer to~~

The Chemours Company and its consolidated subsidiaries. References herein to “DuPont” refer to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries, unless the context otherwise requires.

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” The objective of this standard is to remove inconsistent practices with regard to revenue recognition between U.S. GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with Topic 606. The provisions of ASU No. 2014-09 and its related updates will be effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company will adopt the standard on January 1, 2018 under the modified retrospective transition method.

The Company’s project plan includes a three-phase approach to implementing the standard update. Phase one, the assessment phase, was completed in the first quarter of 2017. In this initial phase, the Company (a) conducted internal surveys of its businesses, (b) held revenue recognition workshops with sales and business unit finance leadership and (c) reviewed a representative sample of revenue arrangements across all businesses to initially identify a set of applicable qualitative revenue recognition changes related to the standard. The Company has also completed phase two of the project, which included (a) establishing and documenting key accounting positions, (b) assessing new disclosure requirements, business process and control impacts and (c) beginning to determine the initial quantitative impacts resulting from the standard. Phase three will include (a) finalizing any changes to accounting policies, (b) preparing new disclosures, (c) implementing new business processes and controls as needed and (d) quantifying the effect of adoption on opening retained earnings.

Based on the analysis conducted to date, the Company believes that the adoption of the standard will not have a material impact on its consolidated financial statements. Substantially all of the Company’s revenue consists of sales of products that represent a single performance obligation where control transfers at the point in time title and risk of loss pass to the customer. The Company continues to evaluate the impact of the standard update on its consolidated financial statements and related disclosures and additional differences may be identified as new or amended contracts with customers that will impact future periods are executed. The Company expects that disclosure in the notes to the consolidated financial statements related to revenue recognition will be expanded in line with the requirements of the standard to further describe the nature, timing and uncertainty of revenue and cash flows arising from contracts with customers.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents an improvement over previous U.S. GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases. Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities.

Certain of the Company’s master services agreements or other arrangements contain take-or-pay clauses, whereby customers are required to ~~measure goodwill impairment. Under~~purchase a fixed minimum quantity of product during a specified period, or pay the ~~amendments, goodwill impairment testing~~Company for such orders, even if not requested by the customer. The Company considers these take-or-pay clauses to be an enforceable contract, and as such, the legally-enforceable minimum amounts under such an arrangement are considered to be outstanding performance obligations on contracts with an original expected duration greater than one year. At September 30, 2023, Chemours had $367 of remaining performance obligations. The Company expects to recognize approximately 9% of its remaining performance obligations as revenue in 2023, approximately 26% as revenue in 2024, and approximately 22% as revenue for each of the years 2025 to 2027. The Company applies the allowable practical expedient and does not include remaining performance obligations that have original expected durations of one year or less, or amounts for variable consideration allocated to wholly-unsatisfied performance obligations or wholly-unsatisfied distinct goods that form part of a single performance obligation, if any. Amounts for contract renewals that are not yet exercised by September 30, 2023 are also excluded.

Notes to ~~be applied to changes~~the Interim Consolidated Financial Statements (Unaudited)

In the Chemicals Solutions segment, following the production shutdown of the Reactive Metals Solutions (RMS) manufacturing plant at Niagara Falls, New York in September 2016, the Company immediately began decommissioning the plant. As a result, the Company recorded $5 and $16 of decommissioning and dismantling-related charges for the three and nine months ended September 30, 2017, respectively, and $7 and $6 for the three and nine months ended September, 30, 2016, respectively. As of September 30, 2017, the Company incurred, in the aggregate, approximately $30 of restructuring costs, excluding non-cash asset-related charges. Additional restructuring charges of approximately $5 for decommissioning and site redevelopment are expected to be incurred for the remainder of 2017, which will be expensed as incurred.

In 2017, the Company announced certain restructuring activities designed to further the cost savings and productivity improvements outlined under management’s transformation plan. These activities include, among other efforts: (a) outsourcing and further centralizing certain business process activities; (b) consolidating existing, outsourced third party information technology (IT) providers; and (c) implementing various upgrades to the Company’s current IT infrastructure. In connection with these corporate function efforts, the Company recorded $3 and $8 in restructuring-related charges for the three and nine months ended September 30, 2017, respectively.

Also, in October 2017, the Company announced a voluntary separation program (VSP) for certain eligible U.S. employees in an effort to better manage anticipated future changes to its workforce. Employees who volunteer for, and are accepted under, the VSP will receive certain financial incentives above the Company’s customary involuntary termination benefits to end their employment with

Chemours after providing a mutually agreed-upon service period. Based on current estimates, Chemours anticipates that approximately 300 to 350 employees will separate from the Company by the end of 2018. An accrual representing the majority of these termination benefits will be recognized in the fourth quarter of 2017, and any remaining incremental, one-time financial incentives under the VSP will be recognized over the period each participating employee continues to provide service to Chemours. No amounts for the VSP have been recognized in the consolidated financial statements as of September 30, 2017.

~~As a result of its 2017 program, the Company expects to incur charges for restructuring-related activities and termination benefits ranging from $45 to $55 through December 31, 2018.~~

~~The following table shows the change in the employee separation-related liability account associated with the Company’s restructuring programs:~~

~~At September 30, 2017, there are no significant outstanding liabilities related to decommissioning and other restructuring-related charges.~~

For the three months ended September 30, 2017 and 2016, Chemours recorded a provision for income taxes of $43 and $30, respectively, resulting in effective income tax rates of approximately 17% and 13%, respectively. For the nine months ended September 30, 2017 and 2016, Chemours recorded a provision for income taxes of $130 and $25, respectively, resulting in effective income tax rates of approximately 20% and 10%, respectively.

The provision for income taxes for the nine months ended September 30, 2017 is inclusive of an $18 benefit from windfalls on share-based payments in accordance with the recently adopted guidance in ASU No. 2016-09, as discussed in Note 2. The remaining change in the effective tax rate from the prior year is primarily due to the Company’s geographical mix of earnings, as well as the impact of the valuation allowance on U.S. foreign tax credits, from which the Company does not expect to benefit in 2017.

Each year, Chemours and/or its subsidiaries file income tax returns in U.S. federal and state and non-U.S. jurisdictions. These tax returns are subject to examination and possible challenge by the cognizant taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by Chemours. As a result, income tax uncertainties are recognized in Chemours’ consolidated financial statements in accordance with accounting for income taxes under Topic 740, “Income Taxes”, when applicable.

Management is not aware of any other matters that would result in significant changes to the amount of unrecognized income tax benefits reflected in the consolidated balance sheets at September 30, 2017.

For the year ended December 31, 2016, the Company established a valuation allowance against its U.S. foreign tax credits. The Company regularly monitors positive and negative evidence that may change the most recent assessment of the Company’s ability to realize a benefit from these deferred tax assets. The Company continues to maintain a valuation allowance against its net deferred tax assets related to U.S. foreign tax credits of $65 and $50 at September 30, 2017 and December 31, 2016, respectively.

~~The following table shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated:~~

~~The following average number of stock options were anti-dilutive and, therefore, were not included in the diluted earnings per share calculation:~~

Note ~~11.~~14. Other Accrued Liabilities

September 30, 2017

December 31, 2016

Compensation and other employee-related costs

$
147

$
154

Employee separation costs ¹

13

31

Accrued litigation ²

13

344

Environmental remediation ²

86

71

Income taxes

55

39

Customer rebates

70

53

Deferred revenue ³

9

76

Accrued interest

73

21

Miscellaneous ⁴

80

83

Total other accrued liabilities

$
546

$
872

The following table sets forth the components of the Company’s other accrued liabilities at September 30, 2023 and December 31, 2022.


	September 30, 2023		December 31, 2022
Accrued litigation (1)	$	658	$	41
Asset retirement obligations (2)		15		10
Income taxes		67		19
Customer rebates		72		90
Accrued interest		47		17
Operating lease liabilities		55		49
Miscellaneous (3)		125		74
Total other accrued liabilities	$	1,039	$	300

(1)

At September 30, 2023, accrued litigation includes $592 for the United States Public Water System Class Action Suit Settlement. Refer to “Note 17 – Commitments and Contingent Liabilities”for further details.

¹	~~Current portion of employee separation costs.~~

(2)

Represents the current portion of asset retirement obligations (see “Note 16 – Other Liabilities”).

²	Current portions of accrued litigation and environmental remediation. Accrued litigation includes the PFOA MDL Settlement accrual of $335 at December 31, 2016, which was paid in full by September 30, 2017.

(3)

Miscellaneous primarily includes accruals related to utility expenses, property taxes, a workers compensation indemnification liability and other miscellaneous expenses.

³	~~Deferred revenue at December 31, 2016 includes $58 in outstanding prepayments by DuPont for specified goods and services. There were no such prepayments at September 30, 2017.~~

⁴	~~Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, asset retirement obligations and other miscellaneous accrued expenses.~~

~~Note 12. Debt~~

September 30, 2017

December 31, 2016

Senior secured term loans:

Tranche B term loan due May 2022

$
—

$
1,372

Tranche B-1 Dollar Term Loan due May 2022

925

—

Tranche B-1 Euro Term Loan due May 2022
(€395 at September 30, 2017 and €0 at December 31, 2016)

464

—

Senior unsecured notes:

6.625% due May 2023

1,158

1,158

7.000% due May 2025

750

750

6.125% due May 2023
(€295 at September 30, 2017 and December 31, 2016)

346

308

5.375% due May 2027

500

—

Capital lease obligations

3

3

Total debt

4,146

3,591

Less: Unamortized issue discounts

9

5

Less: Unamortized debt issuance costs

42

42

Less: Current maturities of long-term debt

14

15

Total long-term debt, net

$
4,081

$
3,529

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Note 15. Debt

The following table sets forth the components of the Company’s debt at September 30, 2023 and December 31, 2022.


	September 30, 2023			December 31, 2022
Senior secured term loans:
Tranche B-2 U.S. dollar term loan due April 2025	$	—		$	766
Tranche B-2 euro term loan due April 2025 (€0 at September 30, 2023 and €333 at December 31, 2022)		—			355
Tranche B-3 U.S. dollar term loan due August 2028		1,070			—
Tranche B-3 euro term loan due August 2028 (€415 at September 30, 2023 and €0 at December 31, 2022)		438			—
Senior unsecured notes:
4.000% due May 2026 (€441 at September 30, 2023 and December 31, 2022)		466			470
5.375% due May 2027		495			495
5.750% due November 2028		783			783
4.625% due November 2029		620			620
Finance lease liabilities		51			61
Financing obligation (1)		92			91
Total debt principal		4,015			3,641
Less: Unamortized issue discounts		(26	)		(4	)
Less: Unamortized debt issuance costs		(22	)		(22	)
Less: Short-term and current maturities of long-term debt		(23	)		(25	)
Total long-term debt, net	$	3,944		$	3,590

(1)

At September 30, 2023 and December 31, 2022, financing obligation relates to the financed portion of the Company’s research and development facility located in the Science, Technology, and Advanced Research Campus of the University of Delaware in Newark, Delaware (“Chemours Discovery Hub”).

Senior Secured Credit Facilities

The Company’s credit agreement, as amended ~~provides~~and restated on April 3, 2018 (the “April 2018 Credit Agreement”), provided for seven-year, senior secured term loans and a five-year ~~$750~~, $800 senior secured revolving credit facility. The senior secured term loan facility under the April 2018 Credit Agreement provided for a class of term loans, denominated in U.S. dollars, in an aggregate principal amount of $900 and a class of term loans, denominated in euros, in an aggregate principal amount of €350. On October 7, 2021, the Company entered into an amendment to the April 2018 Credit Agreement to, among other things, increase the aggregate commitment amount under the credit facility to $900 and extend the stated maturity date to October 7, 2026 (from April 3, 2023). On March 10, 2023, the Company entered into a second amendment to the April 2018 Credit Agreement to replace the interest rate benchmark from LIBOR to the Secured Overnight Financing Rate ("SOFR"). On August 18, 2023, the Company entered into an amendment and restatement credit agreement (the “Restated Credit Agreement”) that provides for a $900 senior secured revolving credit facility ~~(Revolving~~(the “Revolving Credit ~~Facility)~~Facility”) and five-year senior secured term loans (the "Senior Secured Term Loan Facility", collectively, the “New Senior Secured Credit Facilities”). The New Senior Secured Credit Facilities amends and restates in its entirety, the Company’s obligations under the April 2018 Credit Agreement.

The New Senior Secured Term Loan Facility provides for a Tranche B-3 class of term loans, denominated in U.S. dollars, in an aggregate principal amount of $1,070 (the “New Dollar Term Loan”) and a class of Tranche B-3 class term loans, denominated in euros, in an aggregate principal amount of €415 (the “New Euro Term Loan”) (collectively, the “New Term Loans”). The Company received proceeds of $367, net of original issue discount and bank fees of $32. The proceeds of ~~any loans~~the New Term Loans were primarily used to prepay, in full, all outstanding amounts under the April 2018 Credit Agreement, which amounted to $764 for the dollar term loan and €333 for the euro term loan, fees and expenses related therewith, and to fund the Water District Settlement Fund per the terms of the U.S. public water system Settlement Agreement pending final approval (see "Note 17 – Commitments and Contingent Liabilities"). The New Dollar Term Loan bears a variable interest rate equal to, at the election of the Company, adjusted Term SOFR plus 3.50%, subject to an adjusted SOFR floor of 0.50%, or adjusted base rate plus 2.50%, subject to a base rate floor of 0.0%. The New Euro Term Loan bears a variable interest rate equal to adjusted Euro Interbank Offered Rate ("EURIBOR") plus 4.00%, subject to an adjusted EURIBOR floor of 0.0%. The New Term Loans will mature on August 18, 2028, and are subject to acceleration in certain circumstances. The Restated Credit Agreement is subject to a springing maturity in the event that the senior unsecured notes due in May 2026 are not redeemed, repaid, modified, and/or refinanced within the 91-day period prior to their maturity date.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Borrowings made under the Revolving Credit Facility ~~can~~may be used for ~~capital expenditures, acquisitions,~~ working capital ~~needs~~ and other general corporate ~~purposes. No borrowings were outstanding under~~purchases and other transactions not prohibited by the ~~Revolving~~Restated Credit Facility at September 30, 2017 or December 31, 2016; however, Chemours had $102 and $132 in letters of credit issued and outstanding under this facility at September 30, 2017 and December 31, 2016, respectively.Agreement. The Revolving Credit Facility bears a variable interest ~~of a~~rate range based on ~~Chemours’~~the Company’s total net leverage ratio, as defined in the Restated Credit Agreement, between ~~(a)~~(i) a ~~0.50%~~0.25% and ~~1.25%~~a 1.00% spread for adjusted base rate loans, and ~~(b)~~(ii) a ~~1.50%~~1.25% and ~~2.25%~~a 2.00% spread for ~~LIBOR~~SOFR and EURIBOR loans. ~~The applicable margins were 0.50% for base rate loans and 1.50% for LIBOR loans at September 30, 2017.~~ In addition, the Company is required to pay a commitment fee on the average daily unused amount of the Revolving Credit Facility ~~at a~~within an interest rate range based on its total net leverage ratio, between ~~0.20%~~0.10% and ~~0.35%~~0.25%.

There were no borrowings under the Revolving Credit Facility at September 30, 2023 and December 31, 2022. Issued and outstanding letters of credit under the Revolving Credit Facility amounted to $99 and $108 at September 30, 2023 and December 31, 2022, respectively. At September 30, ~~2017,~~2023, the effective interest rates on the New Dollar Term Loan and the New Euro Term Loan were 8.82% and 7.86%, respectively, and commitment fees on the Revolving Credit Facility were assessed at a rate of ~~0.20%~~0.15% per annum.

On April 3, 2017, the Company completed an amendment (April 2017 Amendment) to its credit agreement which provides for a new class of term loans, denominated in Euros, in an aggregate principal amount of €400 (Euro Term Loan), and a new class of term loans, denominated in U.S. Dollars, in an aggregate principal amount of $940 (Dollar Term Loan, and, collectively with the Euro Term Loan, the New Term Loans).

The New Term Loans replaced in full the prior term loan (Prior Term Loan) outstanding as of March 31, 2017. The New Term Loans mature on May 12, 2022, which is the same maturity date of the Prior Term Loan. The Euro Term Loan bears a variable interest rate equal to EURIBOR plus 2.25%, subject to a EURIBOR floor of 0.75%, and the Dollar Term Loan bears a variable interest rate equal to LIBOR plus 2.50%, subject to a LIBOR floor of 0.00%. The April 2017 AmendmentRestated Credit Agreement also ~~modified~~modifies certain provisions of the ~~credit agreement,~~April 2018 Credit Agreement, including ~~increasing~~ certain ~~incurrence limits~~negative covenants to allow further flexibility for the Company. ~~All other provisions, including financial covenants, remained unchanged. No incremental debt was issued as a result of~~Under the April 2017 Amendment, although the Euro Term Loan is subject to remeasurement gains or losses. The Company recorded a $3 loss on debt extinguishment and related amendment fees in the second quarter of 2017. The effective interest rates on the Dollar Term Loan and the Euro Term Loan were approximately 3.74% and 3.00%, respectively, for the quarter ended September 30, 2017.

~~The credit agreement contains financial covenants which,~~Restated Credit Agreement, solely with respect to the Revolving Credit Facility, ~~as amended, require Chemours~~the Company is required to not to exceed a maximum senior secured net leverage ratio ~~of: (a) 3.50~~of 2.00 to 1.00 ~~each quarter~~ in any period of four consecutive fiscal quarters through December 31, 2016; (b) 3.00 to 1.00 through June 30, 2017; and (c) further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. Chemours is also required to maintain a minimum interest coverage ratiothe date of ~~1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter.~~maturity. In addition, the ~~credit agreement contains~~New Term Loans contain customary affirmative and negative covenants that, among other things, limit or restrict ~~Chemours’~~the Company’s and its subsidiaries’ ability, subject to certain exceptions, to incur ~~liens, merge, consolidate~~additional indebtedness or ~~sell, transfer or lease assets, make investments,~~liens, pay dividends, ~~transact with subsidiaries~~ and ~~incur indebtedness.~~engage in certain transactions, including mergers, acquisitions, asset sales, or investments, outside of specified carve-outs. The ~~credit agreement~~Restated Credit Agreement also contains customary representations and warranties and events of ~~default. Chemours was~~default, which are substantially similar to those in ~~compliance with its debt covenants at September 30, 2017.~~the April 2018 Credit Agreement.

The obligations under the New Senior ~~Unsecured Notes~~Secured Credit Facilities are guaranteed on a senior secured basis by all of the Company’s material, wholly-owned domestic subsidiaries, subject to certain agreed upon exceptions. The obligations under the New Senior Secured Credit Facilities are also, subject to certain agreed upon exceptions, secured by a first priority lien on substantially all of the Company’s assets and substantially all of the assets of the Company’s material, wholly-owned domestic subsidiaries, including 100% of the stock of certain of the Company’s domestic subsidiaries and 65% of the stock of certain of the Company’s foreign subsidiaries.

On May 23, 2017, Chemours issued a $500 aggregate principal amount of 5.375% senior unsecured notes due May 2027 (2027 Notes). The 2027 Notes require payment of principal at maturity and interest semi-annually in cash and in arrears on May 15 and November 15 of each year.

Accounts Receivable Securitization Facility

The Company, ~~received proceeds~~through a wholly-owned special purpose entity (“SPE”), maintains an amended and restated receivables purchase agreement dated March 9, 2020, which was amended on March 5, 2021 and further amended on November 24, 2021 (the “Amended Purchase Agreement”). Pursuant to the Amended Purchase Agreement, the Company does not maintain effective control over the transferred receivables, and therefore accounts for these transfers as sales of ~~$489, net of~~receivables.

On March 23, 2023, the Company, through the SPE, entered into an ~~original issue discount of $5~~amendment to its Amended Purchase Agreement to, among other things, increase the facility limit under the arrangement from $150 to $175, replace the interest rate benchmark from LIBOR to SOFR, add a conduit purchaser, and ~~underwriting fees and other related expenses of $6, which are deferred and amortized to interest expense using the effective interest method over~~extend the term of the ~~2027 Notes. A portion~~Amended Purchase Agreement, such that the SPE may sell certain receivables and request investments and letter of credit until the ~~net proceeds~~earlier of March 31, 2025 or another event that constitutes a "Termination Date" under the Amended Purchase Agreement.

Cash received from ~~the 2027 Notes was~~collections of sold receivables is used to ~~pay~~fund additional purchases of receivables at 100% of face value on a revolving basis, not to exceed the ~~$335 accrued~~facility limit, which is the aggregate purchase limit. During the three and nine months ended September 30, 2023, the Company received $398 and $1,079, respectively, of cash collections on receivables sold under the Amended Purchase Agreement, following which it sold and derecognized $372 and $1,079, respectively, of incremental accounts receivable. During the three and nine months ended September 30, 2022, the Company received $393 and $1,071, respectively, of cash collections on receivables sold under the Amended Purchase Agreement, following which it sold and derecognized $393 and $1,071, respectively, of incremental accounts receivable. The Company maintains continuing involvement as it acts as the servicer for the global settlement of the multi-district PFOA litigation, as discussed in Note 13. The remaining proceeds from the 2027 Notes are available for general corporate purposes. The offering of the 2027 Notes was registered under the Securities Act of 1933, as amended, under a registration statement on Form S-3 filed with the U.S. Securitiessold receivables and ~~Exchange Commission on May, 4, 2017.~~

~~The 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis by each of the existing and future domestic subsidiaries that (a) incurs or~~ guarantees indebtedness under the Senior Secured Credit Facilities or (b) guarantees other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $100. The guarantees of the 2027 Notes will rank equally with all other senior indebtedness of the guarantors. The 2027 Notes rank equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and are senior in right of payment to all of Chemours’ existing and future debt that is by its terms expressly subordinated in right of payment to the ~~2027 Notes.~~bank. As collateral against the sold receivables, the SPE maintains a certain level of unsold receivables, which amounted to $126 and $46 at September 30, 2023 and December 31, 2022, respectively. The ~~2027 Notes~~Company incurred $1 and $2 of fees associated with the Securitization Facility during the three and nine months ended September 30, 2023 and 2022, respectively. Costs associated with the sales of receivables are ~~subordinated to indebtedness under~~reflected in the ~~Senior Secured Credit Facilities as well as any future secured debt to~~Company’s consolidated statements of operations for the ~~extent of~~periods in which the ~~value of the assets securing such debt, and structurally subordinated to the liabilities of any non-guarantor subsidiaries.~~sales occur.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Chemours may redeem the 2027 Notes, in whole or in part, at an amount equal to 100% of the aggregate principal amount plus a specified “make-whole” premium and accrued and unpaid interest, if any, to the date of purchase prior to February 15, 2027. Chemours may also redeem some or all of the 2027 Notes by means other than a redemption, including tender offer and open market repurchases. Chemours is obligated to offer to purchase the 2027 Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events. Maturities

~~Maturities~~

~~Chemours~~The Company has required quarterly principal payments related to the ~~senior secured term loans~~New Dollar Term Loan equivalent to ~~1.00%~~1.00% per annum through ~~March 2022,~~June 2028, with the balance due at maturity. Term loan principal maturities, as amended, over the next five years are $3 for the remainder of 2017 and approximately $14 in each year from 2018 to 2021. Debt maturities related to the New Term Loans and the Notes (collectively, the 2023 Notes, the 2025 Notes, the Euro Notes and the 2027 Notes) in 2022 and beyond will be $4,085.

~~Following the end of each fiscal year commencing on the year ended December 31, 2016,~~maturity. Also, on an annual basis, the Company is ~~also~~ required to make additional principal ~~repayments,~~payments depending on leverage levels, as defined in the ~~credit agreement,~~Credit Agreement, equivalent to up to ~~50%~~50% of excess cash ~~flow~~flows based on certain leverage targets with ~~stepdowns~~step-downs to ~~25%~~25% and 0%0% as actual leverage decreases to below a ~~3.00~~3.50 to 1.00 leverage target. ~~No principal repayments were~~The Company was not required to ~~be made~~make additional principal payments in ~~2017 based upon~~2023.

The following table sets forth the ~~December 31, 2016 excess cash flow determined under~~Company’s debt principal maturities for the ~~credit agreement.~~next five years and thereafter.


	Senior Debt		Finance Lease Liabilities			Financing Obligation			Total
Remainder of 2023	$	3	$	3		$	2		$	8
2024		11		13			7			31
2025		11		13			7			31
2026		476		10			7			493
2027		505		8			7			520
Thereafter		2,866		11			136			3,013
Total payments		3,872		58			166			4,096
Less: Imputed interest		—		(7	)		(74	)		(81	)
Total principal maturities on debt	$	3,872	$	51		$	92		$	4,015

Debt Fair Value

The ~~fair values of~~following table sets forth the Dollar Term Loan, the Euro Term Loan, the 2023 Notes, the 2025 Notes, the Euro Notes and the 2027 Notes at September 30, 2017 were approximately $931, $469, $1,235, $834, $372 and $520, respectively. The estimated fair values of the ~~New Term Loans and the Notes~~Company’s senior debt issues, which are based on quotes received from ~~third party~~third-party brokers, and are classified as Level 2 financial instruments in the fair value hierarchy.


	September 30, 2023					December 31, 2022
	Carrying Value			Fair Value		Carrying Value			Fair Value
Senior secured term loans:
Tranche B-2 U.S. dollar term loan due April 2025	$	—		$	—	$	766		$	755
Tranche B-2 euro term loan due April 2025 (€0 at September 30, 2023 and €333 at December 31, 2022)		—			—		355			345
Tranche B-3 U.S. dollar term loan due August 2028		1,070			1,070		—			—
Tranche B-3 euro term loan due August 2028 (€415 at September 30, 2023 and €0 at December 31, 2022)		438			437		—			—
Senior unsecured notes:
4.000% due May 2026 (€441 at September 30, 2023 and December 31, 2022)		466			432		470			422
5.375% due May 2027		495			457		495			459
5.750% due November 2028		783			679		783			702
4.625% due November 2029		620			496		620			509
Total senior debt principal		3,872		$	3,571		3,489		$	3,192
Less: Unamortized issue discounts		(26	)				(4	)
Less: Unamortized debt issuance costs		(22	)				(22	)
Total senior debt, net	$	3,824				$	3,463

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Note ~~13.~~16. Other Liabilities

The following table sets forth the components of the Company’s other liabilities at September 30, 2023 and December 31, 2022.


	September 30, 2023		December 31, 2022
Employee-related costs (1)	$	69	$	82
Accrued litigation (2)		66		55
Asset retirement obligations (3)		69		73
Miscellaneous (4)		120		109
Total other liabilities	$	324	$	319

(1)

Employee-related costs primarily represents liabilities associated with the Company’s long-term employee benefit plans.

(2)

Represents the long-term portion of accrued litigation (see “Note 17 – Commitments and Contingent ~~Liabilities~~Liabilities”).

(3)

Represents the long-term portion of asset retirement obligations, which totaled $84 and $83 when combined with the current portion at September 30, 2023 and December 31, 2022, respectively (see “Note 14 – Other Accrued Liabilities”). For the nine months ended September 30, 2023, liabilities incurred during the period, reduction in estimated cash outflows, liabilities settled in the current period were not material. Accretion expense amounted to $(3) and $2 for the three and nine months ended September 30, 2023, respectively, and $1 and $5 for the three and nine months ended September 30, 2022, respectively.

(4)

Miscellaneous includes long-term income tax liabilities from uncertain tax positions. Miscellaneous also includes an accrued workers compensation indemnification liability of $30 and $33 at September 30, 2023 and December 31, 2022, respectively.

The Chemours Company

~~Litigation~~

~~In addition~~Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Note 17. Commitments and Contingent Liabilities

Litigation Overview

The Company and certain of its subsidiaries, from time to time, are subject to various lawsuits, claims, assessments, and proceedings with respect to product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental, anti-trust, and other such matters ~~discussed below,~~that arise in the ordinary course of business. In addition, Chemours, by virtue of its status as a subsidiary of ~~DuPont~~EID prior to ~~the~~its separation on July 1, 2015 (the “Separation”), is subject to or required under the ~~separation-related~~Separation-related agreements executed prior to the ~~separation~~Separation to indemnify ~~DuPont~~EID against various pending legal proceedings arising out of the normal course of Chemours’ business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcomes of these various proceedings. Except ~~for the litigation specific to PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) and Fayetteville, North Carolina for which separate assessments are provided~~as noted below, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on ~~Chemours’~~the Company’s consolidated financial position, results of operations, or ~~liquidity.~~cash flows. It is not possible to predict the outcomes of these various lawsuits, claims, assessments, or proceedings. Disputes between Chemours and ~~DuPont~~EID may ~~also~~ arise ~~with respect to~~regarding indemnification matters, including disputes based on matters of law or contract interpretation. ~~If and to the extent these~~Should disputes arise, they could materially adversely affect Chemours.

If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. When a material loss contingency is reasonably possible, but not probable, the Company does not record a liability, but instead discloses the nature of the matter and an estimate of the loss or range of loss, to the extent such estimate can be made. Significant judgment is required in both the determination of probability and whether an exposure is reasonably estimable. The Company’s judgments are subjective based on the status of the legal or regulatory proceedings, the merits of the Company’s defenses and consultation with in-house and outside legal counsel. Because of uncertainties related to these matters, accruals are based on the best information available at the time, including, among others, settlement agreements. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates accordingly. Due to the inherent uncertainties of the legal and regulatory process in the multiple jurisdictions in which Chemours operates, management’s judgments may be materially different than the actual outcomes. Legal costs such as outside counsel fees and expenses are charged to expense in the period services are rendered.

Management believes the Company’s litigation accruals are appropriate based on the facts and circumstances for each matter, which are discussed in further detail below.

~~(a)~~

~~Asbestos~~

The following table sets forth the components of the Company’s accrued litigation at September 30, 2023 and December 31, 2022.


	September 30, 2023		December 31, 2022
Asbestos	$	35	$	35
PFOA (1)		49		45
PFAS (2)		633		2
All other matters		7		14
Total accrued litigation	$	724	$	96

(1)

PFOA includes matters under the "PFOA" section within this "Note 17 - Commitments and Contingent Liabilities".

(2)

PFAS includes matters under the "PFAS" section within this "Note 17 - Commitments and Contingent Liabilities".

The following table sets forth the current and long-term components of the Company’s accrued litigation and their balance sheet locations at September 30, 2023 and December 31, 2022.


	Balance Sheet Location	September 30, 2023		December 31, 2022
Accrued Litigation:
Current accrued litigation	Other accrued liabilities (Note 14)	$	658	$	41
Long-term accrued litigation	Other liabilities (Note 16)		66		55
Total accrued litigation		$	724	$	96

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Memorandum of Understanding (the “MOU”) with DuPont, Corteva and EID

In January 2021, Chemours, DuPont, Corteva, and EID, a subsidiary of Corteva, entered into a binding MOU, reflecting the parties’ agreement to share potential future legacy liabilities relating to per- and polyfluoroalkyl substances (“PFAS”) arising out of pre-July 1, 2015 conduct (i.e., “Indemnifiable Losses”, as defined in the separation agreement, dated as of June 26, 2015, as amended, between EID and Chemours (the “Separation Agreement”)) until the earlier to occur of: (i) December 31, 2040; (ii) the day on which the aggregate amount of Qualified Spend is equal to $4,000; or, (iii) a termination in accordance with the terms of the MOU (e.g., non-performance of the escrow funding requirements pursuant to the MOU by any party). As defined in the MOU, Qualified Spend includes:

•

All Indemnifiable Losses (as defined in the Separation Agreement), including punitive damages, to the extent relating to, arising out of, by reason of, or otherwise in connection with PFAS Liabilities as defined in the MOU (including any mutually agreed-upon settlements);

•

Any costs or amounts to abate, remediate, financially assure, defend, settle, or otherwise pay for all pre-July 1, 2015 PFAS Liabilities or exposure, regardless of when those liabilities are manifested; includes Natural Resources Damages claims associated with PFAS Liabilities;

•

Fines and/or penalties from governmental agencies for legacy EID PFAS emissions or discharges prior to the spin-off; and,

•

Site-Related GenX Claims as defined in the MOU.

The parties have agreed that, during the term of the cost-sharing arrangement, Chemours will bear half of the cost of such future potential legacy PFAS liabilities, and DuPont and Corteva will collectively bear the other half of the cost of such future potential legacy PFAS liabilities up to an aggregate $4,000, of which approximately $2,300 is available after consideration of the funding of the Water District Settlement Fund (discussed below). Any recoveries of Qualified Spend from DuPont and/or Corteva under the cost-sharing arrangement will be recognized as an offset to the Company’s cost of goods sold or selling, general, and administrative expense, as applicable, when realizable. Any Qualified Spend incurred by DuPont and/or Corteva under the cost-sharing arrangement will be recognized in the Company’s cost of goods sold or selling, general, and administrative expense, as applicable, when the amounts of such costs are probable and estimable or expensed as incurred with respect to period costs, such as legal expenses. The Company incurred expenditures subject to cost-sharing as Qualified Spend under the MOU of approximately $35 and $112 during the three and nine months ended September 30, 2023, respectively, and $44 and $108 during the three and nine months ended September 30, 2022, respectively.

After the term of this arrangement, Chemours’ indemnification obligations under the Separation Agreement would continue unchanged, subject in each case to certain exceptions set out in the MOU. Pursuant to the terms of the MOU, the parties have agreed to release certain claims regarding Chemours’ Delaware lawsuit and confidential arbitration (concerning the indemnification of specified liabilities that EID assigned to Chemours in its spin-off), including that Chemours has released any claim set forth in the complaint filed in the Delaware lawsuit, any other similar claims arising out of or resulting from the facts recited by Chemours in the complaint or the process and manner in which EID structured or conducted the spin-off, and any other claims that challenge the spin-off or the assumption of Chemours Liabilities (as defined in the Separation Agreement) by Chemours and the allocation thereof, subject in each case to certain exceptions set out in the MOU. The parties have further agreed not to bring any future, additional claims regarding the Separation Agreement or the MOU outside of arbitration.

The parties have also agreed to establish an escrow account to support and manage the payments for potential future PFAS liabilities. The MOU provides that: (i) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 into an escrow account and DuPont and Corteva shall together deposit $100 in the aggregate into an escrow account, and (ii) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 into an escrow account and DuPont and Corteva shall together deposit $50 in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year. Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700, Chemours will make 50% of the deposits and DuPont and Corteva together will make 50% of the deposits necessary to restore the balance of the escrow account to $700. Such payments will be made in a series of consecutive annual equal installments commencing on September 30, 2029 pursuant to the escrow account replenishment terms as set forth in the MOU. Any funds that remain in escrow at termination of the MOU will revert to the party that deposited them. As such, future payments made by the Company into the escrow account will remain an asset of Chemours, and such payments will be reflected as a transfer to restricted cash and restricted cash equivalents on its consolidated balance sheets. As per the terms of the MOU, the Company deposited $100 into the escrow account in September 2022 and in 2021, which is recognized as restricted cash and restricted cash equivalents on its consolidated balance sheets at December 31, 2022. No withdrawals are permitted from the escrow account before January 2026, except for funding mutually agreed-upon third-party settlements in excess of $125. Starting in January 2026, withdrawals may be made from the escrow account to fund Qualified Spend if the parties’ aggregate Qualified Spend in that particular year is greater than $200. Starting in January 2031, the amounts in the escrow account can be used to fund any Qualified Spend. Future payments from the escrow account for potential future PFAS liabilities will be reflected on the Company’s consolidated statement of cash flows at that point in time.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

In September 2023, the parties entered into a supplemental agreement to the MOU, whereby i) the parties agreed to release the funds held in escrow to fund, in part, the Water District Settlement Fund (discussed further below), ii) waive the escrow funding obligation of each party due no later than September 30, 2023, and iii) with respect to the escrow funding obligation due no later than September 30, 2024, will be waived by each of the parties under certain conditions as agreed to by the parties.

The parties will cooperate in good faith to enter into additional agreements reflecting the terms set forth in the MOU.

Asbestos

In the ~~separation, DuPont~~Separation, EID assigned its asbestos docket to Chemours. At September 30, ~~2017~~2023 and December 31, ~~2016,~~2022, there were approximately ~~1,600 and 1,900~~900 lawsuits pending ~~respectively,~~ against ~~DuPont~~EID alleging personal injury from exposure to ~~asbestos.~~asbestos, respectively. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside of the U.S. Most of the actions were brought by contractors who worked at sites between ~~1950~~the 1950s and the 1990s. A small number of cases involve similar allegations by ~~DuPont~~EID employees or household members of contractors or ~~DuPont~~EID employees. Finally, certain lawsuits allege personal injury as a result of exposure to ~~DuPont~~EID products.

At September 30, ~~2017~~2023 and December 31, ~~2016,~~2022, Chemours had ~~an accrual~~accruals of ~~$41~~$35 related to this matter. Chemours reviews this estimate and related assumptions quarterly. Management believes that the likelihood is remote that Chemours would incur losses in excess of the amounts accrued in connection with this matter.these matters.

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~Benzene

~~(Dollars in millions, except per share amounts)~~

~~(b)~~

~~Benzene~~

In the ~~separation, DuPont~~Separation, EID assigned its benzene docket to Chemours. ~~As of~~At September 30, ~~2017~~2023 and December 31, ~~2016,~~2022, there were 2017 and 2718 cases pending against ~~DuPont~~EID alleging benzene-related illnesses, respectively. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at ~~DuPont~~EID sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture ~~DuPont~~EID products such as paints, thinners, and reducers.

A benzene case (Hood v. DuPont) was tried to a verdict in Texas state court on October 20, 2015. Plaintiffs alleged that Mr. Hood’s Acute Myelogenous Leukemia was the result of 24 years of occupational exposure to trace benzene found in DuPont automotive paint products and that DuPont negligently failed to warn him that its paints, reducers and thinners contained benzene that could cause cancer or leukemia. The jury found in the plaintiffs’ favor, awarding $6.9 in compensatory damages and $1.5 in punitive damages. In March 2016, acting on the Company’s motion, the court struck the punitive award. Through DuPont, Chemours has filed an appeal on the remaining award based upon substantial errors made at the trial court level. Plaintiffs have filed a cross appeal.

Management believes that a loss is reasonably possible ~~related~~as to ~~these matters;~~the docket as a whole; however, given the evaluation of each benzene matter is highly fact-driven and impacted by disease, exposure, and other factors, a range of such losses cannot be reasonably estimated at this time.

~~(c)~~

~~PFOA~~

In May 2021, the Company and EID filed suit in Delaware state court against multiple insurance companies for breach of their contractual obligations to indemnify Chemours and EID against liabilities, costs and losses relating to benzene litigation which are covered under liability insurance policies purchased by EID during the period 1967 to 1986. EID and Chemours are seeking payment of all costs and settlement amounts for past and future benzene cases falling under those policies. The outcome of this matter is not expected to have a material impact on Chemours’ results of operations or financial position.

PFOA

Chemours does not, and has never, used “PFOA” (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) as a polymerization aid nor sold it as a commercial product. Prior to the ~~fourth quarter of 2014,~~Separation, the performance chemicals segment of ~~DuPont~~EID made PFOA at its Fayetteville Works site in Fayetteville, North Carolina ~~plant~~(“Fayetteville”) and used PFOA as a ~~processing~~polymerization aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites, including: Washington Works, Parkersburg, West Virginia; Chambers Works, Deepwater, New Jersey; Dordrecht Works, Netherlands; Changshu Works, China; and, Shimizu, Japan. These sites are now owned and/or operated by Chemours.

~~Chemours recorded accruals of $15 and $349 related to the PFOA matters discussed below at~~

At September 30, ~~2017~~2023 and December 31, ~~2016, respectively. Specific to the PFOA MDL Settlement (also discussed below), the Company recorded~~2022, Chemours maintained an accrual of ~~$335 at December 31, 2016, which was paid in installments of $15~~$26 and ~~$320 during the second and third quarters of 2017, respectively.~~

~~These accruals also include charges~~$25, respectively, related to ~~DuPont’s~~PFOA matters under the Leach Settlement (discussed below), EID’s obligations under agreements with the U.S. Environmental Protection Agency ~~(EPA)~~(the “EPA”), and voluntary commitments to the New Jersey Department of Environmental ~~Protection.~~Protection (the “NJ DEP”). These obligations and voluntary commitments include surveying, sampling, and testing drinking water in and around certain Company sites, and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national health advisory. A provisional health advisory level was set by the EPA in 2009 at 0.4 parts per billion (ppb) that includes PFOA in drinking water. In May 2016, the EPA announced a health advisory level of 0.07 ppb that includes PFOA in drinking water. As a result, Chemours recorded an additional $4 in the second quarter of 2016 based on management’s best estimate of the impact of the new health advisory level on the Company’s obligations to the EPA, which have expanded the testing and water supply commitments previously established. Based on prior testing, the Company has initiated additional testing and treatment in certain additional locations in and around the Chambers Works and Washington Works plants.applicable levels. The Company will continue to work with ~~the~~ EPA, NJ DEP and other authorities regarding the extent of work that may be required with respect to these matters.

~~Drinking Water Actions~~

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Leach Settlement

In ~~August 2001,~~2004, EID settled a class action captioned Leach v. DuPont ~~was~~, filed in West Virginia state court, alleging that approximately 80,000 residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

~~DuPont and attorneys for~~ Among the ~~class reached a~~ settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community health project. DuPontterms, EID funded a series of health studies ~~which were completed in October 2012~~ by an independent science panel of experts ~~(C8~~(“C8 Science ~~Panel). The studies were conducted in communities exposed to PFOA~~Panel”) to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and ~~human~~ disease.

The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and diagnosed high cholesterol.

~~The Chemours Company~~

~~Notes to~~ Under the ~~Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

~~In May 2013, a panel~~terms of ~~three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014,~~ the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. DuPontsettlement, EID is obligated to fund up to ~~$235~~$235 for a medical monitoring program for eligible class members and ~~in addition,~~pay the administrative ~~cost~~costs associated with the program, including class counsel fees. ~~In January 2012, DuPont, put $1 in an escrow account to fund medical monitoring as required by the settlement agreement.~~ The court-appointed Director of Medical Monitoring ~~established~~implemented the program, ~~to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening~~ and testing is ongoing ~~and~~with associated payments to service providers ~~are being~~ disbursed from an escrow account which the ~~escrow account. As of~~Company replenishes pursuant to the settlement agreement. Through September 30, ~~2017, less than $1~~2023, approximately $2 has been disbursed from ~~the~~ escrow ~~account~~ related to medical monitoring. While it is ~~probable~~reasonably possible that the Company will incur additional costs related to the medical monitoring program, ~~discussed above,~~ such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing.

In addition, under the Leach settlement agreement, ~~DuPont~~EID must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts and private well users. At ~~separation,~~Separation, this obligation was assigned to Chemours ~~which~~and is included in the ~~accrual amounts recorded as of~~$26 and $25 accrued at September 30, ~~2017.~~2023 and December 31, 2022, respectively.

~~Under~~

PFOA Leach Class Personal Injury

Further, under the Leach settlement, class members may pursue personal injury claims against ~~DuPont~~EID only for those ~~human~~ diseases for which the C8 Science Panel determined a probable link exists. Approximately 3,500 lawsuits were subsequently filed in various federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation ~~(MDL)~~(“MDL”) in Ohio federal court.

~~Settlement of MDL between DuPont and MDL Plaintiffs~~

In These were resolved in March 2017 ~~DuPont~~ when EID entered into an agreement ~~with the~~settling all MDL ~~plaintiffs’ counsel providing for a global settlement of all~~ cases and claims, ~~in the MDL,~~ including all filed and unfiled personal injury cases and claims that ~~are~~were part of the plaintiffs’ counsel’s ~~claim~~claims inventory, as well as cases ~~that have been~~ tried to a jury verdict ~~(MDL Settlement). The total settlement amount is $670.7~~(the “First MDL Settlement”) for $670.7 in cash, with half paid by Chemours, and half paid by ~~DuPont. DuPont’s payment~~EID.

Concurrently with the First MDL Settlement, EID and Chemours agreed to a limited sharing of potential future PFOA costs (i.e. “Indemnifiable Losses”, as defined in the Separation Agreement between EID and Chemours) for a period of five years. The cost-sharing agreement entered concurrently with the First MDL Settlement has been superseded by the binding MOU addressing certain PFAS matters and costs. For more information on this matter refer to “Memorandum of Understanding (the “MOU”) with Dupont, Corteva and EID” within this “Note 17 – Commitments and Contingent Liabilities”.

While all MDL lawsuits were dismissed or resolved through the First MDL Settlement, the First MDL Settlement did not resolve PFOA personal injury claims of plaintiffs who did not have cases or claims in the MDL or personal injury claims based on diseases first diagnosed after February 11, 2017. Approximately 96 plaintiffs filed matters after the First MDL Settlement. In January 2021, EID and Chemours entered into settlement agreements with counsel representing these plaintiffs, providing for a settlement of all but one of the 96 then filed and pending cases, as well as additional pre-suit claims, under which those cases and claims of settling plaintiffs were resolved for approximately $83 (the “Second MDL Settlement”). Chemours contributed approximately $29, and DuPont and Corteva each contributed approximately $27 to the Second MDL Settlement.

The single matter not included in the settlement is a testicular cancer case tried in March 2020 to a verdict of $40 in compensatory and emotional distress damages and $10 in loss of consortium damages. The jury found that EID’s conduct did not warrant punitive damages. In March 2021, the trial court issued post trial rulings which reduced the consortium damages to $0.25. EID appealed the verdict to the United States Court of Appeals for the 6th Circuit and, in December 2022, the 6th Circuit affirmed the verdict in a two-to-one decision, with one judge dissenting on two grounds including the district court’s grant of collateral estoppel. In January 2023, EID petitioned for a rehearing of the appeal by the 6th Circuit en banc, which was denied in February 2023. EID has petitioned the United States Supreme Court to review the decision. The outcome of such petition is not determinable at this time and has significant uncertainties. Given the current status of this case and the significant uncertainties, the Company has a reserve for potential loss, on this matter of $20 at September 30, 2023 and December 31, 2022, representing Chemours’ share of the verdict under the terms of the MOU and in accordance with accounting guidance on obligations resulting from joint and several liability arrangements. The Company has reserved for pre-judgment and post-judgment interest.

In December 2022, the Judicial Panel on Multi-District Litigation (JPML) declined to close the Ohio MDL. As of September 30, 2023, 23 plaintiffs purporting to be Leach class members have filed personal injury cases and these matters are expected to proceed in the Ohio MDL.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

State of Ohio

In February 2018, the State of Ohio initiated litigation against EID regarding historical PFOA emissions from the Washington Works site. Chemours is an additional named defendant. Ohio alleges damage to natural resources and fraudulent transfer in the spin-off that created Chemours and seeks damages including remediation and other costs and punitive damages. The parties are engaged in ongoing settlement discussions related to this matter.

PFAS

EID and Chemours have received governmental and regulatory inquiries and have been named in other litigations, including class actions, brought by individuals, municipalities, businesses, and water districts alleging exposure to and/or contamination from PFAS, including PFOA. Many actions include an allegation of fraudulent transfer in the spin-off that created Chemours. Chemours has declined EID’s requests for indemnity for fraudulent transfer claims.

Chemours has responded to letters and inquiries from governmental law enforcement entities regarding PFAS, including in January 2020, a letter informing it that the U.S. Department of Justice, Consumer Protection Branch, and the United States Attorney’s Office for the Eastern District of Pennsylvania are considering whether to open a criminal investigation under the Federal Food, Drug, and Cosmetic Act and asking that it retain its documents regarding PFAS and food contact applications. In July 2020, Chemours received a grand jury subpoena for documents. The Company is presently unable to predict the duration, scope, or result of any potential governmental, criminal, or civil proceeding that may result, the imposition of fines and penalties, and/or other remedies. The Company is also unable to develop a reasonable estimate of a possible loss or range of losses, if any.

Fayetteville Works, Fayetteville, North Carolina

For information regarding the Company’s ongoing litigation and environmental remediation matters at Fayetteville, refer to “Fayetteville Works, Fayetteville, North Carolina” under the “Environmental Overview” within this “Note 17 – Commitments and Contingent Liabilities”.

Aqueous Film Forming Foam Matters

Chemours does not, and has never, manufactured nor sold aqueous film forming foam (“AFFF”). Numerous defendants, including EID and Chemours, have been named in approximately 5,400 matters involving AFFF, which is used to extinguish hydrocarbon-based (i.e., Class B) fires and subject to ~~indemnification~~U.S. military specifications. Most matters have been transferred to or ~~reimbursement~~filed directly into a multi-district litigation (“AFFF MDL”) in South Carolina federal court or identified by a party for transfer. The matters pending in the AFFF MDL allege damages as a result of contamination, in most cases due to migration from military installations or airports, or personal injury from exposure to AFFF. Plaintiffs seek to recover damages for investigating, monitoring, remediating, treating, and otherwise responding to the contamination. Others have claims for personal injury, property diminution, and punitive damages.

In March 2021, ten water provider cases within the AFFF MDL were approved by the court for purposes of commencing initial discovery (Tier One discovery) and in October 2021, the court approved three of these cases for additional discovery (Tier Two discovery). In September 2022, a water provider action filed by the City of Stuart, Florida was selected for the first bellwether trial. The court encouraged all parties to discuss resolution of the water provider category of cases, and in October 2022 appointed a mediator to facilitate discussions among and between the parties. Consistent with the court’s instruction and under the mutual obligations of the MOU, Chemours, Corteva/EID and DuPont, together, engaged with Plaintiffs’ Counsel on these cases, including through the court-appointed mediation. Prior to the public water system class action suit settlement discussed below, in May 2023, the Plaintiffs filed, and the court granted, a motion to sever all claims against Chemours and EID from the first bellwether trial for the water provider cases.

For non-water provider cases in the AFFF MDL, the parties will now proceed with Tier One discovery on 28 personal injury cases, with those cases to be identified in December 2023.

There are other AFFF lawsuits pending outside the AFFF MDL that have not been designated by a party for inclusion in the MDL. These matters identifying EID and/or Chemours ~~accrued $335 associated~~as a defendant are:

Valero Refining (“Valero”) has five pending state court lawsuits filed commencing in June 2019 regarding its Tennessee, Texas, Oklahoma, California, and Louisiana facilities. These lawsuits allege that several defendants that designed, manufactured, marketed, and/or sold AFFF or PFAS incorporated into AFFF have caused Valero to incur damages and costs including remediation, AFFF disposal, and replacement. Valero also alleges fraudulent transfer.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

In New York, four individuals filed a lawsuit against numerous defendants including Chemours. The lawsuit alleges personal injury resulting from exposure to AFFF in Long Island drinking water and violation of New York Uniform Fraudulent Conveyance Act. Plaintiffs seek compensatory and punitive damages and medical monitoring.

In Illinois, a lawsuit was filed in May 2022 in the state court against numerous defendants, including EID. The lawsuit alleges personal injury from occupational exposure, including from AFFF-related materials/products, and seeks compensatory damages and punitive damages. In July 2023, an agreement to resolve the lawsuit was reached. This matter is now closed. In February 2023, a separate lawsuit was filed in the state court against numerous defendants, including EID, which also alleges personal injury from occupational exposure, including from AFFF-related materials/products, and seeks compensatory damages and punitive damages. Chemours is not a named defendant in either of these lawsuits.

In Ontario, Canada, three lawsuits were filed by two parties in December 2022, against DuPont de Nemours, Inc. and another defendant, seeking contribution and indemnification, interest, and costs in connection with ~~this matter~~three underlying actions filed by property owners in Canada, and a related third-party action filed by some defendants in one of the matters. The plaintiffs in the underlying actions allege PFAS contamination of their respective properties from the use of firefighting foam. Chemours is not a named defendant in any of these matters but has agreed to defend pursuant to the MOU. These lawsuits against DuPont were noticed for discontinuance by one of the filing parties.

United States Public Water System Class Action Suit Settlement

On June 1, 2023, Chemours, Corteva/EID, and DuPont, together, entered into a binding agreement in principle to comprehensively resolve all drinking water claims related to PFAS of a defined class of U.S. public water systems that serve the vast majority of the United States population arising out of the AFFF MDL, that was finalized by a definitive agreement on June 30, 2023 (the "Settlement Agreement"), subject to approval by the United States District Court for the District of South Carolina (the “Court”). A preliminary approval of the Settlement Agreement by the Court was granted on August 22, 2023.

Under the Settlement Agreement, Chemours, Corteva and DuPont collectively established and contributed a total of $1,185 to a qualified settlement fund (“Water District Settlement Fund”). Contribution rates were consistent with the MOU, with Chemours (together with its subsidiaries) contributing 50%, and DuPont and Corteva collectively (together with their subsidiaries) contributing the remaining 50%. The settlement amounts were funded in full and deposited into the Water District Settlement Fund within ten business days following preliminary approval of the settlement by the Court. On September 6, 2023, Chemours deposited $592 into the Water District Settlement Fund, which is recognized as restricted cash and restricted cash equivalents on its consolidated balance sheet at ~~December 31, 2016.~~September 30, 2023 as Chemours maintains a proportional reversionary interest to the underlying restricted cash equivalents in the Water District Settlement Fund. In exchange for the payment to the Water District Settlement Fund, Chemours, Corteva and DuPont (together with their subsidiaries) will receive a release of the ~~total settlement amount, DuPont and Chemours received a complete release of all~~ claims from the Class (as defined below), upon entry into final judgment by the ~~settling plaintiffs. As described below,~~Court in accordance with the ~~settling plaintiffs include all but approximately 10 of the plaintiffs who filed cases in the MDL.~~Settlement Agreement. The ~~MDL Settlement~~agreement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by ~~DuPont~~Chemours or ~~Chemours. As~~the other parties.

The class represented in the Settlement Agreement is composed of ~~September 30, 2017, Chemours has paid the full $335 accrued~~all Public Water Systems, as defined in 42 U.S.C. § 300f, with a current detection of PFAS or that are currently required to monitor for PFAS under the ~~MDL Settlement.~~

~~Settlement between DuPont~~Environmental Protection Agency’s Fifth Unregulated Contaminant Monitoring Rule or other applicable federal or state law (the “Class”). The following systems are excluded from the settlement class: water systems owned and ~~Chemours Related~~operated by a State or the United States government; small systems that have not detected the presence of PFAS and are not currently required to ~~MDL~~

~~DuPont~~monitor for it under federal or state requirements; and ~~Chemours agreed to a limited sharing~~water systems in the lower Cape Fear River Basin of ~~potential future PFOA costs (indemnifiable losses,~~North Carolina (which are included only if they so request). PFAS, as defined in the ~~separation agreement between DuPont~~Settlement Agreement, includes PFOA and ~~Chemours) for~~HFPO-DA among a ~~period~~broad range of ~~five years. During~~fluorinated organic substances. While it is reasonably possible that ~~five-year period, Chemours will annually pay~~the excluded systems or claims could result in additional future ~~PFOA costs up~~lawsuits, claims, assessments or proceedings, it is not possible to ~~$25 and, if such amount is exceeded, DuPont will pay any excess amount up to~~predict the ~~next $25 (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess costs under the terms~~outcome of the separation agreement. After the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the separation agreement will continue unchanged. Chemours has also agreed that it will not contest its indemnification obligations to DuPont under the separation agreement for PFOA costs on the basis of ostensible defenses generally applicable to the indemnification provisions under the separation agreement, including defenses relating to punitive damages, fines or penalties or attorneys’ fees, and waives any such ~~defenses with respect~~matters, and as such, the Company is unable to ~~PFOA costs. Chemours has, however, retained other defenses, including as to whether~~develop an estimate of a possible loss or range of losses, if any, ~~particular PFOA claim is within the scope of the indemnification provisions of the separation agreement.~~at this time.

~~Post-MDL~~

The Settlement ~~Injury Matters~~

~~There are approximately 10 plaintiffs who declined to participate in the MDL Settlement. Counsel representing most of these plaintiffs have filed motions to withdraw their representation.~~

~~The MDL Settlement~~Agreement does not resolve ~~PFOA personal-injury~~ claims of ~~plaintiffs who did~~Public Water Systems that are not ~~have cases or claims~~included in the settlement as described above, or of Public Water Systems that request exclusion from the Class (“opt out”) pursuant to the process established by the Court. It also does not resolve potential future claims of Public Water Systems that have not detected and do not detect any PFAS contamination, but where such contamination first occurs in the future. The Settlement Agreement also does not resolve certain claims not related to drinking water, such as certain specified separate alleged claims relating to stormwater or wastewater treatment, or other alleged types of claims such as for personal injury or for natural resource damages claimed by state attorneys general, that remain outstanding in the AFFF MDL or ~~personal-injury~~other courts. Matters related to claims ~~based on diseases first diagnosed after February 11, 2017. Since the resolution of the MDL, three personal-injury cases have been filed in West Virginia courts.~~from other public water systems, state natural resources damages and other PFAS matters are further described below.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

As part of the preliminary approval of the Settlement Agreement in August 2023, notice of the Settlement Agreement has been provided to class members and such members have until November 11, 2023 to object to the settlement or December 4, 2023 to submit a request for exclusion, indicating they wish to opt-out of the settlement class. The Companies can then determine whether to exercise their walk-away right. A Final Fairness Hearing on the Settlement Agreement is scheduled for December 14, 2023. Opt out notices or other inquiries have been received from certain water utilities, including some in the litigation identified below. While it is reasonably possible that claims from such utilities could result in additional future lawsuits, assessments or proceedings, unless provided herein, it is not possible to predict the outcome of any such matters due to various reasons including, among others, future actions and decisions relating to the Settlement Agreement and factual and legal issues to be resolved with individual water utilities. As such, the Company is unable to develop an estimate of a possible loss or range of losses, if any, for these claims at this time.

If the Settlement Agreement is not approved, and plaintiffs elect to pursue their claims in court, the parties will continue to assert their strong legal defenses in pending litigation. Chemours, Corteva and DuPont deny the allegations in the underlying litigation and reserve all legal and factual defenses against such claims if they were litigated to conclusion.

For the nine months ended September 30, 2023, the Company accrued $592, included in selling, general, and administrative expense, representing Chemours’ share of the settlement under the terms of the MOU and in accordance with accounting guidance on obligations resulting from joint and several liability arrangements.

Other Public Water System Matters

In addition to the matters described in the AFFF MDL, other public water systems have filed lawsuits against Chemours, Corteva/EID, and DuPont including the following:

In New York, 22 Long Island water suppliers that have filed lawsuits against several defendants including EID and Chemours alleging PFAS, PFOA, and perfluorooctanesulfonic acid (“PFOS”) contamination through releases from industrial and manufacturing facilities and business locations where PFAS-contaminated water was used for irrigation and sites where consumer products were disposed. Claims vary between matters but include claims of personal injury alleging various disease conditions, product liability, negligence, nuisance, trespass and fraudulent transfer. All matters are seeking compensatory and punitive damages and, in certain cases, medical monitoring, declaratory and/or injunctive relief. In January 2022, Chemours filed a third-party claim for indemnity in connection with one of the Long Island water supplier matters.

The Town of Petersburgh in New York also filed suit in New York state court in August 2022 alleging defendants 3M, EID, and other defendants, are responsible for PFOA contamination of its municipal drinking water supply. The complaint alleges product liability claims, negligence, and trespass. Plaintiff seeks injunctive and declaratory relief as well as compensatory and punitive damages.

In New York and New Jersey, lawsuits were filed by Suez Water against several defendants, including EID and Chemours, alleging damages from PFAS releases into the environment, including PFOA and PFOS, that impacted water sources that the utilities use to provide water, as well as products liability, negligence, nuisance, and trespass. Defendants filed motions to dismiss the complaints in both matters. The motion was denied in the Suez Water New Jersey lawsuit in October 2021. In January 2022, the court granted defendants’ motion to dismiss in the Suez New York lawsuit without prejudice and the plaintiff filed a second amended complaint in February 2022. Following the filing of the second amended complaint in the Suez New York lawsuit, the defendants filed a motion to dismiss. In March 2023, the court granted in part defendants’ motion to dismiss the second amended complaint, dismissing all claims against Chemours with prejudice, and finding a claim for design defect could be maintained against EID.

In California, several lawsuits were filed in state court against several defendants, including EID and Chemours. The complaints allege product liability, negligence, nuisance and trespass. Plaintiffs seek declaratory and injunctive relief, including abatement, as well as compensatory and punitive damages. The lawsuits, which have been transferred to the AFFF MDL, include matters filed by:

•

11 southern California public water systems, the City of Corona, California and the Corona Utility Authority that allege manufacturers of PFOA and PFOS are responsible for contaminating the drinking water supply. The matter involving the 11 southern California public water systems has been transferred to the AFFF MDL. In the matter involving the City of Corona, California and the Corona Utility Authority, in February 2022, the court dismissed the case against EID and Chemours on jurisdictional grounds and the plaintiffs appealed the decision.

•

Atascadero Mutual Water Company in San Luis Obispo County, California alleging damages to drinking water supply from PFAS releases, including PFOA and PFOS, into the environment.

•

Sacramento Suburban Water District alleging damages from PFAS releases into the environment, including PFOA and PFOS, that impacted water sources the Water District uses to provide water.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

In Georgia and Alabama, lawsuits were filed against numerous carpet manufacturers, certain municipal defendants, and suppliers and former suppliers, including EID and Chemours. The lawsuits include a matter filed by the Water Works and Sewer Board of the Town of Centre, Alabama alleging negligence, nuisance, and trespass in the release of PFAS, including PFOA, into a river leading to the town’s water source. The matter filed by the Town of Centre, Alabama was scheduled for trial in November 2023, but has been stayed pursuant to the order granting preliminary approval to the Settlement Agreement, as described above.

Also, in Alabama, a purported class action was filed in July 2022 in Alabama federal court on behalf of certain drinking water utilities against 3M, EID, Corteva and the Company alleging contamination of drinking water. The complaints allege negligence, public nuisance, private nuisance and trespass. The plaintiffs seek injunctive relief as well as compensatory and punitive damages. In April 2023, Shelby County, Alabama and Talladega County, Alabama, filed suit in Alabama state court against numerous carpet manufacturers located near Dalton Georgia, suppliers, EID, Chemours, and other defendants to be named later. The complaint alleges negligence, nuisance and trespass in the release by the carpet mills of PFAS compounds, including PFOA, into the water sources used by the Counties to provide drinking water. The Counties seek compensatory and punitive damages as well as injunctive relief to remove PFAS from the water supply and prevent alleged ongoing contamination. In May 2023 the matter was removed to federal court.

In Georgia, a lawsuit was filed by the City of Rome against numerous carpet manufacturers, certain municipal defendants, and suppliers and former suppliers, including EID and Chemours, alleging negligence, nuisance, and trespass in the release of PFAS, including PFOA, into a river leading to the town’s water source. In June 2023, Chemours, DuPont and Corteva entered into a confidential settlement with the City of Rome and its claims against these parties related to this matter have been released and the matter dismissed. The settled amount was included in Accrued Litigation at September 30, 2023.

Additionally, in Georgia, a putative class action was filed on behalf of customers of the Rome, Georgia water division and the Floyd County, Georgia water department alleging negligence and nuisance and related to the release of perfluorinated compounds, including PFOA, into a river leading to their water sources. This matter is pending in court. 

State Natural Resource Damages Matters

In addition to the State of New Jersey actions (as detailed below) and the State of Ohio action (as detailed above), a majority of the states and certain territories of the U.S., have filed lawsuits against various defendants, including EID and Chemours, relating to the alleged contamination of state natural resources with PFAS compounds either from AFFF and/or other sources. These lawsuits seek damages including costs to investigate, clean up, restore, treat, monitor, or otherwise respond to contamination of natural resources and some include counts for fraudulent transfer. Chemours, Corteva/EID and DuPont, together under the MOU, are engaged with States and their counsel on certain of these cases, including through court-appointed mediations in the New Jersey and North Carolina actions outside of the AFFF MDL. It is reasonably possible that these discussions could result in a loss, which could be material; however, at this time, the Company is unable to predict the duration, scope, or result of such discussions, and because of these uncertainties, the Company is also unable to develop a reasonable estimate of a possible loss or range of losses, if any.

On July 13, 2021, Chemours, DuPont, Corteva, and EID entered into a settlement agreement with the State of Delaware to settle such potential claims, including for environmental releases or sales of products containing PFAS or other known contaminants. Under the agreement, in January 2022, the companies paid a total amount of $50 to the State of Delaware, which shall be utilized to fund a Natural Resources and Sustainability Trust (the “Trust”) to be used for environmental restoration and enhancement of resources, sampling and analysis, community environmental justice and equity grants, and other natural resource needs. Chemours contributed $25 to the settlement and the remaining $25 was divided between DuPont and Corteva which shall be treated as Qualified Spend under the MOU. If the companies enter into a proportionally similar agreement to settle or resolve claims of another state for PFAS-related natural resource damages, for an amount greater than $50, the companies may be required to make one or more supplemental payment(s) directly to the Trust, with such payment(s) not to exceed $25 in the aggregate.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Other PFAS Matters

In New York courts, EID has been named in approximately 40 lawsuits, which are not part of the Leach class, brought by individual plaintiffs alleging negligence and other claims in the release of PFAS, including PFOA, into drinking water against current and former owners and suppliers of a manufacturing facility in Hoosick Falls, New York. Two additional lawsuits have been filed by a business seeking to recover its losses and by nearby property owners and residents in a putative class action. The lawsuit filed by the business was dismissed, but the claims by the individual business owner were allowed to proceed. In September 2022, the Court certified the class action, and EID filed a petition for review of the certification, which was denied in January 2023. Chemours and EID, entered into settlement agreements in principle to resolve all but seven of the pending lawsuits, including the class action suit, during the second quarter of 2023, and such amount was included in the Accrued Litigation at September 30, 2023.

In New Jersey, lawsuits were filed against several defendants including EID and Chemours. The lawsuits include ten lawsuits alleging that defendants are responsible for PFAS contamination, including PFOA and PFOS, in groundwater and drinking water. During the second quarter of 2023, the companies resolved these claims. Eight lawsuits were also filed alleging exposure to PFAS and other chemicals, including two lawsuits by parents on behalf of their adult children claiming pre-natal exposure, resulted in the children’s cognitive delays, neurological, genetic, and autoimmune conditions. Further, eleven additional lawsuits were filed in state court with similar allegations of personal injury, which have been removed to New Jersey federal court. Plaintiffs seek certain damages including punitive damages.

In Ohio, a putative class action (“Hardwick”) was filed against several defendants including 3M, EID and Chemours seeking class action status for U.S. residents having a detectable level of PFAS in their blood serum. The complaint seeks declaratory and injunctive relief, including the establishment of a “PFAS Science Panel”. In March 2022, the court granted in part and denied in part the plaintiff’s class certification and certified a class covering anyone subject to Ohio laws having minimal levels of PFOA plus at least one other PFAS in their blood. The court requested further briefing on whether the class should be extended to include other states that recognize the claims for relief filed in the action. The defendants, including EID and Chemours, jointly filed a petition to appeal the class certification decision and in September 2022 the petition was granted and appellate review is proceeding. Defendants will continue to defend at the trial court level while this appeal is pending. Management believes that a loss is reasonably possible as to the ~~probability~~Hardwick matter, but not estimable at this time given the significant class issues to be resolved and that the discovery phase is pending the appellate review.

In Delaware, a putative class action was filed against two electroplating companies, 3M and EID, and two other defendants added in an amended complaint, alleging responsibility for PFAS contamination, including PFOA and PFOS, in drinking water and the environment in the nearby community. Although initially named in the lawsuit, Chemours was subsequently dismissed. The putative class of residents alleges negligence, nuisance, trespass, and other claims and seeks medical monitoring, personal injury and property damages, and punitive damages.

In South Carolina, a putative class action was filed in March 2022 in the state court against 3M, EID and the Company alleging PFAS contamination from a former textile plant located in Society Hill, South Carolina which allegedly used PFAS containing textile treatment chemicals supplied by the defendants. The lawsuit alleges negligence, trespass, strict liability and nuisance and seeks monetary damages, including property diminution, and injunctive relief, including water treatment and remediation, as well as punitive damages. The matter has been removed to federal court.

In Maine, a previously filed lawsuit in federal court by individuals against various paper mills owners in Maine was amended in October 2022 to add various alleged suppliers to the paper mills as defendants, including EID. The lawsuit alleges PFAS chemicals were used in making paper products at the mills and that discharges, waste disposal and the selling of byproducts from paper mills caused property damages as well as personal injury to the plaintiffs. The lawsuit alleges various claims against the mills; alleges negligence, strict liability and nuisance against the supplier defendants; and seeks monetary damages. In March 2023, plaintiffs dismissed the case against EID and other defendants.

In the Netherlands, Chemours, along with DuPont and Corteva, received a civil summons filed before the Court of Rotterdam by four municipalities (Dordrecht, Papendrecht, Sliedrecht and Molenlanden) seeking liability declarations relating to the Dordrecht site’s operations and emissions. Chemours reviewed the summons and filed a statement of defense during the fourth quarter of 2021, and in September 2022 the court entered an interlocutory judgment denying in part certain aspects of such statement of defense. A hearing on the merits of the municipalities’ claims took place in March 2023. On September 27, 2023, the court entered a second interlocutory judgment, ruling, inter alia, that defendants were liable to the municipalities for (i) PFOA emissions during a certain time period and (ii) removal costs if deposited emissions on the municipalities land infringes their property rights by an objective standard. Additional briefing is expected on this judgment and any damages will be decided in a separate, subsequent proceeding. Chemours is in discussions with the municipalities to identify actions that may resolve their and other community concerns, including providing technical and financial support for activities. An estimate of a liability was included in Accrued Litigation at September 30, 2023.

Further in The Netherlands, in September 2023, a Dutch criminal defense lawyer announced a criminal complaint with the support of a few thousand citizens against Chemours and its current and former directors for alleged unlawful emissions of PFOA and GenX in Dordrecht. This claim has been filed with the Office of the Public Prosecutor, which will proceed with the investigation.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

In addition to the above matters, the Company may engage in discussions with various parties regarding other claims and potential resolutions of such matters. In the three and nine months ended September 30, 2023, the Company recorded an amount related to one or more of these matters. The Company does not expect the outcome of any of these matters, individually and in aggregate, to have a material impact on Chemours’ results of operations or financial position.

New Jersey Department of Environmental Protection Directives and Litigation

In March 2019, NJ DEP issued two Directives and filed four lawsuits against Chemours and other defendants. The Directives are: (i) a state-wide PFAS Directive issued to EID, DowDuPont, DuPont Specialty Products USA (“DuPont SP USA”), Solvay S.A., 3M, and Chemours seeking a meeting to discuss future costs for PFAS-related costs incurred by NJ DEP and establishing a funding source for such costs by the Directive recipients, and information relating to historic and current use of certain PFAS compounds; and, (ii) a Pompton Lakes Natural Resources Damages (“NRD”) Directive to EID and Chemours demanding $0.1 to cover the cost of preparation of a natural resource damage assessment plan and access to related documents.

The lawsuits filed in New Jersey state courts by NJ DEP are: (i) in Salem County, against EID, 3M, and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, the Water Pollution Control Act (“WPCA”), the Industrial Site Recovery Act (“ISRA”), and common law regarding past and present operations at Chambers Works, a site assigned to Chemours at Separation; (ii) in Middlesex County, against EID, DuPont SP USA, 3M, and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, ISRA, WPCA, and common law regarding past and present operations at Parlin, an EID owned site; (iii) in Gloucester County, against EID and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, WPCA, and common law regarding past operations at Repauno, a non-operating remediation site assigned to Chemours at Separation which has been sold; and, (iv) in Passaic County, against EID and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, WPCA, and common law regarding past operations at Pompton Lakes, a non-operating remediation site assigned to Chemours at Separation. The alleged pollutants listed in the Salem County and Middlesex County matters above include PFAS. Each lawsuit also alleges fraudulent transfer.

In August 2020, a Second Amended Complaint was filed in each matter, adding fraudulent transfer and other claims against DuPont SP USA, Corteva, and DuPont. For the Salem County matter, NJ DEP added claims relating to failure to comply with state directives, including the state-wide PFAS Directive.

The matters were removed to federal court and consolidated for case management and pretrial purposes. In December 2021, the federal court entered a consolidated order granting, in part, and denying, in part, a motion to dismiss or strike parts of the Second Amended Complaints. In January 2022, NJ DEP filed a motion for a preliminary injunction requiring EID and Chemours to establish a remediation funding source (“RFS”) in the amount of $943 for the Chambers Works site, the majority of which is for non-PFAS remediation items. In March 2023 the four NJDEP lawsuits were referred to mediation by the federal court, with the proceedings in the matters stayed pending the mediation. Chemours believes that the January 2022 motion as directed to it is not supported by applicable law and the RFS sought by NJ DEP is not an appropriate estimate of remedial cost for the Chambers Works site and, subject to the discussions regarding overall remediation costs under “Environmental Overview” within this Note 17 – Commitments and Contingent Liabilities, management believes that a loss is reasonably possible, but not estimable at this time, due to various reasons, including ~~among others,~~ that the ~~proceedings are~~motion is in its early stages and there are significant factual issues and legal questions to be resolved.

~~Centre Water~~

~~In May 2017,~~EID requested that Chemours defend and indemnify it in these matters. Chemours has accepted the ~~Water Works~~indemnity and ~~Sewer Board~~defense of EID while reserving rights and declining EID’s demand as to matters involving other EID entities, as well as ISRA and fraudulent transfer, subject to the terms of the ~~Town of Centre, Alabama filed suit against numerous carpet manufacturers located in Dalton, Georgia~~MOU.

PFOA and ~~suppliers and former suppliers, including DuPont, in Alabama state court. The complaint alleges negligence, nuisance and trespass in~~PFAS Summary

With the release of perfluorinated compounds, including PFOA, into a river leading to the town’s water source, and seeks compensatory and punitive damages. Management believes that the probability of loss is remote.

~~PFOA Summary~~

Chemours accrued $335 associated with the MDL Settlement at December 31, 2016, of which all $335 has been paid through September 30, 2017. There could be additional lawsuits filed related to DuPont’s use of PFOA, its manufacture of PFOA or its customers’ use of DuPont products that may not be within the scopeexception of the ~~MDL Settlement. Any such litigation could result in Chemours incurring additional costs and liabilities. Management~~matters noted otherwise above, management believes that it is reasonably possible that the Company could incur losses related to ~~other~~ PFOA and/or PFAS matters in excess of amounts accrued, but any such losses, which could be material, are not estimable at this time due to various reasons, including, among others, that ~~such~~some matters are in their early stages and ~~have~~that there are significant factual issues to be resolved.

~~(d)~~

~~U.S. Smelter and Lead Refinery, Inc.~~

~~Six~~

U.S. Smelter and Lead Refinery, Inc.

There are six lawsuits, including ~~one~~a putative class action, ~~are pending against DuPont~~ by area residents concerning the U.S. Smelter and Lead Refinery multi-party Superfund site in East Chicago, Indiana. ~~Five~~Several of the lawsuits allege that Chemours is now responsible for ~~DuPont~~EID environmental liabilities. The lawsuits include allegations for personal injury damages, property diminution, and ~~damages under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA, often referred to as Superfund).~~other damages. At ~~separation, DuPont~~Separation, EID assigned Chemours its former plant site, which is located south of the residential portion of the Superfund area, and its responsibility for the environmental remediation at the Superfund site. ~~DuPont has requested that~~

The Chemours ~~defend and indemnify it, and Chemours has agreed~~Company

Notes to ~~do so under a reservation of rights.~~ the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Management believes a loss is reasonably possible, but not estimable at this time due to various reasons including, among others, that such matters are in their early stages and have significant factual issues to be resolved.

~~(e)~~

~~Fayetteville, North Carolina~~

~~As reported in the press and noted in public statements by the Company, governmental agencies and local community members have made inquiries and engaged in discussions with the Company with respect~~

Environmental Overview

Chemours, due to the ~~discharge~~terms of the polymerization processing aid HFPO Dimer Acid (sometimes referred to as GenX or C3 Dimer) and perfluorinated and polyfluorinated compounds from the Company’s facility in Fayetteville, North Carolina into the Cape Fear River, groundwater and air. The Company believes that such discharges have not impacted the safety of drinking water in North Carolina. Nevertheless, to address community concerns, the Company has voluntarily commenced capturing and separately disposing certain process wastewater from the Fayetteville facility. The Company is also cooperatingSeparation-related agreements with ~~a variety of ongoing inquiries and investigations from federal, state and local authorities, regulators and other governmental entities, including responding to two federal grand jury subpoenas.~~

On September 5, 2017, the North Carolina Department of Environmental Quality (NC DEQ) issued a 60-day notice of intent to suspend the permit for the Fayetteville facility and the State of North Carolina filed an action in North Carolina state court regarding the discharges seeking a temporary restraining order and preliminary injunction, as well as other relief including abatement and site correction. On September 8, 2017, a partial consent order was entered partially resolving the State’s action in return for the Company’s agreement to continue and supplement the voluntary wastewater-disposal measures it had previously commenced and to provide certain information. On October 24, 2017, NC DEQ informed the Company that, based on measures taken by the Company following September 5, 2017, it has concluded at the present time, that it is not necessary to suspend the permit for the Fayetteville facility. The Company is continuing to cooperate with and discuss these matters with the State and NC DEQ.

A number of additional actions have been filed against the Company and DuPont in North Carolina federal court relating to discharges from the Fayetteville site, including an action brought by the Cape Fear Public Utility Authority and one brought by Brunswick County, both seeking damages and injunctive relief, and multiple purported class actions seeking medical monitoring and property damage and/or other monetary and injunctive relief on behalf of the putative classes of property owners and residents in areas near or

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

that draw drinking water from the Cape Fear River. It is also possible that additional litigation may be filed against the Company and/or DuPont concerning the discharges. The Company believes it has valid defenses to such litigation including that the discharges did not impact the safety of drinking water or cause any damages or injury.

As these issues are in their early stages, however, it is not possible at this point to predict the timing, course or outcome of the governmental and regulatory inquiries, the notice issued by NC DEQ, the action brought by North Carolina and the other litigation, and it is possible that these matters could materially affect the Company’s results and operations. In addition, local communities, organizations and regulatory agencies have raised questions concerning HFPO Dimer Acid at certain other manufacturing sites operated by the Company, and it is possible that similar developments to those described above and centering on the Fayetteville site could arise in other locations.

~~Environmental~~

~~Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation,~~EID, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances, ~~by Chemours or other parties.~~which are attributable to EID’s activities before it spun-off Chemours. Much of this liability results from ~~CERCLA,~~the Comprehensive Environmental Response Compensation and Liability Act (“CERCLA”, often referred to as “Superfund”), the Resource Conservation and Recovery Act (“RCRA”), and similar federal, state, local, and ~~global~~foreign laws. These laws may require Chemours to undertake certain investigative, remediation, and restoration activities at sites where ownership was transferred to Chemours ~~conducts or once conducted operations~~under the Separation-related agreements or at sites where ~~Chemours-generated~~EID-generated waste was ~~disposed.~~disposed before the 2015 separation. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Where the available information is only sufficient to establish a range of probable liability, and no point within the range is more likely than any other, the lower end of the range has been used. Estimated liabilities are determined based on existing remediation laws and technologies and the Company’s planned remedial responses, which are derived from environmental studies, sampling, testing, and analyses. Inherent uncertainties exist in such evaluations, primarily due to unknown environmental conditions, changing governmental regulations regarding liability, and emerging remediation technologies. The Company, from time to time, may engage third parties to assist in obtaining and/or evaluating relevant data and assumptions when estimating its remediation liabilities. These liabilities are adjusted periodically as remediation efforts progress and as additional technological, regulatory, and legal information becomes available. Environmental liabilities and expenditures include claims for matters that are liabilities of EID and its subsidiaries, which Chemours may be required to indemnify pursuant to the Separation-related agreements. These accrued liabilities are undiscounted and do not include claims against third parties. Costs related to environmental remediation are charged to expense in the period that the associated liability is accrued.

The following table sets forth the Company’s environmental remediation liabilities at September 30, ~~2017~~2023 and December 31, ~~2016,~~2022 for the ~~consolidated balance sheets included a liability relating~~five sites that are deemed the most significant, together with the aggregate liabilities for all other sites.


	September 30, 2023		December 31, 2022
Chambers Works, Deepwater, New Jersey	$	30	$	30
Fayetteville Works, Fayetteville, North Carolina (1)		399		465
Pompton Lakes, New Jersey		41		41
USS Lead, East Chicago, Indiana		13		17
Washington Works, West Virginia		22		17
All other sites		100		98
Total environmental remediation	$	605	$	668

(1)

For more information on this matter refer to ~~these matters~~“Fayetteville Works, Fayetteville, North Carolina” within this “Note 17 – Commitments and Contingent Liabilities”.

The following table sets forth the current and long-term components of ~~$268~~the Company’s environmental remediation liabilities at September 30, 2023 and ~~$278, respectively, which,~~December 31, 2022.


	September 30, 2023		December 31, 2022
Current environmental remediation	$	138	$	194
Long-term environmental remediation		467		474
Total environmental remediation	$	605	$	668

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in ~~management’s opinion, is appropriate based on existing facts and circumstances. The~~millions, except per share amounts)

Typically, the time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of ~~ongoing~~operation, maintenance, and monitoring ~~(OM&M)~~(“OM&M”) activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, and diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify ~~DuPont~~EID pursuant to the ~~separation-related~~Separation-related agreements, Chemours, through ~~DuPont,~~EID, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, ~~although deemed remote,~~management currently estimates the potential ~~liability~~liabilities may range up to approximately ~~$510~~$730 above the amount accrued at September 30, ~~2017.~~2023. This estimate is not intended to reflect an assessment of Chemours’ maximum potential liability. As noted above, the estimated liabilities are determined based on existing remediation laws and technologies and the Company’s planned remedial responses, which are derived from environmental studies, sampling, testing, and analyses. Inherent uncertainties exist in such evaluations, primarily due to unknown environmental conditions, changing governmental regulations regarding liability, and emerging remediation technologies. Management will continue to evaluate as new or additional information becomes available in the determination of its environmental remediation liability.

~~For~~

In October 2021, EPA released its PFAS Strategic Roadmap, identifying a comprehensive approach to addressing PFAS. The PFAS Strategic Roadmap sets timelines by which EPA plans to take specific actions through 2024, including establishing a national primary drinking water regulation ("NPDWR") for PFOA and PFOS and taking Effluent Limitations Guidelines actions to regulate PFAS discharges from industrial categories among other actions. As provided under its roadmap, EPA also released its National PFAS Testing Strategy, under which the agency will identify and select certain PFAS compounds for which it will require manufacturers to conduct testing pursuant to the Toxic Substances Control Act ("TSCA") section 4. Chemours has received various test orders and has formed consortia to jointly manage compliance with the test order requirements. Chemours expects to receive future test orders, however the timing of the remaining test orders is not determinable at this time.

The environmental remediation liabilities and accrued litigation, as applicable, recorded for Fayetteville, Washington Works, Parkersburg, West Virginia and Chambers Works, Deepwater, New Jersey as of September 30, 2023 are based upon the existing Consent Orders, agreements and/or voluntary commitments with EPA, state and other local regulators and depending on the ultimate outcome of EPA’s actions, could require adjustment to meet any new drinking water standards. It is reasonably possible that additional costs could be incurred in connection with EPA’s actions, however, the Company cannot estimate the potential impact or additional cost at this time, due in part to the uncertainties on EPA’s final rule making after the MCL comment period, regulatory implementation site by site, where applicable, the current condition and the additional sampling required to determine the level of contamination at the site, possible method(s) of remediation that may be required, and determination of other potential responsible parties. Refer to “Fayetteville Works, Fayetteville, North Carolina” below for further detail on the impact of EPA’s final drinking water health advisory for GenX compounds, including HFPO Dimer Acid.

Chemours environmental remediation expenses were $20 and $50 for the three and nine months ended September 30, ~~2017~~2023, respectively, and ~~2016,~~$24 and $235 for the three and nine months ended September 30, 2022, respectively, of which $4 and $18 for the three and nine months ended September 30, 2023, respectively, and $8 and $201 for the three and nine months ended September 30, 2022, respectively, relate to Fayetteville (discussed further below).

The Chemours ~~incurred~~Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Fayetteville Works, Fayetteville, North Carolina

Fayetteville has been in operation since the 1970s and is located next to the Cape Fear River southeast of the City of Fayetteville, North Carolina. HFPO Dimer Acid, (sometimes referred to as “GenX” or “C3 Dimer Acid”) is manufactured at Fayetteville. The Company has operated the site since its Separation from EID in 2015.

While the Company believes that discharges from Fayetteville to the Cape Fear River, on-site surface water, groundwater, and air emissions have not impacted the safety of drinking water in North Carolina, the Company is cooperating with a variety of ongoing inquiries and investigations from federal, state, and local authorities, regulators, and other governmental entities including EPA.

Consent Order with North Carolina Department of Environmental Quality (“NC DEQ”)

In February 2019, the North Carolina Superior Court for Bladen County approved a Consent Order (“CO”) between NC DEQ, Cape Fear River Watch ("CFRW"), and the Company, resolving the State’s and CFRW’s lawsuits and other matters (including Notices of Violation (“NOVs”) issued by the State). Under the terms of the CO, Chemours paid $13 in March 2019 to cover a civil penalty and investigative costs and agreed to certain compliance measures (with stipulated penalties for failures to do so), including the following:

•

Install a thermal oxidizer (“TO”) to control all PFAS in process streams from certain processes at Fayetteville at an efficiency of 99.99%;

•

Develop, submit, and implement, subject to approval from NC DEQ and CFRW, a plan for interim actions that are economically and technologically feasible to achieve the maximum PFAS reduction from Fayetteville to the Cape Fear River within a two-year period;

•

Develop and implement, subject to approval, a Corrective Action Plan (“CAP”) that complies with North Carolina’s groundwater standards and guidance provided by NC DEQ. At a minimum, the CAP must require Chemours to reduce the total loading of PFAS originating from Fayetteville to surface water by at least 75% from baseline, as defined by the CO; and,

•

Provide and properly maintain permanent drinking water supplies, including via whole-building filtration units and reverse osmosis (“RO”) units to qualifying surrounding properties with private drinking water wells.

In August 2020, NC DEQ, CFRW, and the Company reached agreement on the terms of an addendum to the CO (the “Addendum”), which includes procedures for implementing specified remedial measures for reducing PFAS loadings from Fayetteville to the Cape Fear River. The Addendum also includes stipulated financial penalties, inclusive of daily and weekly fines for untimeliness in meeting deadlines for construction, installation and other requirements, as well as intermittent performance-based fines for noncompliance in meeting PFAS loading reduction requirements and removal efficiency targets. After a period of public comment in October 2020, the Addendum was approved by the North Carolina Superior Court for Bladen County. A Motion to Intervene filed by Cape Fear Public Utility Authority was denied.

The following table sets forth the on-site and off-site components of the Company’s accrued environmental remediation liabilities related to PFAS at Fayetteville at September 30, 2023 and December 31, 2022.


	September 30, 2023		December 31, 2022
On-site remediation	$	219	$	264
Off-site groundwater remediation		180		201
Total Fayetteville environmental remediation	$	399	$	465

The following table sets forth the current and long-term components of the Company’s accrued environmental remediation liabilities related to PFAS at Fayetteville at September 30, 2023 and December 31, 2022.


	September 30, 2023		December 31, 2022
Current environmental remediation	$	90	$	139
Long-term environmental remediation		309		326
Total Fayetteville environmental remediation	$	399	$	465

Chemours environmental remediation expenses related to Fayetteville were $4 and $18 for the three and nine months ended September 30, 2023, respectively, and $8 and $201 for the three and nine months ended September 30, 2022, respectively.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Emissions to air

Fayetteville operates multiple permitted air discharge stacks, blowers, and vents as part of ~~$36~~its manufacturing activities. A TO became fully operational at the site on December 27, 2019, and ~~$16, respectively.~~Chemours switched to the permitted operating scenario for the TO on December 31, 2019 as set forth in the CO. The TO is designed to reduce aerial PFAS emissions from Fayetteville, and testing results showed that the TO is controlling PFAS emissions at an average efficiency exceeding 99.999%. Testing was conducted by Chemours and monitored by the North Carolina Division of Air Quality (“NC DAQ”). The cost related to the installation of the TO were capitalized in accordance with the Company’s policy.

~~Based~~

Off-site replacement drinking water supplies

The CO requires the Company to provide permanent replacement drinking water supplies, including via connection to public water supply, whole building filtration units and/or RO units, to qualifying surrounding residents, businesses, schools, and public buildings with private drinking water wells. Qualifying surrounding properties with private drinking water wells that have tested for GenX above the state provisional health goal of 140 ppt, or any applicable health advisory, whichever is lower, may be eligible for public water or a whole building filtration system. Qualifying surrounding properties with private drinking water wells that have tested above 10 ppt for GenX or other perfluorinated compounds (“Table 3 Compounds”) are eligible for three under-sink RO units. The Company provides bottled drinking water to a qualifying property when it becomes eligible for a replacement drinking water supply, and continues to provide delivery of bottled drinking water to the qualifying property until the eligible supply is established or installed. Under the terms of the CO, Chemours must make the offer to install a water treatment system to property owners in writing multiple times, and property owners have approximately one year to accept the Company’s offer before it expires. In September 2021, the Company entered into an agreement with Bladen County, North Carolina to fund public water system upgrades and connections associated with providing permanent replacement drinking water supplies under the CO.

Further, in addition to the surrounding counties, in November 2021, NC DEQ sent a notice to Chemours regarding PFAS contamination from the Cape Fear River of groundwater monitoring wells and water supply wells in New Hanover County and potentially three other downstream counties based on ~~existing~~new sampling data by NC DEQ and its determination of Chemours’ obligations for such contamination. NC DEQ directed Chemours to submit for its review and approval a comprehensive groundwater contamination assessment in such counties, as well as an updated drinking water program to provide for sampling under the CO in such counties. In response, in February 2022, the Company submitted an interim drinking water plan and a separate assessment framework plan, which were subsequently updated and resubmitted in August 2022, based on comments received from NC DEQ. On January 30, 2023, NC DEQ provided additional comments to the August 2022 submittal identifying additional actions regarding the groundwater assessment as well as the drinking water program, which the Company responded to on March 16, 2023.

In June 2022, following EPA’s release of a final drinking water health advisory for GenX compounds, including HFPO Dimer Acid, by EPA, NC DEQ sent a notice to Chemours requiring the Company to revise its drinking water compliance plan and feasibility study report, and to provide public water or whole building filtration systems to eligible properties with a private drinking water well that have tested above 10 ppt for GenX compounds under Paragraph 19 of the CO.

In July 2022, Chemours submitted its response to NC DEQ, providing information and other items requested by NC DEQ for its approval. Notwithstanding the Petition for Review of the EPA GenX compounds health advisory, and reserving its rights related thereto, the Company proposed a plan to extend Paragraph 19 options to properties that have tested above 10 ppt for GenX compounds, including conducting a feasibility review. As a result of Chemours’ proposed plan in response to the NC DEQ notice, the Company recorded approximately $108 in selling, general, and administrative expense, reflecting a change in estimate for the estimated qualifying properties previously qualified for under-sink RO units that may now be eligible for public water or a whole building filtration system resulting from the lower health advisory for GenX of 10ppt.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

The Company’s estimated liability for off-site replacement drinking water supplies is based on management’s assessment of the current facts and circumstances ~~management does~~for this matter, including comments received from NC DEQ, which are subject to various assumptions that include, but are not ~~believe that~~limited to, the number of affected surrounding properties, response rates to the Company’s offer, the timing of expiration of offers made to the property owners, the type of water treatment systems selected (i.e., public water, whole building filtration, or RO units), the cost of the selected water treatment systems, and any ~~loss,~~related OM&M requirements, fines and penalties, and other charges contemplated by the CO. For off-site drinking water supplies, OM&M is accrued for 20 years on an undiscounted basis based on the Company’s current plans under the CO.

At September 30, 2023 and December 31, 2022, the Company had $151 and $163 of accrued liabilities, respectively, for off-site groundwater testing and water treatment system installations at qualifying third-party properties primarily in ~~excess~~Bladen and Cumberland counties surrounding Fayetteville, which is expected to be disbursed over approximately 20 years. In addition, as of ~~amounts~~September 30, 2023 and December 31, 2022, the Company had $29 and $38, respectively, of accrued liabilities for the assessment and for sampling related to ~~remediation activities~~potential PFAS contamination of groundwater and supply of alternative drinking water in New Hanover and three other downstream counties. Off-site installation, maintenance, and monitoring cost estimates are based on management’s assessment of the current facts and circumstances for these matters, including comments received from NC DEQ, and could change as actual experience may differ from management's estimates or new information may become available.

The estimated liability was based on certain assumptions, which management believes are reasonable under the circumstances and include, but are not limited to, implementation of the soil and groundwater assessment, the source and cause of PFAS contamination for the four downstream counties, the estimated number of properties at ~~any individual site~~which sampling is conducted and whether such property will qualify for an alternative drinking water supply, other potentially responsible parties and the method of long-term alternative water supply, if any. Further, management’s estimate of the ultimate liability for this matter is dependent upon NC DEQ approval of the proposed plans in response to various NC DEQ letters, obtaining additional information, implementation of EPA’s health advisories, additional feasibility and investigation work that has not yet been scoped or performed, and the estimated additional future cost of OM&M. The ultimate resolution of the matters could have a material ~~impact~~adverse effect on the Company’s financial position, results of operations orand cash ~~flows in any given year, as such obligation can be satisfied or settled over many years.~~flow.

~~Note 14. Financial Instruments~~

~~Derivative Instruments~~On-site surface water and groundwater remediation

~~Foreign Currency Forward Contracts~~

Abatement and remediation measures already taken by Chemours, ~~uses foreign currency forward contracts~~including the capture and disposal of its operations’ process wastewater and other interim actions, have addressed and abated nearly all PFAS discharges from the Company’s continuing operations at Fayetteville. However, the Company continues to have active dialogue with NC DEQ and other stakeholders regarding the potential incremental remedies that are both economically and technologically feasible to achieve the CO and Addendum objectives related to the impact of site surface water and groundwater contamination from historical operations, during and subsequent to the optimization period of the groundwater treatment system and following installation of the barrier wall.

In 2019, the Company completed and submitted its Cape Fear River PFAS Loading Reduction Plan - Supplemental Information Report and its CAP to NC DEQ. The Supplemental Information Report provided information to support the evaluation of potential interim remedial options to reduce PFAS loadings to surface waters. The CAP described potential long-term remediation activities to address PFAS in groundwater and surface waters at the site, in accordance with the requirements of the CO and the North Carolina groundwater standards, and built upon the previous submissions to NC DEQ. The NC DEQ received comments on the CAP during a public comment period, and the Company is awaiting formal response to the CAP from NC DEQ. With respect to the CO, the Addendum was approved by the North Carolina Superior Court for Bladen County in October 2020 and establishes the procedure to implement specified remedial measures for reducing PFAS loadings from Fayetteville to the Cape Fear River, including construction of a barrier wall with a groundwater extraction system to be completed by March 15, 2023, or the extended date consistent with the CO and Addendum, as noted by the NC DEQ in its ~~net exposure,~~letter dated March 2, 2023 (discussed further below).

The Company began operation of a capture and treatment system from the site’s old outfall channel following the issuance of a National Pollutant Discharge Elimination System ("NPDES") permit by ~~currency,~~NC DEQ in September 2020. In January 2021, the operation of the old outfall treatment system was interrupted on two occasions, and notice was provided to NC DEQ of the low treatment flow conditions through the system. The Company received an NOV from NC DEQ, alleging violations of the CO and the NPDES water permit arising from the design and operation of the treatment system related to ~~non-functional currency-denominated monetary assets~~the old outfall. The Company and ~~liabilities~~its third-party service provider have taken, and continue to take, interim actions intended to improve the operation of the old outfall treatment system and address challenges posed by substantial rain events, sediment loading into the system, and variability in water influent conditions. In addition, the Company and its ~~operations so that exchange gains and losses resulting~~third-party service provider are actively working on long-term enhancements to the treatment system based on learnings from ~~exchange rate changes are minimized. These derivative instruments are not part~~the recent challenges. System enhancements completed or being implemented consist of a ~~cash flow hedge program or a fair value hedge program,~~holding pond, installation of new ultra-filtration units and ~~have not been designated as a hedge. Although all~~additional water pretreatment equipment which is anticipated to be completed by the end of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis on its consolidated balance sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the consolidated statements of operations during the period in which they occurred.2023.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

In 2021, work commenced on the detailed engineering design of the barrier wall and refinement of models for the planned groundwater extraction system. Engineering designs for the Company’s major construction projects are typically reviewed at 30%, 60% and 90% complete. Chemours submitted the design reports for the 90% stage in March 2022 and received final approval of the 90% design from NC DEQ in October 2022. In June 2023, the Company completed the construction of the barrier wall and the groundwater extraction and treatment system in accordance with the requirements under the CO, subject to its terms and receipt of final quality assurance samples and engineer certification. Under the Addendum specific penalties of $0.15 plus an additional $0.02 per week if the company did not achieve project completion as provided therein. As construction is complete, payment of financial penalties is deemed remote.

In September 2022, NC DEQ issued a permit for discharge of treated groundwater and surface water associated with the project. The permit contained conditions and limits that exceeded the requirements contained within the CO and the previously public-noticed draft discharge permit. The Company filed an administrative petition contesting the discharge permit on October 14, 2022. On November 14, 2022, the Company reached an agreement with NC DEQ and the Cape Fear Public Utility Authority with respect to the discharge permit that, inter alia, facilitated the construction of the barrier wall and groundwater extraction and treatment system and recognizes an optimization period after commencement of discharge from the system. Chemours has since dismissed its petition without prejudice pursuant to the agreement.

Based on the CO, the Addendum, the CAP, and management’s plans, which are based on current regulations and technology, the Company has accrued $219 and $264 at September 30, 2023 and December 31, 2022, respectively, related to the estimated cost of on-site remediation, based on the range of potential outcomes on current potential remedial options, and the projected amounts to be paid over a period of approximately 20 years. The final costs of any selected remediation will depend primarily on performance during the optimization period, permit compliance requirements, and ongoing dialogue with NC DEQ and other stakeholders regarding the potential incremental remedies that are both economically and technologically feasible to achieve the CO and Addendum objectives, and estimated future cost and time period of OM&M. Further, the final cost of the on-site groundwater treatment system depends on water treatment requirements and estimated carbon usage and achieving the successful optimization of the system during the period stated in the permit. As such, cost estimates could change as actual experience may differ from management's estimates. Changes in estimates are recorded in results of operations in the period that the events and circumstances giving rise to such changes occur.

The Company’s estimated liability for the remediation activities that are probable and estimable is based on the CO, the Addendum, the CAP, and management’s assessment of the current facts and circumstances, which is subject to various assumptions including the transport pathways (being pathways by which PFAS reaches the Cape Fear River) that will require remedial actions, the types of interim and permanent site surface water and on-site remedies and treatment systems selected and implemented, the estimated cost of such potential remedies and treatment systems, any related OM&M requirements, and other charges contemplated by the CO and the Addendum.

The Company accrued 20 years of OM&M for Fayetteville environmental remediation systems based on the CO and Addendum, which includes estimated higher power consumption, ongoing monitoring, pretreatment, filtering supplies (principally carbon) and regular maintenance of the system over a 20-year period of estimated operation starting in 2023.

It is possible that issues relating to site discharges in various transport pathways, the selection of remediation alternatives to achieve PFAS loading reductions, or the operating effectiveness of the TO could result in further litigation and/or regulatory demands with regards to Fayetteville, including potential permit modifications or penalties under the CO and the Addendum. It is also possible that, as additional data is collected on the transport pathways and dialogue continues with NC DEQ and other stakeholders, the type or extent of remediation actions required to achieve the objectives committed to in the CO may change (increase or decrease) or remediation activities could be delayed. If such issues arise, or if the CO is further amended, an additional loss is reasonably possible, but not estimable at this time.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Litigation and Other matters related to Fayetteville

In February 2019, the Company received an NOV from EPA, alleging certain TSCA violations at Fayetteville. Matters raised in the NOV could have the potential to affect operations at Fayetteville. For this NOV, the Company responded to EPA in March 2019, asserting that the Company has not violated environmental laws. The Company also received an NOV in April 2020 from NC DEQ, alleging an air permit violation under the North Carolina Administrative Code. As of September 30, 2023, management does not believe that a loss is probable.

Civil actions have been filed against EID and Chemours in North Carolina courts relating to discharges from Fayetteville. These actions include a consolidated action brought by public water suppliers seeking damages and injunctive relief, a consolidated purported class action seeking medical monitoring, and property damage and/or other monetary and injunctive relief on behalf of the putative classes of property owners and residents in areas near or that draw drinking water from the Cape Fear River, and two actions encompassing approximately 2,300 private well owners seeking compensatory and punitive damages. Ruling on the Company’s motions in April 2019, the court dismissed the medical monitoring, injunctive demand, and many other alleged causes of actions in these lawsuits. In October 2023, the court certified the property damages class action. In March 2023, one of the public water suppliers brought a complaint in Delaware Chancery Court against EID, Chemours, Corteva and DuPont alleging voidable transfer and other claims arising from the Chemours separation and DowDuPont merger and subsequent restructurings, asset transfers and separations.

In addition to natural resource damages matter filed by the State of North Carolina (as discussed within the “PFAS” section of this “Note 17 – Commitments and Contingent Liabilities”), in September 2020, three additional lawsuits were filed in North Carolina state court against Chemours and EID, as well as other defendants. One of the lawsuits is a putative class action on behalf of residents who are served by the Cape Fear Public Water utility, alleges negligence, nuisance, and other claims related to the release of perfluorinated compounds from Fayetteville, and seeks compensatory and punitive damages and medical monitoring. The other two lawsuits were filed on behalf of individuals residing near Fayetteville and allege negligence, nuisance, and other claims related to the release of perfluorinated compounds. The individuals seek compensatory property damages, punitive damages, and, in some cases, medical monitoring. All three lawsuits allege fraudulent transfer against EID and other EID entities, but not against Chemours. In October 2020, the cases were removed to federal court and then the two lawsuits filed on behalf of individuals were remanded back to state court.

In March 2022, a lawsuit was filed on behalf of an individual residing near the Fayetteville site against Chemours, EID and other defendants alleging negligence, nuisance and other claims related to the discharges from the Fayetteville site. The individual seeks compensatory property damages, punitive damages and medical monitoring. The lawsuit also alleges fraudulent transfer against EID and other EID entities, but not against Chemours.

Also, in March 2022, Cumberland County, North Carolina filed suit in state court against Chemours, EID and other defendants related to discharges from the Fayetteville site alleging negligence, nuisance, trespass and fraudulent transfer. The lawsuit seeks damages as well as injunctive and equitable relief.

In December 2022, Aqua North Carolina, Inc. filed suit in North Carolina state court alleging EID, DuPont, DowDuPont, Inc and the Company are responsible for polyfluorinated chemical contamination of the Cape Fear River, groundwater and other water sources used by Aqua North Carolina across the state to serve its water customers. The complaint alleges product liability, negligence, trespass, deceptive trade practices, unjust enrichment and fraudulent transfer. Plaintiff seeks equitable relief as well as compensatory and punitive damages. In February 2023, the matter was removed to federal court.

As of October 2023, two lawsuits were filed in the Eastern District of North Carolina on behalf of individuals residing near Fayetteville against Chemours, EID, Corteva and DuPont alleging personal injury and property diminution related to the discharges from Fayetteville. The individuals seek compensatory and punitive damages. The lawsuits also allege fraudulent transfer against the defendants.

It is possible that additional litigation may be filed against the Company and/or EID concerning the Fayetteville discharges. It is not possible at this point to predict the timing, course, or outcome of all governmental and regulatory inquiries and notices and litigation related to Fayetteville, and it is reasonably possible that these matters could have a material adverse effect on the Company’s financial position, results of operations, and cash flows. In addition, local communities, organizations, and federal and state regulatory agencies have raised questions concerning HFPO Dimer Acid and other perfluorinated and polyfluorinated compounds at certain other manufacturing sites operated by the Company. It is possible that additional developments similar to those described above and centering on Fayetteville could arise in other locations.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Other

In addition, in the ordinary course of business, the Company may make certain commitments, including representations, warranties, and indemnities relating to current and past operations, including environmental remediation and other potential costs related to divested assets and businesses, and issue guarantees of third-party obligations. The Company accrues for these matters when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. In connection with the sale of the Mining Solutions business, the Company provided a limited indemnification with respect to environmental liabilities that may arise from activities prior to the closing date. Such indemnification would not exceed approximately $78 and will expire on December 1, 2026. No liabilities have been recorded at September 30, 2023 and December 31, 2022 with respect to this indemnification.

Note 18. Equity

2018 Share Repurchase Program

The following table sets forth the Company’s share repurchase activity under the 2018 Share Repurchase Program for the three and nine months ended September 30, 2023 and 2022, respectively.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Total number of shares purchased		—		—		—		7,824,039
Total amount for shares purchased	$	—	$	—	$	—	$	251
Average price paid per share	$	—	$	—	$	—	$	32.06

On May 19, 2022, the Company completed the aggregate $1,000 in authorized purchases of Chemours' issued and outstanding common stock under the 2018 Share Repurchase Program, which amounted to a cumulative 28,603,784 shares purchased at an average share price of $34.96 per share.

2022 Share Repurchase Program

On April 27, 2022, the Company’s board of directors approved a share repurchase program authorizing the purchase of shares of Chemours’ issued and outstanding common stock in an aggregate amount not to exceed $750, plus any associated fees or costs in connection with the Company’s share repurchase activity (the “2022 Share Repurchase Program”). Under the 2022 Share Repurchase Program, shares of Chemours’ common stock can be purchased in the open market from time to time, subject to management’s discretion, as well as general business and market conditions. The Company’s 2022 Share Repurchase Program became effective on April 27, 2022 and is scheduled to continue through the earlier of its expiration on December 31, 2025 or the completion of repurchases up to the approved amount. The program may be suspended or discontinued at any time. All common shares purchased under the 2022 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method.

The following table sets forth the Company’s share repurchase activity under the 2022 Share Repurchase Program for the three and nine months ended September 30, 2023 and 2022, respectively.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Total number of shares purchased		450,667		2,910,688		2,108,408		3,462,181
Total amount for shares purchased	$	17	$	87	$	69	$	106
Average price paid per share	$	37.60	$	29.69	$	32.48	$	30.56

Through September 30, 2023, the Company purchased a cumulative 10,342,722 shares of Chemours’ issued and outstanding common stock under the 2022 Share Repurchase Program, which amounted $309 at an average share price of $29.90 per share. The aggregate amount of Chemours’ common stock that remained available for purchase under the 2022 Share Repurchase Program at September 30, 2023 was $441.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Note 19. Stock-based Compensation

The Company’s total stock-based compensation expense amounted to $6 and $13 for the three and nine months ended September 30, 2023, respectively, and $7 and $24 for the three and nine months ended September 30, 2022, respectively.

Stock Options

During the nine months ended September 30, 2023, Chemours granted approximately 560,000 non-qualified stock options to certain of its employees. These awards will vest over a three-year period and expire 10 years from the date of grant. The fair value of the Company’s stock options is based on the Black-Scholes valuation model.

The following table sets forth the assumptions used at the grant date to determine the fair value of the Company’s stock option awards granted during the nine months ended September 30, 2023.


	Nine Months Ended September 30, 2023
Risk-free interest rate		4.18	%
Expected term (years)		6.00
Volatility		55.63	%
Dividend yield		2.87	%
Fair value per stock option	$	15.36

The Company recorded $2 and $6 in stock-based compensation expense specific to its stock options for both the three and nine months ended September 30, 2023 and 2022, respectively. At September 30, ~~2017, there were 26~~2023, approximately 3,696,000 stock options remained outstanding.

Restricted Stock Units

During the nine months ended September 30, 2023, Chemours granted approximately 443,000 restricted stock units (“RSUs”) to certain management and employees. These awards generally vest over a three-year period and, upon vesting, convert one-for-one to Chemours’ common stock. The fair value of all stock-settled RSUs is based on the market price of the underlying common stock at the grant date.

The Company recorded $4 and $6 in stock-based compensation expense specific to its RSUs for the three and nine months ended September 30, 2023, respectively, and $3 and $9 for the three and nine months ended September 30, 2022, respectively. At September 30, 2023, approximately 1,197,000 RSUs remained non-vested.

Performance Share Units

On March 1, 2023, Chemours granted approximately 103,000 performance share units (“PSUs”) to key senior management employees. Upon vesting, these awards convert one-for-one to Chemours’ common stock if specified performance goals, including certain market-based conditions, are met over the three-year performance period specified in the grant, subject to exceptions through the vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount depending on the Company’s performance against stated performance goals.

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using a Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based conditions are satisfied.

The Company recorded less than $1 in stock-based compensation expense specific to its PSUs for both the three and nine months ended September 30, 2023, and $2 and $9 for the three and nine months ended September 30, 2022, respectively, based on its assessment of Company performance relative to award-based financial objectives. At September 30, 2023, approximately 394,000 PSUs at 100% of the target amount remained non-vested.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Performance Stock Options

On March 1, 2023, the Company granted approximately 240,000 performance stock options (“PSOs”) to certain of its key senior management employees. These awards have a strike price that is 10% above the closing stock value on the grant date and become exercisable when vested and this market condition is satisfied. These awards will vest over a three-year period and expire 10 years from the date of grant. The fair value of the Company's PSOs was estimated using a Monte Carlo valuation method.

The following table sets forth the assumptions used at the grant date to determine the fair value of the Company’s performance stock option awards granted during the nine months ended September 30, 2023.


	Nine Months Ended September 30, 2023
Risk-free interest rate		4.13	%
Expected term (years)		7.00
Volatility		56.32	%
Dividend yield		2.87	%
Fair value per performance stock option (1)	$	14.97

(1)

Represents the weighted-average fair value at each point of projected exercise under the Monte Carlo valuation method.

The Company recorded less than $1 and $1 in stock-based compensation expense specific to its PSOs for the three and nine months ended September 30, 2023, respectively. At September 30, 2023, approximately 175,000 PSOs remained non-vested.

Note 20. Accumulated Other Comprehensive Loss

The following table sets forth the changes and after-tax balances of the Company’s accumulated other comprehensive loss for the nine months ended September 30, 2023 and 2022.


	Net Investment Hedge			Cash Flow Hedge			Cumulative Translation Adjustment			Defined Benefit Plans			Total
Balance at January 1, 2023	$	19		$	6		$	(268	)	$	(100	)	$	(343	)
Other comprehensive income (loss)		10			(4	)		9			13			28
Balance at September 30, 2023	$	29		$	2		$	(259	)	$	(87	)	$	(315	)

Balance at January 1, 2022	$	(21	)	$	5		$	(236	)	$	(112	)	$	(364	)
Other comprehensive income (loss)		106			22			(216	)		19			(69	)
Balance at September 30, 2022	$	85		$	27		$	(452	)	$	(93	)	$	(433	)

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Note 21. Financial Instruments

Objectives and Strategies for Holding Financial Instruments

In the ordinary course of business, Chemours enters into contractual arrangements to reduce its exposure to foreign currency risks. The Company has established a financial risk management program, which includes distinct risk management instruments: (i) foreign currency forward contracts, which are used to minimize the volatility in the Company’s earnings related to foreign exchange gains and losses resulting from remeasuring its monetary assets and liabilities that are denominated in non-functional currencies; (ii) foreign currency forward contracts, which are used to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of the Company’s international subsidiaries that use the euro as their functional currency; (iii) interest rate swaps, which are used to mitigate the volatility in the Company’s cash payments for interest due to fluctuations in variable interest rates, as is applicable to the portion of the Company’s senior secured term loan facility denominated in U.S. dollars; and, (iv) euro-denominated debt, which is used to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar for certain of its international subsidiaries that use the euro as their functional currency. The Company’s financial risk management program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The program operates within Chemours’ financial risk management policies and guidelines, and the Company does not enter into derivative financial instruments for trading or speculative purposes.

Net Monetary Assets and Liabilities Hedge – Foreign Currency Forward Contracts

At September 30, 2023, the Company had 11 foreign currency forward contracts outstanding with an aggregate gross notional ~~value~~U.S. dollar equivalent of ~~$619.~~$268, and an average maturity of one month. At December 31, 2022, the Company had 9 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of $180, and an average maturity of one month. Chemours recognized ~~in other income,~~ net losses of ~~the consolidated statements of operations, a net loss of $1~~$1 and ~~a net gain of $6~~$8 for the three and nine months ended September 30, ~~2017,~~2023, respectively, and net ~~losses~~gains of $2$3 for both the three and nine months ended September 30, 2022, respectively, in other income (expense), net.

Cash Flow Hedge – Foreign Currency Forward Contracts

At September 30, 2023, the Company had 157 foreign currency forward contracts outstanding under its cash flow hedge program with an aggregate notional U.S. dollar equivalent of $193, and an average maturity of five months. At December 31, 2022, the Company had 153 foreign currency forward contracts outstanding under its cash flow hedge program with an aggregate notional U.S. dollar equivalent of $180, and an average maturity of four months. Chemours recognized pre-tax gains of $7 and $5 for the three and nine months ended September 30, ~~2016.~~

~~Net Investment Hedge - Foreign Currency Borrowings~~

~~Chemours designated its Euro Notes~~2023, respectively, and ~~beginning in April 2017, also designated its new Euro Term Loan as a hedge~~pre-tax gains of its net investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the Euro with respect to the U.S. Dollar. Chemours uses the spot method to measure the effectiveness of its net investment hedge. For each reporting period, the change in the carrying value of the Euro Notes$18 and the Euro Term Loan due to remeasurement of the effective portion are reported in accumulated other comprehensive loss on the consolidated balance sheets, and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income, net in the consolidated statements of operations. Chemours evaluates the effectiveness of its net investment hedge quarterly. Chemours did not record any ineffectiveness$30 for the three and nine months ended September 30, ~~2017 or 2016.~~ 2022, respectively, within accumulated other comprehensive loss. For the three and nine months ended September 30, 2023, $1 of loss and $5 of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively. For the three and nine months ended September 30, 2022, $5 and $11 of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively.

The Company expects to reclassify approximately $3 of net pre-tax gain, based on current foreign currency exchange rates, from accumulated other comprehensive loss to the cost of goods sold over the next 12 months.

Cash Flow Hedge – Interest Rate Swaps

In September 2022, the Company terminated all of its outstanding interest rate swaps, which resulted in a cash settlement of $8. Chemours recognized a pre-tax ~~losses~~gains of ~~$26~~$2 and ~~$76 on its net investment hedges~~$8 for the three and nine months ended September 30, ~~2017,~~2022, respectively, within accumulated other comprehensive loss. For the three and nine months ended September 30, 2023, $0 and $4 of gain were reclassified to interest expense, net from accumulated other comprehensive loss, respectively. For the three and nine months ended September 30, 2022, $2 of gain was reclassified to interest expense, net from accumulated other comprehensive loss, respectively.

Net Investment Hedge – Foreign Currency Borrowings

The Company recognized pre-tax ~~losses~~gains of $6$35 and ~~$9 on its net investment hedges~~$13 for the three and nine months ended September 30, ~~2016, respectively.~~2023, respectively, and pre-tax gains of $81 and $139 for the three and nine months ended September 30, 2022, respectively, on its net investment hedge within accumulated other comprehensive loss. No amounts were reclassified from accumulated other comprehensive loss for the Company’s net investment hedges during the three and nine months ended September 30, 2023 and 2022.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Fair Value of Derivative Instruments

The following table ~~below presents~~sets forth the fair value of ~~Chemours’~~the Company’s derivative assets and liabilities ~~within the fair value hierarchy:~~at September 30, 2023 and December 31, 2022.


		Fair Value Using Level 2 Inputs					Fair Value Using Level 2 Inputs
	Balance Sheet Location	September 30, 2017		December 31, 2016		Balance Sheet Location	September 30, 2023		December 31, 2022
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	3	$	2
Foreign currency forward contracts not designated as a hedging instrument						Accounts and notes receivable, net (Note 8)	$	1	$	—
Foreign currency forward contracts designated as a cash flow hedge						Accounts and notes receivable, net (Note 8)		6		2
Total asset derivatives		$	3	$	2		$	7	$	2

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	4	$	4
Foreign currency forward contracts not designated as a hedging instrument						Other accrued liabilities (Note 14)	$	1	$	1
Foreign currency forward contracts designated as a cash flow hedge						Other accrued liabilities (Note 14)		—		4
Total liability derivatives		$	4	$	4		$	1	$	5

The Company’s foreign currency forward contracts are classified as Level 2 financial instruments within the fair value hierarchy as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data, and are subjected to ~~tolerance/~~tolerance and/or quality checks.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Summary of Financial Instruments

The following table sets forth the pre-tax changes in fair value of the Company’s financial instruments for the three and nine months ended September 30, 2023 and 2022.


	Gain (Loss) Recognized In
									Accumulated
									Other
	Cost of			Interest		Other Income			Comprehensive
Three Months Ended September 30,	Goods Sold			Expense, Net		(Expense), Net			Loss
2023
Foreign currency forward contracts not designated as a hedging instrument	$	—		$	—	$	(1	)	$	—
Foreign currency forward contracts designated as a cash flow hedge		(1	)		—		—			7
Euro-denominated debt designated as a net investment hedge		—			—		—			35

2022
Foreign currency forward contracts not designated as a hedging instrument	$	—		$	—	$	3		$	—
Foreign currency forward contracts designated as a cash flow hedge		5			—		—			18
Interest rate swaps designated as a cash flow hedge		—			2		—			2
Euro-denominated debt designated as a net investment hedge		—			—		—			81




	Gain (Loss) Recognized In
									Accumulated
									Other
	Cost of			Interest		Other Income			Comprehensive
Nine Months Ended September 30,	Goods Sold			Expense, Net		(Expense), Net			Loss
2023
Foreign currency forward contracts not designated as a hedging instrument	$	—		$	—	$	(8	)	$	—
Foreign currency forward contracts designated as a cash flow hedge		5			—		—			5
Interest rate swaps designated as a cash flow hedge		—			4		—			—
Euro-denominated debt designated as a net investment hedge		—			—		—			13

2022
Foreign currency forward contracts not designated as a hedging instrument	$	—		$	—	$	3		$	—
Foreign currency forward contracts designated as a cash flow hedge		11			—		—			30
Interest rate swaps designated as a cash flow hedge		—			2		—			8
Euro-denominated debt designated as a net investment hedge		—			—		—			139

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Note ~~15.~~22. Long-term Employee Benefits

Chemours sponsors defined benefit pension plans for certain of its employees in various jurisdictions outside of the U.S. The Company’s net periodic pension (cost) income is based on estimated values and ~~an extensive~~the use of assumptions about the discount rate, expected return on plan assets, and the rate of future compensation increases received by its employees.

The following table sets forth the ~~Company's employees.~~

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

~~The components of~~Company’s net periodic pension cost and amounts recognized in other comprehensive income (loss) for ~~all significant pension plans were as follows:~~the three and nine months ended September 30, 2023 and 2022.

Three Months Ended September 30,

Nine Months Ended September 30,

2017

2016

2017

2016

Net periodic pension cost (income):

Service cost

$
4

$
3

$
11

$
10

Interest cost

4

5

11

15

Expected return on plan assets

(18
)

(16
)

(52
)

(49
)
Amortization of actuarial loss

5

9

15

20

Amortization of prior service gain

(1
)

—

(1
)

(1
)
Curtailment gain

—

—

—

(2
)
Settlement loss

1

—

1

—

Net periodic pension (income) cost

$
(5
)

$
1

$
(15
)

$
(7
)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Service cost	$	(2	)	$	(3	)	$	(7	)	$	(10	)
Interest cost		(4	)		(1	)		(11	)		(5	)
Expected return on plan assets		5			4			15			14
Amortization of actuarial loss		(3	)		(2	)		(7	)		(6	)
Amortization of prior service gain		1			—			2			1
Total net periodic pension cost	$	(3	)	$	(2	)	$	(8	)	$	(6	)

Net loss	$	(1	)	$	—		$	(1	)	$	—
Amortization of actuarial loss		3			2			7			6
Amortization of prior service gain		(1	)		—			(2	)		(1	)
Curtailment gain		10			—			10			—
Effect of foreign exchange rates		4			9			2			16
Benefit recognized in other comprehensive income		15			11			16			21
Total changes in plan assets and benefit obligations recognized in other comprehensive income	$	12		$	9		$	8		$	15

The Company made cash contributions of $4$2 and ~~$14~~$9 to its defined benefit pension plans during the three and nine months ended September 30, ~~2017~~2023 and 2022, respectively. The Company expects to make additional cash contributions of ~~$11~~$2 to its defined benefit pension plans during the ~~fourth~~remainder of 2023.

During the third quarter of ~~2017. Of these remaining contributions, $10 relates~~2023, the Company announced the closure of its manufacturing site in Kuan Yin, Taiwan, which will result in employment termination of substantially all of the employees based in Kuan Yin by the second quarter of 2024. The employee terminations related to the ~~settlement~~shutdown meets the definition of a plan curtailment event by eliminating the additional accrual of defined benefits for impacted employees. As a result of the ~~U.S. Pension Restoration Plan (U.S. PRP),~~curtailment, the Company remeasured its Taiwan projected pension obligation and recorded a $1 mark-to-market loss on remeasurement of the pension liability as a result of a decrease in discount rates since December 31, 2022, and recorded a curtailment gain of $10 which was ~~a supplemental pension plan for certain U.S. employees. The liability associated with the U.S PRP was transferred~~recognized in accumulated other comprehensive income and will be amortized to Chemours from DuPont at the date of separation, at which point the plan ceased accepting new participants. In October 2017, the Company made a cash payment of $10 to settle the remaining liability attributable to the remaining participants in the U.S. PRP.

~~Note 16. Stock-based Compensation~~

~~Total stock-based compensation cost included in~~ the consolidated statements of operations ~~was $6~~as the impacted employees are terminated from the plan.

Note 23. Supplemental Cash Flow Information

The following table provides a reconciliation of cash and $21 for the three and nine months ended September 30, 2017, respectively, and $6 and $17 for the three and nine months ended September 30, 2016, respectively. The income tax provision for the three and nine months ended September 30, 2017 is inclusive of $5 and $18 in income tax benefit from windfallscash equivalents, as reported on ~~share-based payments, respectively, due to~~ the Company’s ~~adoption of ASU No. 2016-09 during 2017.~~

~~The Chemours Company 2017 Equity~~consolidated balance sheets, to cash, cash equivalents, restricted cash and Incentive Plan (2017 Plan) and The Chemours Company Equity and Incentive Plan (Prior Plan) provide for grants to certain employees, independent contractors or non-employee directors of the Company of different forms of awards, including stock options, RSUs and performance share units (PSUs). On April 26, 2017, Chemours’ stockholders approved the 2017 Plan. As a result, no further grants will be made under the Prior Plan, which provided for DuPont equity awards that converted into new Chemours equity awards at the separation date and had a maximum shares reserve of 13,500,000 for the grant of equity awards.

~~A total of 19,000,000 shares of~~restricted cash equivalents, as reported on the Company’s common stock may be subject to awards granted under the 2017 Plan, less one share for every one share that was subject to an option or stock appreciation right granted after December 31, 2016 under the Prior Plan, and one-and-a-half shares for every one share that was subject to an award other than an option or stock appreciation right granted after December 31, 2016 under the Prior Plan. Any shares that are subject to options or stock appreciation rights will be counted against this limit as one share for every one share granted, and any shares that are subject to awards other than options or stock appreciation rights will be counted against this limit as one-and-a-half shares for every one share granted. Awards that were outstanding under the Prior Plan remain outstanding under the Prior Plan in accordance with their terms. Shares underlying awards granted under the Prior Plan after December 31, 2016 that are forfeited, cancelled or that otherwise do not result in the issuanceconsolidated statements of ~~shares, will be available for issuance under the 2017 Plan.~~ cash flows.


	September 30, 2023		December 31, 2022
Cash and cash equivalents	$	852	$	1,102
Restricted cash and restricted cash equivalents (1)		595		202
Cash, cash equivalents, restricted cash and restricted cash equivalents	$	1,447	$	1,304

(1)

At September 30, ~~2017, 17,650,034 shares~~2023, the restricted cash and restricted cash equivalents balance includes cash and cash equivalents deposited in the Water District Settlement Fund related to the U.S. Public Water System Class Action Suit Settlement and is classified as a current asset. At December 31, 2022, restricted cash and restricted cash equivalents includes cash and cash equivalents deposited in an escrow account as per the terms of ~~equity~~the MOU and ~~incentive plan reserve are available~~was classified as a noncurrent asset. See "Note 2 - Summary of Significant Accounting Policies" and "Note 17 - Commitments and Contingent Liabilities" for ~~grants under the 2017 Plan.~~further details.

~~The Chemours Compensation Committee determines the long-term incentive mix, including stock options, RSUs and PSUs, and may authorize new grants annually.~~

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

~~Stock Options~~Note 24. Segment Information

Chemours ~~granted non-qualified options to certain of~~operates through its ~~employees,~~three reportable segments, which ~~will serially vest over a three-year period and expire 10 years from the date of grant. The expense related to stock options granted in the nine months ended September 30, 2017 was~~were organized based on ~~the weighted-average assumptions shown in the table below:~~

Nine Months Ended September 30, 2017

Risk-free interest rate

2.14
%
Expected term (years)

6.00

Volatility

44.49
%
Dividend yield

0.35
%
Fair value per stock option

$
15.21

The Company determined the dividend yield by dividing the expected annual dividend on the Company's stock by the option exercise price. A historical daily measurement of volatility is determined based on the average volatility of peer companies adjusted for the Company’s debt leverage. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. Expected life is determined using a simplified approach, calculated as the midpoint between the graded vesting period and the contractual life of the award.

~~The following table summarizes Chemours’ stock option activity for the nine months ended September 30, 2017:~~

Number of
Shares
(in thousands)

Weighted-Average Exercise Price
(per share)

Weighted-Average
Remaining Contractual Term (years)

Aggregate
Intrinsic Value
(in thousands)

Outstanding, December 31, 2016

7,969

$
13.72

5.08

$
66,668

Granted

878

34.84

Exercised

(1,987
)

14.41

Forfeited

(40
)

19.10

Expired

(28
)

12.00

Outstanding, September 30, 2017

6,792

$
15.69

5.27

$
237,179

Exercisable, September 30, 2017

3,814

$
14.03

3.63

$
139,523

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day at the end of the quarter and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at quarter-end. The amount changes based on the fair market value of the Company’s stock. The total intrinsic value of options exercised for the nine months ended September 30, 2017 was $42. The total intrinsic value of options exercised for the nine months ended September 30, 2016 was insignificant.

~~At September 30, 2017, $8 of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted-average period of 2.18 years.~~

~~RSUs~~

Chemours granted RSUs to key management employees that generally vest over a three-year period and, upon vesting, convert one-for-one to Chemours’ common stock. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date.

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

Non-vested awards of RSUs primarily include awards without a performance condition, as well as a small subset of awards for which specific levels of cost savings and revenue enhancements must be achieved for vesting to occur. Non-vested awards, both with and without a performance condition, at September 30, 2017 are shown below:

Number of Shares
(in thousands)

Weighted-Average
Grant Date
Fair Value
(per share)

Non-vested, December 31, 2016

2,316

$
11.23

Granted

211

36.42

Vested

(1,275
)

11.09

Forfeited

(39
)

15.10

Non-vested, September 30, 2017

1,213

$
15.46

~~At September 30, 2017, there was $7 of unrecognized stock-based compensation expense related to non-vested awards, which is expected to be recognized over a weighted-average period of 0.78 years.~~

~~PSUs~~

Chemours issued PSUs to key senior management employees which, upon vesting, convert one-for-one to Chemours’ common stock if specified performance goals, including certain market-based conditions, are met over the three-year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount depending on the Company’s performance against stated performance goals. The Company recorded stock-based compensation related to PSUs as a component of selling, general and administrative expense of approximately $2 and $5 for the three and nine months ended September 30, 2017, respectively, and less than $1 and $1 for the three and nine months ended September 30, 2016, respectively.

~~The following table provides compensation costs for stock-based compensation related to PSUs at 100% of target amounts:~~

Number of Shares
(in thousands)

Weighted-Average
Grant Date
Fair Value
(per share)

Non-vested, December 31, 2016

803

$
6.10

Granted

211

40.30

Vested

—

—

Forfeited

(27
)

16.62

Non-vested, September 30, 2017

987

$
12.94

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based condition is satisfied. The per unit weighted-average fair value at the date of grant for PSUs granted during the three and nine months ended September 30, 2017 was $55.02 and $40.30, respectively. The fair value of each PSU grant is amortized monthly into compensation expense based on their respective vesting conditions over three annual measurement periods. The accrual of compensation costs is based on our estimate of the final expected value of the award, and is adjusted as required for the portion based on the performance-based condition. The Company assumes that forfeitures will be minimal and recognizes forfeitures as they occur, which results in a reduction in compensation expense. As the payout of PSUs includes dividend equivalents, no separate dividend yield assumption is required in calculating the fair value of the PSUs.

~~At September 30, 2017, based on the Company’s assessment of its performance goals for 2016 and 2017, approximately 450,000 additional shares may be awarded under the 2016 and 2017 grant awards.~~

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

~~Employee Stock Purchase Plan~~

On January 26, 2017, the Company’s board of directors approved The Chemours Company Employee Stock Purchase Plan (ESPP), which was approved by Chemours’ stockholders on April 26, 2017. Under the ESPP, a total of 7,000,000 shares of Chemours’ common stock are reserved and authorized for issuance to participating employees, as defined by the ESPP, which excludes executive officers of the Company. The ESPP provides for consecutive 12-month offering periods, each with four purchase periods beginning and ending on the calendar quarters within those offering periods. The initial offering period under the ESPP began on October 2, 2017. Participating employees will be eligible to purchase the Company’s common stock at a discounted rate equal to 95% of its fair value on the last trading day of each purchase period.

~~Note 17. Segment Information~~

~~Chemours’ operations are classified into three reportable segments based on~~ similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution, and regulatory ~~environments. Chemours’ reportable segments are:~~environments: Titanium Technologies, ~~Fluoroproducts~~Thermal & Specialized Solutions, and ~~Chemical Solutions.~~Advanced Performance Materials. The Company’s Performance Chemicals and Intermediates business is included in Other Segment. Corporate costs and certain legal and environmental expenses, ~~that are not allocated to the reportable segments~~stock-based compensation expenses, and foreign exchange gains and losses arising from the remeasurement of balances in currencies other than the functional currency of the Company’s legal entities are reflected in Corporate and Other.

Segment sales include transfers to another reportable segment. Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Depreciation and amortization includes depreciation on research and development facilities and amortization of other intangible assets, excluding write-down of assets.

Adjusted earnings before interest, taxes, depreciation, and amortization ~~(Adjusted EBITDA)~~("Adjusted EBITDA") is the primary measure of segment profitability used by the Company’s Chief Operating Decision Maker ("CODM") and is defined as income (loss) before income taxes, excluding the following:

•

interest expense, depreciation, and amortization;

•

non-operating pension and other post-retirement employee benefit costs, which ~~represent~~represents the ~~components~~non-service cost component of net periodic pension ~~(income) costs excluding service cost component;~~

costs;

•

exchange (gains) losses included in other income (expense), net;

•

restructuring, asset-related, ~~charges~~ and other ~~charges, net;~~

charges;

•

~~asset impairments;~~

(gains) losses on ~~sale~~sales of ~~business or assets;~~assets and

businesses; and,

•

other items not considered indicative of the Company’s ongoing operational performance and expected to occur ~~infrequently.~~

infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company’s cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA.

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

Three Months Ended September 30,

Titanium
Technologies

Fluoroproducts

Chemical
Solutions

Corporate and
Other

Total

2017

Net sales to external customers

$
799

$
637

$
148

$
—

$
1,584

Adjusted EBITDA

249

158

18

(44
)

381

Depreciation and amortization

24

28

4

6

62

2016

Net sales to external customers

$
625

$
591

$
182

$
—

$
1,398

Adjusted EBITDA

144

143

9

(28
)

268

Depreciation and amortization

32

26

6

9

73

Nine Months Ended September 30,

Titanium
Technologies

Fluoroproducts

Chemical
Solutions

Corporate and
Other

Total

2017

Net sales to external customers

$
2,173

$
1,998

$
437

$
—

$
4,608

Adjusted EBITDA

601

510

37

(120
)

1,028

Depreciation and amortization

89

81

13

21

204

2016

Net sales to external customers

$
1,742

$
1,695

$
641

$
—

$
4,078

Adjusted EBITDA

309

333

30

(89
)

583

Depreciation and amortization

87

75

24

26

212

The following ~~is a tabular reconciliation of consolidated income before income taxes to Adjusted EBITDA:~~

Three Months Ended September 30,

Nine Months Ended September 30,

2017

2016

2017

2016

Income before income taxes

$
250

$
234

$
649

$
262

Interest expense, net

55

51

161

157

Depreciation and amortization

62

73

204

212

Non-operating pension and other post-retirement employee benefit income

(7
)

(5
)

(24
)

(19
)
Exchange losses (gains)

4

17

(3
)

37

Restructuring charges

8

14

31

41

Asset-related charges

1

46

3

109

Gain on sale of assets and businesses

—

(169
)

(14
)

(258
)
Transaction costs ¹

1

2

3

18

Legal and other charges ²

7

5

18

24

Adjusted EBITDA

$
381

$
268

$
1,028

$
583

¹	~~Includes accounting, legal and bankers’ transaction fees incurred related to the Company's strategic initiatives.~~

²	~~Includes litigation settlements, water treatment accruals related to PFOA, employee separation costs and lease termination charges.~~

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

~~Note 18. Guarantor Condensed Consolidating Financial Information~~

~~The following guarantor~~table sets forth certain summary financial information is included in accordance with Rule 3-10 of Regulation S-X (Rule 3-10) in connection with the issuance of the Notes by The Chemours Company (Parent Issuer). The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis, in each case, subject to certain exceptions, by the Parent Issuer and by certain subsidiaries (together, Guarantor Subsidiaries). Each of the Guarantor Subsidiaries is 100% owned by the Company. No other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, Non-Guarantor Subsidiaries). The Guarantor Subsidiaries may be automatically released from those guarantees upon the occurrence of certain customary release provisions.

~~The following condensed consolidating financial information is presented to comply with~~for the Company’s ~~requirements under Rule 3-10:~~

reportable segments for the ~~condensed consolidating statements of comprehensive income~~periods presented.


	Titanium Technologies		Thermal & Specialized Solutions		Advanced Performance Materials		Other Segment		Segment Total
Three Months Ended September 30, 2023
Net sales to external customers	$	690	$	436	$	343	$	18	$	1,487
Adjusted EBITDA		69		162		68		2		301
Depreciation and amortization		34		15		21		1		71

Three Months Ended September 30, 2022
Net sales to external customers	$	877	$	417	$	450	$	33	$	1,777
Adjusted EBITDA		137		162		112		3		414
Depreciation and amortization		31		13		20		2		66

	Titanium Technologies		Thermal & Specialized Solutions		Advanced Performance Materials		Other Segment		Segment Total
Nine Months Ended September 30, 2023
Net sales to external customers	$	2,029	$	1,445	$	1,118	$	74	$	4,666
Adjusted EBITDA		226		561		233		18		1,038
Depreciation and amortization		101		47		64		5		217

Nine Months Ended September 30, 2022
Net sales to external customers	$	2,774	$	1,360	$	1,236	$	86	$	5,456
Adjusted EBITDA		559		549		306		1		1,415
Depreciation and amortization		93		40		61		6		200

Total Assets
September 30, 2023	$	2,275	$	1,370	$	1,803	$	98	$	5,546
December 31, 2022		2,384		1,238		1,742		124		5,488

Corporate and Other depreciation and amortization expense amounted to $5 and $16 for the three and nine months ended September 30, ~~2017~~2023, respectively, and ~~2016;~~

~~the condensed consolidating balance sheets as of September 30, 2017~~$6 and ~~December 31, 2016; and~~

~~the condensed consolidating statements of cash flows~~$17 for the three and nine months ended September 30, ~~2017~~2022, respectively. Corporate and ~~2016.~~

The condensed consolidating financial information is presented using the equity method of accounting for the Company’s investments in 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recordedOther total assets amounted to $2,402 and $2,152 at ~~cost~~September 30, 2023 and adjusted for Chemours’ share of the subsidiaries’ cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this footnote should be read in conjunction with the consolidated financial statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.December 31, 2022, respectively.

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

~~Condensed Consolidating Statements~~The following table sets forth a reconciliation of ~~Comprehensive Income~~

Three Months Ended September 30, 2017

Parent Issuer

Guarantor Subsidiaries

Non-Guarantor Subsidiaries

Eliminations and Adjustments

Consolidated

Net sales
$
—

$
960

$
1,053

$
(429
)

$
1,584

Cost of goods sold

—

773

753

(409
)

1,117

Gross profit

—

187

300

(20
)

467

Selling, general and administrative expense

7

105

43

(7
)

148

Research and development expense

—

19

1

—

20

Restructuring and asset-related charges, net

—

8

—

—

8

Total expenses

7

132

44

(7
)

176

Equity in earnings of affiliates

—

—

9

—

9

Equity in earnings of subsidiaries

233

—

—

(233
)

—

Interest (expense) income, net

(57
)

2

—

—

(55
)
Intercompany interest income (expense), net

16

—

(16
)

—

—

Other income (expense), net

6

22

(17
)

(6
)

5

Income before income taxes

191

79

232

(252
)

250

(Benefit from) provision for income taxes

(16
)

18

42

(1
)

43

Net income

207

61

190

(251
)

207

Less: Net income attributable to non-controlling interests

—

—

—

—

—

Net income attributable to Chemours
$
207

$
61

$
190

$
(251
)

$
207

Comprehensive income attributable to Chemours
$
228

$
63

$
225

$
(288
)

$
228

Three Months Ended September 30, 2016

Parent Issuer

Guarantor Subsidiaries

Non-Guarantor Subsidiaries

Eliminations and Adjustments

Consolidated

Net sales
$
—

$
961

$
847

$
(410
)

$
1,398

Cost of goods sold

—

791

656

(391
)

1,056

Gross profit

—

170

191

(19
)

342

Selling, general and administrative expense

5

115

34

(6
)

148

Research and development expense

—

19

—

—

19

Restructuring and asset-related charges, net

—

60

—

—

60

Total expenses

5

194

34

(6
)

227

Equity in earnings of affiliates

—

1

8

—

9

Equity in earnings of subsidiaries

226

—

—

(226
)

—

Interest expense, net

(50
)

(1
)

—

—

(51
)
Intercompany interest income (expense), net

15

1

(16
)

—

—

Other income, net

5

70

94

(8
)

161

Income before income taxes

191

47

243

(247
)

234

(Benefit from) provision for income taxes

(13
)

29

29

(15
)

30

Net income

204

18

214

(232
)

204

Less: Net income attributable to non-controlling interests

—

—

—

—

—

Net income attributable to Chemours
$
204

$
18

$
214

$
(232
)

$
204

Comprehensive income attributable to Chemours
$
210

$
18

$
226

$
(244
)

$
210

~~The Chemours Company~~

~~Notes~~Segment Adjusted EBITDA to the Company’s consolidated income (loss) before income taxes for the three and nine months ended September 30, 2023 and 2022.


	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Segment Adjusted EBITDA	$	301		$	414		$	1,038		$	1,415
Corporate and Other expenses (excluding items below)		(54	)		(51	)		(164	)		(174	)
Interest expense, net		(55	)		(41	)		(145	)		(123	)
Depreciation and amortization		(76	)		(72	)		(233	)		(217	)
Non-operating pension and other post-retirement employee (cost) income		(1	)		1			(1	)		4
Exchange (losses) gains, net		(9	)		13			(21	)		11
Restructuring, asset-related, and other charges (1)		(153	)		2			(168	)		(14	)
(Loss) gain on extinguishment of debt		(1	)		7			(1	)		7
Gain on sales of assets and businesses (2)		106			—			106			27
Transaction costs (3)		(7	)		—			(7	)		—
Qualified spend recovery (4)		11			14			43			41
Litigation-related charges (5)		(31	)		23			(675	)		15
Environmental charges (6)		(8	)		(11	)		(9	)		(182	)
Income (loss) before income taxes	$	23		$	299		$	(237	)	$	810

(1)

Refer to "Note 5 – Restructuring, Asset-related, and Other charges" for further details. In addition, the periods ended in September 30, 2023 include $28 related to the write-off of certain raw materials inventory from the Kuan Yin, Taiwan plant closure. In 2022, the nine months ended September 30, 2022 includes asset charges and write-offs resulting from the conflict between Russia and Ukraine and the Company’s decision to suspend its business with Russian entities. Refer to "Note 5 – Restructuring, Asset-related, and Other Charges" for further details.

(2)

Refer to “Note 6 – Other Income (Expense), Net” to the Interim Consolidated Financial Statements ~~(Unaudited)~~ for further details.

(3)

Includes costs associated with the New Senior Secured Credit Facilities entered into during the third quarter of 2023 which is discussed in further detail in "Note 15 – Debt".

(4)

Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 – Commitments and Contingent Liabilities".

(5)

Litigation-related charges pertains to litigation settlements, PFOA drinking water treatment accruals, and related legal fees. In the periods ended in September 30, 2022, litigation-related charges include proceeds from a settlement in a patent infringement matter. Refer to “Note 17 – Commitments and Contingent Liabilities” for further details.

(6)

Environmental charges pertains to management’s assessment of estimated liabilities associated with certain non-recurring environmental remediation expenses at various sites. In 2022, environmental charges include $175 primarily related to an update to the off-site drinking water programs at Fayetteville and changes in estimates related to the barrier wall constructions. Refer to “Note 17 – Commitments and Contingent Liabilities”for further details.

~~(Dollars in millions, except per share amounts)~~

~~Condensed Consolidating Statements of Comprehensive Income (Loss)~~

Nine Months Ended September 30, 2017

Parent Issuer

Guarantor Subsidiaries

Non-Guarantor Subsidiaries

Eliminations and Adjustments

Consolidated

Net sales
$
—

$
2,904

$
2,941

$
(1,237
)

$
4,608

Cost of goods sold

—

2,358

2,210

(1,227
)

3,341

Gross profit

—

546

731

(10
)

1,267

Selling, general and administrative expense

26

339

101

(22
)

444

Research and development expense

—

57

4

—

61

Restructuring and asset-related charges, net

—

28

3

—

31

Total expenses

26

424

108

(22
)

536

Equity in earnings of affiliates

—

—

26

—

26

Equity in earnings of subsidiaries

594

—

—

(594
)

—

Interest (expense) income, net

(164
)

1

2

—

(161
)
Intercompany interest income (expense), net

48

—

(48
)

—

—

Other income (expense), net

19

93

(37
)

(22
)

53

Income before income taxes

471

216

566

(604
)

649

(Benefit from) provision for income taxes

(47
)

40

136

1

130

Net income

518

176

430

(605
)

519

Less: Net income attributable to non-controlling interests

—

—

1

—

1

Net income attributable to Chemours
$
518

$
176

$
429

$
(605
)

$
518

Comprehensive income attributable to Chemours
$
675

$
178

$
640

$
(818
)

$
675

Nine Months Ended September 30, 2016

Parent Issuer

Guarantor Subsidiaries

Non-Guarantor Subsidiaries

Eliminations and Adjustments

Consolidated

Net sales
$
—

$
2,898

$
2,367

$
(1,187
)

$
4,078

Cost of goods sold

—

2,506

1,921

(1,160
)

3,267

Gross profit

—

392

446

(27
)

811

Selling, general and administrative expense

17

350

103

(16
)

454

Research and development expense

—

58

2

—

60

Restructuring and asset-related charges (credits), net

—

147

(2
)

—

145

Total expenses

17

555

103

(16
)

659

Equity in (loss) earnings of affiliates

—

(2
)

19

—

17

Equity in earnings of subsidiaries

307

—

—

(307
)

—

Interest expense, net

(155
)

(2
)

—

—

(157
)
Intercompany interest income (expense), net

44

4

(48
)

—

—

Other income, net

15

178

72

(15
)

250

Income before income taxes

194

15

386

(333
)

262

(Benefit from) provision for income taxes

(43
)

25

53

(10
)

25

Net income (loss)

237

(10
)

333

(323
)

237

Less: Net income attributable to non-controlling interests

—

—

—

—

—

Net income (loss) attributable to Chemours
$
237

$
(10
)

$
333

$
(323
)

$
237

Comprehensive income (loss) attributable to Chemours
$
250

$
(10
)

$
355

$
(345
)

$
250

2948

The Chemours Company

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

~~Condensed Consolidating Balance Sheets~~

September 30, 2017

Parent Issuer

Guarantor Subsidiaries

Non-Guarantor Subsidiaries

Eliminations and Adjustments

Consolidated

Assets

Current assets:

Cash and cash equivalents
$
—

$
504

$
1,031

$
—

$
1,535

Accounts and notes receivable - trade, net

—

316

626

—

942

Intercompany receivable

19

684

196

(899
)

—

Inventories

—

348

592

(63
)

877

Prepaid expenses and other

—

59

20

—

79

Deferred income taxes

—

—

—

—

—

Total current assets

19

1,911

2,465

(962
)

3,433

Property, plant and equipment

—

6,346

2,066

—

8,412

Less: Accumulated depreciation

—

(4,410
)

(1,052
)

—

(5,462
)
Property, plant and equipment, net

—

1,936

1,014

—

2,950

Goodwill and other intangible assets, net

—

153

14

—

167

Investments in affiliates

—

—

166

—

166

Investment in subsidiaries

4,114

—

—

(4,114
)

—

Intercompany notes receivable

1,150

—

—

(1,150
)

—

Other assets

35

101

292

(24
)

404

Total assets
$
5,318

$
4,101

$
3,951

$
(6,250
)

$
7,120

Liabilities and equity

Current liabilities:

Accounts payable
$
—

$
589

$
421

$
—

$
1,010

Current maturities of long-term debt

14

—

—

—

14

Intercompany payable

354

196

349

(899
)

—

Other accrued liabilities

72

310

164

—

546

Total current liabilities

440

1,095

934

(899
)

1,570

Long-term debt, net

4,078

3

—

—

4,081

Intercompany notes payable

—

—

1,150

(1,150
)

—

Deferred income taxes

—

107

92

(24
)

175

Other liabilities

—

392

97

—

489

Total liabilities

4,518

1,597

2,273

(2,073
)

6,315

Commitments and contingent liabilities

Equity

Total Chemours stockholders’ equity

800

2,504

1,673

(4,177
)

800

Non-controlling interests

—

—

5

—

5

Total equity

800

2,504

1,678

(4,177
)

805

Total liabilities and equity
$
5,318

$
4,101

$
3,951

$
(6,250
)

$
7,120

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

~~Condensed Consolidating Balance Sheets~~

December 31, 2016

Parent Issuer

Guarantor Subsidiaries

Non-Guarantor Subsidiaries

Eliminations and Adjustments

Consolidated

Assets

Current assets:

Cash and cash equivalents
$
—

$
224

$
678

$
—

$
902

Accounts and notes receivable - trade, net

—

299

508

—

807

Intercompany receivable

3

1,050

46

(1,099
)

—

Inventories

—

341

476

(50
)

767

Prepaid expenses and other

—

38

32

7

77

Total current assets

3

1,952

1,740

(1,142
)

2,553

Property, plant and equipment, net

—

6,136

1,861

—

7,997

Less: Accumulated depreciation

—

(4,285
)

(928
)

—

(5,213
)
Property, plant and equipment, net

—

1,851

933

—

2,784

Goodwill and other intangible assets, net

—

156

14

—

170

Investments in affiliates

—

—

136

—

136

Investment in subsidiaries

3,258

—

—

(3,258
)

—

Intercompany notes receivable

1,150

—

—

(1,150
)

—

Other assets

13

178

226

—

417

Total assets
$
4,424

$
4,137

$
3,049

$
(5,550
)

$
6,060

Liabilities and equity

Current liabilities:

Accounts payable
$
—

$
573

$
311

$
—

$
884

Current maturities of long-term debt

15

—

—

—

15

Intercompany payable

762

46

291

(1,099
)

—

Other accrued liabilities

21

718

133

—

872

Total current liabilities

798

1,337

735

(1,099
)

1,771

Long-term debt, net

3,526

3

—

—

3,529

Intercompany notes payable

—

—

1,150

(1,150
)

—

Deferred income taxes

—

59

73

—

132

Other liabilities

—

428

96

—

524

Total liabilities

4,324

1,827

2,054

(2,249
)

5,956

Commitments and contingent liabilities

Equity

Total Chemours stockholders’ equity

100

2,310

991

(3,301
)

100

Non-controlling interests

—

—

4

—

4

Total equity

100

2,310

995

(3,301
)

104

Total liabilities and equity
$
4,424

$
4,137

$
3,049

$
(5,550
)

$
6,060

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

~~Condensed Consolidating Statements of Cash Flows~~

Nine Months Ended September 30, 2017

Parent Issuer

Guarantor Subsidiaries

Non-Guarantor Subsidiaries

Eliminations and Adjustments

Consolidated

Operating activities

Cash (used for) provided by operating activities
$
(60
)

$
32

$
364

$
—

$
336

Investing activities

Purchases of property, plant and equipment

—

(204
)

(42
)

—

(246
)
Proceeds from sales of assets and businesses, net

—

39

—

—

39

Intercompany investing activities

—

408

—

(408
)

—

Foreign exchange contract settlements, net

—

5

—

—

5

Cash provided by (used for) investing activities

—

248

(42
)

(408
)

(202
)
Financing activities

Proceeds from the issuance of debt, net

494

—

—

—

494

Intercompany short-term borrowing repayments, net

(408
)

—

—

408

—

Debt repayments

(24
)

—

—

—

(24
)
Dividends paid

(16
)

—

—

—

(16
)
Debt issuance costs

(6
)

—

—

—

(6
)
Tax payments related to withholdings on vested restricted stock units

(10
)

—

—

—

(10
)
Proceeds from issuance of stock options, net

30

—

—

—

30

Cash provided by financing activities

60

—

—

408

468

Effect of exchange rate changes on cash and cash equivalents

—

—

31

—

31

Increase in cash and cash equivalents

—

280

353

—

633

Cash and cash equivalents at beginning of the period

—

224

678

—

902

Cash and cash equivalents at end of the period
$
—

$
504

$
1,031

$
—

$
1,535

~~The Chemours Company~~

~~Notes to the Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~

~~Condensed Consolidating Statements of Cash Flows~~

Nine Months Ended September 30, 2016

Parent Issuer

Guarantor Subsidiaries

Non-Guarantor Subsidiaries

Eliminations and Adjustments

Consolidated

Operating activities

Cash (used for) provided by operating activities
$
(105
)

$
173

$
256

$
—

$
324

Investing activities

Purchases of property, plant and equipment

—

(142
)

(93
)

—

(235
)
Proceeds from sales of assets and businesses, net

—

590

117

—

707

Intercompany investing activities

—

(328
)

—

328

—

Foreign exchange contract settlements

—

(1
)

—

—

(1
)
Investment in affiliates

—

—

(2
)

—

(2
)
Cash provided by investing activities

—

119

22

328

469

Financing activities

Intercompany short-term borrowings, net

328

—

—

(328
)

—

Debt repayments

(205
)

(7
)

—

—

(212
)
Dividends paid

(16
)

—

—

—

(16
)
Deferred financing fees

(2
)

—

—

—

(2
)
Cash provided by (used for) financing activities

105

(7
)

—

(328
)

(230
)
Effect of exchange rate changes on cash and cash equivalents

—

—

28

—

28

Increase in cash and cash equivalents

—

285

306

—

591

Cash and cash equivalents at beginning of the period

—

95

271

—

366

Cash and cash equivalents at end of the period
$
—

$
380

$
577

$
—

$
957

~~The Chemours Company~~


Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

~~Introduction~~

This Management’s ~~discussion~~Discussion and ~~analysis~~Analysis of ~~our results~~Financial Condition and Results of ~~operations and financial condition, which we refer to as “MD~~Operations (“MD&A”,) supplements the unaudited ~~interim consolidated financial statements~~Interim Consolidated Financial Statements and the related notes thereto included elsewhere herein to help provide an understanding of our financial condition, changes in our financial condition, and the results of our operations. The discussion and analysis presented below, refer to, and should be read in conjunction with, the unaudited interim consolidated financial statements and the related notes included in Item 1 of this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and the related notes included in our Annual Report on Form 10-Koperations for the ~~year ended December 31, 2016.~~

periods presented. Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our Company”, “we”, “us”, and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to ~~“DuPont”~~“EID” refer to ~~E.I.~~EIDP, Inc., formerly known as E. I. du Pont de Nemours and Company, which is our former parent company and is now a subsidiary of Corteva, Inc. (“Corteva”), a Delaware ~~corporation,~~corporation. References herein to “DuPont” refer to DuPont de Nemours, Inc., a Delaware Corporation.

This MD&A should be read in conjunction with the unaudited Interim Consolidated Financial Statements and ~~its consolidated subsidiaries, unless~~ the ~~context otherwise requires.~~related notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, as well as our audited Consolidated Financial Statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022.

~~Forward-Looking Statements~~

This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the ~~safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995,~~federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words “believe”, “expect”, “anticipate”, “plan”, “estimate”, “target”, “project”, and similar expressions, among others, generally identify “forward-looking statements”, which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements.

~~Forward-looking~~

Our forward-looking statements are based on certain assumptions and expectations of future events ~~which~~that may not be accurate or realized. These statements, as well as our historical performance, are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties ~~many of which~~that are beyond ~~Chemours’~~our control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements. Factors that could cause or contribute to these differences include, ~~those~~but are not limited to, the risks, uncertainties, and other factors discussed in the ~~Forward-Looking~~Forward-looking Statements and the Risk Factors sections in our Annual Report on Form 10-K for the year ended December 31, ~~2016. The Company assumes~~2022, and as otherwise discussed in this report. We assume no obligation to revise or update any forward-looking statement for any reason, except as required by law.

~~Overview~~

~~Chemours is~~

Overview

We are a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets, including coatings, plastics, ~~and coatings,~~ refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, and ~~mining. Principal~~oil and gas. Our principal products include titanium dioxide ~~(TiO~~_(“TiO2”), pigment, refrigerants, industrial fluoropolymer resins, ~~sodium cyanide~~ and performance chemicals and intermediates.

~~Chemours manages~~ We manage and ~~reports~~report our operating results through three reportable segments: Titanium Technologies, ~~Fluoroproducts~~Thermal & Specialized Solutions, and ~~Chemical Solutions.~~Advanced Performance Materials. Our ~~position~~Titanium Technologies segment is a leading, global provider of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications. Our Thermal & Specialized Solutions segment is a leading, global provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. Our Advanced Performance Materials segment is a leading, global provider of high-end polymers and advanced materials that deliver unique attributes, including low friction coefficients, extreme temperature resistance, weather resistance, ultraviolet and chemical resistance, and electrical insulation. Our Performance Chemicals and Intermediates business is presented under Other Segment.

We are a different kind of chemistry company, driven by our vision to create a better world through the power of our chemistry. Our world-class product portfolio brings everyday convenience to virtually everything people touch in their daily lives, making our products and the solutions they enable both vital and essential. We are committed to creating value for our customers and stakeholders around the world through innovative and sustainable solutions, environmental leadership, community impact and making Chemours the greatest place to work for every employee. Our global workforce, renowned for its deep and unmatched expertise, bring our chemistry to life, guided by five core values that form the bedrock foundation for how we operate: (i) Customer Centricity – driving customer growth, and our own, by understanding our customers’ needs and building long-lasting relationships with ~~each~~them; (ii) Refreshing Simplicity – cutting complexity by investing in what matters, and getting results faster; (iii) Collective Entrepreneurship – empowering our employees to act like they own our business, while embracing the power of ~~these businesses reflects~~inclusion and teamwork; (iv) Safety Obsession – living our steadfast belief that a safe workplace is a profitable workplace; and, (v) Unshakable Integrity – doing what’s right for our customers, colleagues, and communities – always.

The Chemours Company

We recognize that our responsibility to all stakeholders goes well beyond our Corporate Responsibility Commitment ("CRC") goals, and our commitment to sustainability cannot be separated from our growth strategy or our vision. As a result, in 2023 we are aligning our sustainability focus and actions to the ~~strong value proposition~~four key strategic pillars that support our Chemours vision: Innovation and Sustainable Solutions, Environmental Leadership, Community Impact, and Greatest Place to Work for All. The four key areas support an effort to achieve, among other goals, increased sustainability of our products, addressing our carbon emissions, and increased diversity and inclusion in our global workforce. We call this responsible chemistry – it is rooted in who we ~~provide~~are, and we expect that our CRC will drive sustainable, long-term earnings growth.

Our core values, together with our company purpose and vision, underpin our commitment to our ~~customers based~~stakeholders to make chemistry as responsible as it is essential. Sustainability is embedded within our growth strategy as a company, with 10 ambitious goals that we aim to achieve by 2030, built on our ~~long history~~key strategic pillars of Innovation and ~~reputation~~Sustainable Solutions, Environmental Leadership, Community Impact, and Greatest Place to Work for All. These goals are designed to promote accountability to our commitment and position us for sustainable, long-term earnings growth. While we utilize environmental, social, and governance ("ESG") issue prioritization and a defined governance framework to manage sustainability, our goal is to embed sustainability into our organization and our business managing processes. We understand that maintaining safe, sustainable operations has an impact on us, our communities, the environment, and our collective future. With this focus, we invest in ~~the chemical industry for safety, quality~~research and ~~reliability.~~

~~Transformation Plan~~

After the separation from DuPont in 2015, Chemours announced a plan to transform the Company by reducing structural costs, growing market positions, optimizing its portfolio, refocusing investments and enhancing its organization. Chemours expects the transformation plan to deliver at least $500 million of incremental adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) improvement over 2015 through 2017 based on our anticipated cost reduction and growth initiatives. We expect cost savings of approximately $350 million and approximately $150 million in improvements from growth initiatives will also improve our pre-tax earnings by similar amounts. Through year-end 2016, we realized approximately $200 million in cost savings, and we continue to implement additional cost reduction initiativesdevelopment (“R&D”) in order to ~~realize~~develop safer, cleaner, and more efficient products and processes that enable our ~~target additional structural costs savings~~operations, customers, and consumers to reduce their greenhouse gas ("GHG") emissions, carbon footprint, and overall environmental footprint. We value collaboration to drive change and commit to continue working with policymakers, our value chain, and other organizations to encourage collective action to reduce GHG emissions and encourage lower-carbon forms of energy.

Recent Developments

Titanium Technologies Transformation Plan

In line with our strategic priorities for creating long-term shareholder value and building on the legacy of delivering high-quality Ti-PureTM offerings and stable pricing strategy, the Titanium Technologies segment commenced certain transformation initiatives to streamline our workforce and improve other operational costs. We expect these transformation initiatives to deliver an earnings benefit of approximately ~~$150~~$100 million. As part of cost optimization efforts, in July 2023, we announced our decision to shut down our TiO2 manufacturing facility in Kuan Yin, Taiwan.

As a result of the Titanium Technologies Transformation Plan, for the period ended September 30, 2023, we recorded a pre-tax charge of approximately $147 million, ~~through 2018~~comprised primarily of cash charges of $31 million related to severance, contract termination, and ~~beyond. These improvements will be partially offset by~~decommissioning charges, and non-cash charges of approximately $78 million related to asset-related impairments, $28 million related to the ~~impact~~write-off of ~~divestitures~~certain raw materials inventory, and $10 million in other charges. We anticipate additional charges of approximately $20 million to $30 million for decommission, dismantling and removal activities.

Sale of Glycolic Acid Business

On August 1, 2023, we completed ~~during 2016, unfavorable price and mix of other products and may also be impacted by market factors and other costs to achieve our plans. The results~~the sale of our ~~transformation actions are further discussed~~Glycolic Acid business included in Other Segment for net cash proceeds of approximately $138 million under the definitive agreement entered into with PureTech Scientific Inc. on June 1, 2023 (the “Glycolic Acid Transaction”). As a result of the sale, we recorded a net pre-tax gain on sale of $106 million in other income (expense), net in the ~~Results~~consolidated statements of ~~Operations, Segment Reviews~~operations.

Senior Secured Credit Facilities

On August 18, 2023, we entered into an amendment and ~~Outlook sections of this MD&A~~restatement credit agreement, which amends and restates in its entirety the ~~Company’s Annual Report on Form 10-K~~April 2018 Credit Agreement, that provides for five-year senior secured term loans in an aggregate principal amount equal to $1,070 million and €415 million (collectively, the ~~year ended December 31, 2016.~~

~~The Chemours Company~~

~~Recent Developments~~

~~In August 2017, we paid~~"New Term Loans"), and a $900 million senior secured revolving credit facility. Proceeds from the ~~remaining $320 million~~New Term Loans were primarily used to prepay, in full, all outstanding amounts under the April 2018 Credit Agreement and fund our portion of the ~~$335 million in~~qualified settlement ~~payments we accrued in connection with~~fund per the ~~PFOA MDL Settlement for a complete release of all claims by the settling plaintiffs. Details~~terms of the ~~PFOA MDL Settlement are discussed further in Note 13~~U.S. public water system settlement agreement. Refer to "Note 15 - Debt" to the Interim Consolidated Financial Statements in ~~Item 1.~~this Quarterly Report on Form 10-Q for further details.

The Chemours Company

Results of Operations and Business Highlights

Results of Operations

The following table sets forth our results of operations for the three and nine months ended September 30, 2023 and 2022.


	Three Months Ended September 30,						Nine Months Ended September 30,
(Dollars in millions, except per share amounts)	2023			2022			2023			2022
Net sales	$	1,487		$	1,777		$	4,666		$	5,456
Cost of goods sold		1,206			1,345			3,607			4,042
Gross profit		281			432			1,059			1,414
Selling, general, and administrative expense		165			140			1,067			535
Research and development expense		28			32			82			88
Restructuring, asset-related, and other charges		124			(1	)		139			10
Total other operating expenses		317			171			1,288			633
Equity in earnings of affiliates		13			16			38			44
Interest expense, net		(55	)		(41	)		(145	)		(123	)
(Loss) gain on extinguishment of debt		(1	)		7			(1	)		7
Other income, net		102			56			100			101
Income before income taxes		23			299			(237	)		810
Provision for (benefit from) income taxes		3			59			(26	)		135
Net income (loss)		20			240			(211	)		675
Less: Net income attributable to non-controlling interests		—			—			1			—
Net income (loss) attributable to Chemours	$	20		$	240		$	(212	)	$	675
Per share data
Basic earnings (loss) per share of common stock	$	0.13		$	1.54		$	(1.42	)	$	4.30
Diluted earnings (loss) per share of common stock (1)		0.13			1.52			(1.42	)		4.21

(1)

In periods where we incur a net loss, the ~~third quarter~~impact of 2017, we announced a restructuring program designed to outsource and consolidate certain business process activities, consolidate outsourced third party information technology (IT) providers and implement various upgradespotentially dilutive securities is excluded from the calculation of EPS, as their inclusion would have an anti-dilutive effect. As such, with respect to the ~~Company’s IT infrastructure. Further, in October, we announced a voluntary separation program (VSP)~~measure of diluted EPS, the impact of 1,753,788 potentially dilutive securities is excluded from the calculation for ~~certain eligible U.S. employees in an effort to better manage anticipated future~~the nine months ended September 30, 2023.

The Chemours Company

Net Sales

The following table sets forth the impacts of price, volume, currency, and portfolio changes to the Company’s workforce. We anticipate that the Company will incur approximately $45 to $55 in charges for restructuring-related activities and termination benefits through the end of 2018 associated with this program, which is described in further detail in Note 3 to the Interim Consolidated Financial Statements in Item 1.

~~Our Third Quarter 2017 Results and Business Highlights~~

~~Our~~on our net sales for the three and nine months ended September 30, ~~2017~~2023, compared with the same periods in 2022.


Change in net sales from prior period	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Price		(1	)%		2	%
Volume		(15	)%		(16	)%
Currency		—	%		—	%
Total change in net sales		(16	)%		(14	)%

Our net sales decreased by $290 million (or 16%) to $1.5 billion for the three months ended September 30, 2023, compared with net sales of $1.8 billion for the same period in 2022. The decrease in our net sales for the three months ended September 30, 2023 was primarily attributable to a decrease in volume of 15% and a decrease in price of 1%. Volume decreases were ~~$1.6~~attributed to our Titanium Technologies and Advanced Performance Materials segments, partially offset by higher volume in our Thermal & Specialized Solutions segment. Price decreases were attributed to our Titanium Technologies and Thermal & Specialized Solutions segments, partially offset by our Advanced Performance Materials segment.

Our net sales decreased by $790 million (or 14%) to $4.7 billion for the nine months ended September 30, 2023, compared with net sales of $5.5 billion for the same period in 2022. The decrease in our net sales for the nine months ended September 30, 2023 was primarily attributable to a decrease in volume of 16%, partially offset by an increase in price of 2%. Volume decreases were attributed to our Titanium Technologies and Advanced Performance Materials segments, partially offset by higher volume in our Thermal & Specialized Solutions segment. Price increases were attributable to our Thermal & Specialized Solutions and Advanced Performance Materials segments.

The key drivers of these changes for each of our reportable segments are discussed further under the “Segment Reviews” section within this MD&A.

Cost of Goods Sold

Our cost of goods sold (“COGS”) decreased by $139 million (or 10%) and $435 million (or 11%) to $1.2 billion and ~~$4.6~~$3.6 billion for three and nine months ended September 30, 2023, respectively, ~~representing increases of 13% when~~ compared with ~~$1.4~~COGS of $1.3 billion and ~~$4.1~~$4 billion for the same periods in 2022. The decrease in our COGS for the three and nine months ended September 30, 2023 was primarily attributable to lower sales volume, partially offset by higher raw material costs due to inflation, lower fixed cost absorption in all our segments, and $28 million of certain raw materials inventory written off related to the Kuan Yin, Taiwan plant shutdown.

Selling, General, and Administrative Expense

Our selling, general, and administrative (“SG&A”) expense increased by $25 million (or 18%) and $532 million (or 99%) to $165 million and $1.1 billion for the three and nine months ended September 30, ~~2016, respectively.~~

~~We recognized net income~~2023, respectively, compared with SG&A expense of $140 million and $535 million for the same periods in 2022. The increase in our SG&A expense was primarily attributable to ~~Chemours of $207~~the approximately $31 million and ~~$518~~$675 million of legal charges during the three and nine months ended September 30, 2023, respectively, which includes the $592 million of legal charges during the second quarter of 2023 related to the U.S. public water system settlement agreement. The increase was partially offset by lower long-term performance-related compensation expense relative to the third quarter of 2022, and, during the nine months ended September 30, 2023, lower off-site environmental remediation costs of approximately $126 million at our Fayetteville Works site in Fayetteville, North Carolina ("Fayetteville") relative to the nine months ended September 30, 2022, respectively.

Research and Development Expense

Our research and development (“R&D”) expense decreased by $4 million (or 13%) and $6 million (or 7%) to $28 million and $82 million for the three and nine months ended September 30, ~~2017,~~2023, respectively, ~~representing increases of 1% and 119% when~~ compared with ~~$204~~R&D expense of $32 million and ~~$237~~$88 million for ~~the three and nine months ended September 30, 2016, respectively.~~

Our Adjusted EBITDA for the three and nine months ended September 30, 2017 was $381 million and $1.0 billion, respectively, representing increases of 42% and 76% when compared with $268 million and $583 million for the three and nine months ended September 30, 2016, respectively.

~~Our results for the periods presented reflect our customers’ preference and higher global average selling price for Ti-Pure~~^TM ~~TiO~~₂ ~~in our Titanium Technologies segment and strong demand for Opteon~~^TM ~~refrigerants and other fluoropolymers in our Fluoroproducts segment, which are partially offset by the impact of portfolio changes in our Chemical Solutions segment.~~

~~Results of Operations~~

Three Months Ended September 30,

Nine Months Ended September 30,

(Dollars in millions)

2017

2016

2017

2016

Net sales

$
1,584

$
1,398

$
4,608

$
4,078

Cost of goods sold

1,117

1,056

3,341

3,267

Gross profit

467

342

1,267

811

Selling, general and administrative expense

148

148

444

454

Research and development expense

20

19

61

60

Restructuring and asset-related charges, net

8

60

31

145

Total expenses

176

227

536

659

Equity in earnings of affiliates

9

9

26

17

Interest expense, net

(55
)

(51
)

(161
)

(157
)
Other income, net

5

161

53

250

Income before income taxes

250

234

649

262

Provision for income taxes

43

30

130

25

Net income

207

204

519

237

Less: Net income attributable to non-controlling interests

—

—

1

—

Net income attributable to Chemours

$
207

$
204

$
518

$
237

~~Net Sales~~

Our net sales increased by $186 million, or 13%, to $1.6 billion for the three months ended September 30, 2017 from $1.4 billion for the three months ended September 30, 2016. The increase in net sales reflects a 9% improvement in price, primarily attributable to our Titanium Technologies segment, higher demand in all segments driving a volume increase of 6% and slightly favorable foreign currency exchange rates. The increase in net sales was partially offset by a negative 3% impact resulting primarily from portfolio changes in our Chemical Solutions segment.

~~The Chemours Company~~

Our net sales increased by $530 million, or 13%, to $4.6 billion for the nine months ended September 30, 2017 from $4.1 billion for the nine months ended September 30, 2016. The increase in net sales reflects a 7% improvement in price, primarily attributable to our Titanium Technologies segment, and higher demand in all segments driving a volume increase of 12%. The increase in net sales was partially offset by a negative 6% impact resulting primarily from portfolio changes in our Chemical Solutions segment.

The following table shows the impact of price, volume, currency and portfolio changes on net sales for the three and nine months ended September 30, 2017 when compared with the three and nine months ended September 30, 2016:

Change in net sales from prior period

Three Months Ended September 30, 2017

Nine Months Ended September 30, 2017

Price

9
%

7
%
Volume

6
%

12
%
Currency

1
%

—
%
Portfolio / other

(3
)%

(6
)%
Total change

13
%

13
%

~~Cost of goods sold~~

~~Cost of goods sold (COGS) increased by $61 million, or 6%, and $74 million, or 2%, for the three and nine months ended September 30, 2017, respectively, when compared with~~ the same periods in 2016. The increase in COGS for the three months ended September 30, 2017 was primarily driven by costs related to volume increases, incremental increases in raw material inputs and distribution costs, capital-related expenses and expenditures related to Hurricane Harvey. The increase in COGS for the nine months ended September 30, 2017 was primarily driven by increases in volume, as well as costs associated with transformation activities and higher performance-related compensation. These increases were partially offset by the impact of portfolio changes in our Chemical Solutions segment.

~~Selling, general and administrative expense~~

Selling, general and administrative (SG&A) expense for the three months ended September 30, 2017 and 2016 remained flat at $148 million. For the nine months ended September 30, 2017, SG&A expense decreased by $10 million, or 2%, to $444 million when compared with $454 million for the nine months ended September 30, 2016.2022. The decrease in SG&A expense for the nine months ended September 30, 2017 was primarily attributable to a reduction in management and administrative expense. Additionally, we incurred $17 million in transaction-related costs associated with the sale of our Clean & Disinfect (C&D) product line and Sulfur business in 2016 which did not recur in 2017. Our reduction in transaction-related costs was partially offset by $28 million in incremental costs for transformation activities and higher performance-related compensation for the nine months ended September 30, 2017.

~~Research and development expense~~

Research and development (R&D) expense increased marginally to $20 million for the three months ended September 30, 2017 when compared with $19 million for the three months ended September 30, 2016. R&D expense for the nine months ended September 30, 2017 also increased marginally to $61 million when compared with $60 million for the nine months ended September 30, 2016. The marginal increase in R&D expense for the three and nine months ended September 30, ~~2017~~2023 was primarily attributable to ~~increased investment in product development~~decisions to delay certain projects given current macroeconomic conditions.

The Chemours Company

Restructuring, Asset-Related, and ~~higher performance-related compensation.~~Other Charges

~~Restructuring~~

Our restructuring, asset-related, and ~~asset-related~~other charges ~~net~~

~~Restructuring and asset-related charges, net, on a pre-tax basis, amounted to $8~~were $124 million and ~~$31~~$139 million for the three and nine months ended September 30, ~~2017,~~2023, respectively, compared with restructuring, asset-related, and ~~$60~~other charges of $(1) million and $10 million for the three and nine months ended September 30, 2022, respectively.

Restructuring, asset-related, and other charges in the three and nine months ended September 30, 2023 were primarily attributable to $119 million of charges related to the Titanium Technologies Transformation Plan, consisting of $78 million of asset-related charges, employee separation charges of $20 million, $7 million of contract termination costs, and $14 million of decommissioning and other charges. In addition, in the three and nine months ended September 30, 2023, charges included $6 million related to our 2023 Restructuring Program and, in the nine months, charges of $16 million resulting from our decision to abandon the implementation of a new enterprise resource planning ("ERP") software platform.

Restructuring, asset-related, and other charges for the nine months ended September 30, 2022 were primarily attributable to $5 million of asset charges resulting from our decision to suspend business with Russian entities due to the conflict between Russia and Ukraine, and $4 million of employee separation charges incurred in connection with our 2022 restructuring programs.

Equity in Earnings of Affiliates

Our equity in earnings of affiliates decreased by $3 million (or 19%) and $6 million (or 14%) to $13 million and $38 million for the three and nine months ended September 30, 2023, respectively, compared with equity in earnings of affiliates of $16 million and $44 million for the same periods in 2022. The decrease in our equity in earnings of affiliates for the three and nine months ended September 30, 2023 was primarily attributable to lower demand in the region where our investees' operate.

Interest Expense, Net

Our interest expense, net increased by $14 million (or 34%) and $22 million (or 18%) to $55 million and $145 million for the three and nine months ended September 30, ~~2016, respectively. Our restructuring charges~~2023, respectively, compared with interest expense, net of $41 million and $123 million for the same periods in 2022. The increase in our interest expense, net for the three and nine months ended September 30, ~~2017~~2023 was primarily ~~reflect decommissioning and other charges associated with the production shutdown at~~attributable to higher interest rates on our ~~Reactive Metals Solutions (RMS) facility in Niagara Falls, New York, and our 2017 corporate restructuring activities. Our restructuring charges for~~variable rate debt, partially offset by higher interest income.

(Loss) Gain on Extinguishment of Debt

For the three and nine months ended September 30, ~~2016 primarily reflect decommissioning and other charges associated~~2023, we recognized a net loss on extinguishment of debt of $1 million in connection with the ~~closure~~issuance of the New Term Loans.

For the three and nine months ended September 30, 2022, we recognized a net gain on extinguishment of debt of $7 million in connection with the open market repurchases of various portions of our ~~Edge Moor, Delaware production facility, the production shutdown at our RMS facility and asset-related charges of~~senior unsecured notes.

Other Income, Net

Our other income, net increased by $46 million (or 82%) and ~~$58~~decreased by $1 million ~~for pre-tax impairment losses associated with our aniline facility in Pascagoula, Mississippi and the sale of our Sulfur business, respectively.~~

~~Interest expense, net~~

~~We incurred interest expense, net of $55~~(or 1%) to $102 million and ~~$161~~$100 million for the three and nine months ended September 30, ~~2017,~~2023, respectively, ~~and $51~~compared with other income, net of $56 million and ~~$157~~$101 million for the same periods in 2022.

Our other income, net in the three and nine months ended September 30, ~~2016, respectively. Interest~~2023, includes a net pre-tax gain on sale of $106 million, associated with the Glycolic Acid Transaction, partially offset by net losses from foreign currency exchanges, primarily driven by devaluation of the Argentine peso and the strengthening of the euro against the U.S. dollar.

Our other income, net in the three and nine months ended September 30, 2022 includes proceeds from a settlement of a patent infringement matter relating to certain copolymer patents associated with our Advanced Performance Materials segment during the third quarter of 2022 and net gains from foreign currency exchanges, primarily due to the devaluation of the euro against the U.S. dollar. For the nine months ended September 30, 2022, we also recognized a net pre-tax gain on sale of $11 million and $18 million, respectively, associated with the sale of land at our former operating site in Beaumont, Texas (the "Beaumont Transaction") and the stock sale of certain of our wholly-owned subsidiaries and the remaining assets at our former Aniline business facilities in Pascagoula, Mississippi (the "Pascagoula Transaction").

The Chemours Company

~~expense, net increased by $4~~Provision for (Benefit from) Income Taxes

We had a provision for income taxes of $3 million and $59 million for the three months ended September 30, ~~2017, primarily due~~2023 and 2022, respectively, which represented effective tax rates of 13% and 20%, respectively. The $56 million decrease in our provision for income taxes for the three months ended September 30, 2023 was attributable to ~~increased interest resulting~~decreased profitability, changes in our geographic mix of earnings, and changes to non-recurring items. In the third quarter of 2023, we recognized a $28 million income tax benefit associated with the Kuan Yin, Taiwan plant shutdown, net of a $13 million valuation allowance recorded on certain deferred tax assets of one of our Taiwanese subsidiaries. This income tax benefit was offset by $26 million of income tax expense associated with the Glycolic Acid Transaction that occurred during the quarter.

We had a benefit from ~~our issuance~~income taxes of ~~the 2027 Notes in May 2017. Interest expense, net increased by $4~~$26 million and a provision for income taxes of $135 million for the nine months ended September 30, ~~2017, primarily due to the aforementioned increase~~2023 and 2022, respectively, which represented effective tax rates of 11% and 17%, respectively. The $161 million decrease in ~~interest from~~ our ~~2027 Notes, which was partially offset by decreased interest resulting from our April 2017 repricing~~provision for income taxes and lower ~~outstanding principal on our senior secured term loans, 2023 Notes and Euro Notes. In addition,~~effective tax rate for the nine months ended September 30, ~~2016,~~2023 were primarily attributable to the same factors discussed in the preceding paragraph. Additionally, we recorded ~~a non-recurring net gain of $10~~$88 million on debt extinguishment resulting from the repurchase of certain portions of our senior unsecured notes in the open market, which was partially offset by a non-recurring net loss of $4 million resulting from the write-off of unamortized debt issuance coststax benefit associated with the ~~reduction~~ U.S. public water system settlement agreement in ~~commitment on our Revolving Credit Facility.~~

~~Other income, net~~

~~Other income, net was $5 million for~~ the three months ended September 30, 2017, representing a decrease of $156 million when compared with $161 million for the three months ended September 30, 2016. This decrease was primarily attributable to a non-recurring gain of $169 million on the sale of our C&D product line in 2016, partially offset by a $13 million decrease in foreign currency exchange losses in 2017. Other income, net was $53 million for the nine months ended September 30, 2017, representing a decrease of $197 million when compared with $250 million for the nine months ended September 30, 2016. This decrease was primarily attributable to a non-recurring gain of $89 million on the sale of our Beaumont, Texas facility during the firstsecond quarter of 2016, plus the aforementioned sale of our C&D product line during the third quarter of 2016. A non-recurring gain of $12 million on the sale of land which formerly held our Edge Moor, Delaware facility during the first quarter of 2017, and $40 million in net favorable foreign currency exchange activity partially offsets the decrease in other income, net for the nine months ended September 30, 2017 when compared with the same period in 2016.2023.

~~Provision for income taxes~~

We recorded a provision for income taxes of $43 million and $30 million for the three months ended September 30, 2017 and 2016, respectively, resulting in effective income tax rates of 17% and 13%, respectively. For the nine months ended September 30, 2017 and 2016, we recorded a provision for income taxes of $130 million and $25 million, respectively, resulting in effective income tax rates of 20% and 10%, respectively. Our provision for income taxes for the three and nine months ended September 30, 2017 is inclusive of $5 million and $18 million in benefit from windfalls on share-based payments, respectively, due to our adoption of ASU No. 2016-09 during 2017. The remaining change in our effective tax rate from the prior year is primarily due to the Company’s geographical mix of earnings, as well as the impact of the additional valuation allowance on U.S. foreign tax credits of $65 million and $50 million for the three and nine months ended September 30, 2017, respectively, from which the Company does not expect to benefit in the current year.

Segment Reviews

Adjusted ~~EBITDA represents our~~earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is the primary measure of segment ~~performance~~profitability used by our Chief Operating Decision Maker ("CODM") and is defined as income (loss) before income taxes, excluding the following:

•

interest expense, depreciation, and amortization;

•

non-operating pension and other post-retirement employee benefit costs, which ~~represent~~represents the non-service cost component of net periodic pension ~~(income) costs excluding service cost component;~~

costs;

•

exchange (gains) losses included in other income (expense), net;

•

restructuring, asset-related, ~~charges~~ and other ~~charges, net;~~

charges;

•

~~asset impairments;~~

(gains) losses on ~~sale~~sales of ~~business or assets;~~assets and

businesses; and,

•

other items not considered indicative of our ongoing operational performance and expected to occur ~~infrequently.~~

infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the Memorandum of Understanding (“MOU”) that were previously excluded from Adjusted EBITDA.

A reconciliation of ~~Adjusted EBITDA to~~ net income (loss) attributable to Chemours to Adjusted EBITDA for the three and nine months ended September 30, ~~2017~~2023 and ~~2016~~2022 is included in the ~~Non-GAAP~~“Non-GAAP Financial ~~Measures in~~Measures” section of this ~~Item 2.~~MD&A.

~~The Chemours Company~~

The following table ~~represents Chemours’ total consolidated~~sets forth our Adjusted EBITDA by ~~segment:~~

Three Months Ended September 30,

Nine Months Ended September 30,

(Dollars in millions)

2017

2016

2017

2016

Titanium Technologies

$
249

$
144

$
601

$
309

Fluoroproducts

158

143

510

333

Chemical Solutions

18

9

37

30

Corporate and Other

(44
)

(28
)

(120
)

(89
)
Total Adjusted EBITDA

$
381

$
268

$
1,028

$
583

~~Titanium Technologies~~

Three Months Ended September 30,

Nine Months Ended September 30,

(Dollars in millions)

2017

2016

2017

2016

Segment net sales

$
799

$
625

$
2,173

$
1,742

Adjusted EBITDA

249

144

601

309

Adjusted EBITDA margin

31
%

23
%

28
%

18
%

Change in segment net sales from prior period

Three Months Ended September 30, 2017

Nine Months Ended September 30, 2017

Price

18
%

16
%
Volume

8
%

9
%
Currency

2
%

—
%
Portfolio / other

—
%

—
%
Total change

28
%

25
%

~~Segment Net Sales~~

~~Net sales increased by 28% and 25%~~segment for the three and nine months ended September 30, ~~2017, respectively, when compared with~~2023 and 2022.


	Three Months Ended September 30,						Nine Months Ended September 30,
(Dollars in millions)	2023			2022			2023			2022
Titanium Technologies	$	69		$	137		$	226		$	559
Thermal & Specialized Solutions		162			162			561			549
Advanced Performance Materials		68			112			233			306
Other Segment		2			3			18			1
Corporate and Other		(54	)		(51	)		(164	)		(174	)
Total Adjusted EBITDA	$	247		$	363		$	874		$	1,241

The Chemours Company

Titanium Technologies

The following table sets forth the ~~same periods in 2016. For the three months ended September 30, 2017, 18% of the increase in~~ net sales, ~~was attributable to higher global average selling price for TiO~~₂, 8% of the increase was attributable to higher demand and 2% of the increase was attributable to favorable foreign currency exchange rates. For the nine months ended September 30, 2017, 16% of the increase in net sales was attributable to improved price and 9% of the increase was attributable to higher demand.

Adjusted EBITDA, and Adjusted EBITDA ~~Margin~~

~~Adjusted EBITDA increased by 73% and 95%~~margin amounts for our Titanium Technologies segment for the three and nine months ended September 30, ~~2017, respectively, when compared with~~2023 and 2022.


	Three Months Ended September 30,						Nine Months Ended September 30,
(Dollars in millions)	2023			2022			2023			2022
Segment net sales	$	690		$	877		$	2,029		$	2,774
Adjusted EBITDA		69			137			226			559
Adjusted EBITDA margin		10	%		16	%		11	%		20	%

The following table sets forth the ~~same periods in 2016. Our Adjusted EBITDA margin increased by 8%~~impacts of price, volume, currency, and 10% for the three and nine months ended September 30, 2017, respectively, when compared with the same periods in 2016. The increases in Adjusted EBITDA and Adjusted EBITDA margin for the three months ended September 30, 2017 were primarily attributable to the aforementioned increases in price and volume, which were partially offset by incremental increases in raw material inputs and distribution costs. The increases in Adjusted EBITDA and Adjusted EBITDA margin for the nine months ended September 30, 2017 were primarily attributable to the aforementioned increases in price and volume, which were partially offset by costs associated with transformation activities and higher performance-related compensation.

~~Fluoroproducts~~

Three Months Ended September 30,

Nine Months Ended September 30,

(Dollars in millions)

2017

2016

2017

2016

Segment net sales

$
637

$
591

$
1,998

$
1,695

Adjusted EBITDA

158

143

510

333

Adjusted EBITDA margin

25
%

24
%

26
%

20
%

~~The Chemours Company~~

Change in segment net sales from prior period

Three Months Ended September 30, 2017

Nine Months Ended September 30, 2017

Price

2
%

1
%
Volume

5
%

17
%
Currency

1
%

—
%
Portfolio / other

—
%

—
%
Total change

8
%

18
%

~~Segment Net Sales~~

~~Net sales increased by 8% and 18% for the three and nine months ended September 30, 2017, respectively, when compared with the same periods in 2016. The increase in~~portfolio changes on our Titanium Technologies segment’s net sales for the three and nine months ended September 30, ~~2017~~2023, compared with the same periods in 2022.


Change in segment net sales from prior period	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Price		(3	)%		—	%
Volume		(18	)%		(27	)%
Currency		—	%		—	%
Total change in segment net sales		(21	)%		(27	)%

Segment Net Sales

Our Titanium Technologies segment’s net sales decreased by $187 million (or 21%) to $690 million for the three months ended September 30, 2023, compared with segment net sales of $877 million for the same period in 2022. The decrease in segment net sales for the three months ended September 30, 2023 was primarily attributable to ~~continuing solid~~a decrease in volume of 18% and price of 3%. Volumes decreased due to softer market demand in all regions. Prices decreased primarily due to pricing in our market exposed customer portfolio. Currency was flat for ~~Opteon™ refrigerant~~the three months ended September 30, 2023 when compared to the same period of the prior year.

Our Titanium Technologies segment’s net sales decreased by $745 million (or 27%) to $2 billion for the nine months ended September 30, 2023, compared with segment net sales of $2.8 billion for the same period in ~~Europe~~2022. The decrease in segment net sales for the nine months ended September 30, 2023 was primarily attributable to a decrease in volume of 27%. Volumes decreased due to softer market demand in all regions. Prices were flat in comparison with the prior period as contractual price increases offset by decreases in our market exposed customer portfolio. Currency was flat for the nine months ended September 30, 2023 when compared to the same period of the prior year.

Adjusted EBITDA and Adjusted EBITDA Margin

For the ~~U.S. as well as increases~~three months ended September 30, 2023, segment Adjusted EBITDA decreased by $68 million (or 50%) to $69 million and Adjusted EBITDA margin decreased by approximately 600 basis points to 10%, compared with segment Adjusted EBITDA of $137 million and Adjusted EBITDA margin of 16% for the same period in ~~demand~~2022. For the nine months ended September 30, 2023, segment Adjusted EBITDA decreased by $333 million (or 60%) to $226 million and Adjusted EBITDA margin decreased by approximately 900 basis points to 11%, compared with segment Adjusted EBITDA of $559 million and Adjusted EBITDA margin of 20% for the same period in 2022. The decreases in segment Adjusted EBITDA and Adjusted EBITDA margin during the three months ended September 30, 2023, was primarily attributable to the aforementioned decrease in sales volumes and price. The decreases in segment Adjusted EBITDA and Adjusted EBITDA margin during the nine months ended September 30, 2023, were primarily attributable to the aforementioned decrease in sales volumes, the effects of inflation on costs, and lower fixed cost absorption.

The Chemours Company

Thermal & Specialized Solutions

The following table sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our ~~fluoropolymer products, leading to~~Thermal & Specialized Solutions segment for the three and nine months ended September 30, 2023 and 2022.


	Three Months Ended September 30,						Nine Months Ended September 30,
(Dollars in millions)	2023			2022			2023			2022
Segment net sales	$	436		$	417		$	1,445		$	1,360
Adjusted EBITDA		162			162			561			549
Adjusted EBITDA margin		37	%		39	%		39	%		40	%

The following table sets forth the impacts of price, volume, ~~increases of 5%~~currency, and ~~17% over the same periods in 2016, respectively. Marginal price increases and slightly favorable foreign currency exchange rates further improved~~portfolio changes on our Thermal & Specialized Solutions segment’s net sales for the three and nine months ended September 30, ~~2017 when compared with the same period in 2016.~~

~~Adjusted EBITDA and Adjusted EBITDA Margin~~

~~Adjusted EBITDA increased by 10% and 53% for the three and nine months ended September 30, 2017, respectively, when~~2023, compared with the same periods in ~~2016.~~ 2022.


Change in segment net sales from prior period	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Price		(1	)%		2	%
Volume		5	%		4	%
Currency		1	%		—	%
Total change in segment net sales		5	%		6	%

Segment Net Sales

Our ~~Adjusted EBITDA margin~~Thermal & Specialized Solutions segment’s net sales increased by ~~1% and 6%~~$19 million (or 5%) to $436 million for the three months ended September 30, 2023, compared with segment net sales of $417 million for the same period in 2022. The increase in segment net sales for the three months ended September 30, 2023 was primarily attributable to an increase in volume of 5% partially offset by a decrease in price of 1%. Volumes increased due to the continued adoption of OpteonTM products in stationary and automotive original equipment manufacturers. Prices decreased slightly primarily due to unfavorable regional product mix in legacy refrigerants and lower pricing in our automotive end markets. Favorable currency movements added a 1% tailwind to the segment’s net sales during three months ended September 30, 2023.

Our Thermal & Specialized Solutions segment’s net sales increased by $85 million (or 6%) to $1.4 billion for the nine months ended September 30, ~~2017,~~2023, respectively, compared with segment net sales of $1.4 billion for the same period in 2022. The increase in segment net sales for the nine months ended September 30, 2023 was primarily attributable to increases in volume of 4% and price of 2%. Volumes increased due to strong automotive original equipment manufacturer demand and continued adoption of OpteonTM products. Prices increased across the portfolio, excluding automotive end markets, due to changing market and regulatory dynamics and steady value-based pricing growth within our Refrigerants and Foam, Propellants and Other Products portfolio. Currency was flat for the nine months ended September 30, 2023 when compared ~~with~~to the same ~~periods in 2016. The increases in~~ period of the prior year.

Adjusted EBITDA and Adjusted EBITDA Margin

For the three months ended September 30, 2023, segment Adjusted EBITDA was $162 million, which was flat with adjusted EBITDA in the same period in 2022. For the three months ended September 30, 2023, Adjusted EBITDA margin decreased by approximately 200 basis points to 37%, compared with Adjusted EBITDA margin of 39% for the same period in 2022. For the nine months ended September 30, 2023, segment Adjusted EBITDA increased by $12 million (or 2%) to $561 million and Adjusted EBITDA margin decreased by approximately 100 basis points to 39%, compared with segment Adjusted EBITDA of $549 million and Adjusted EBITDA margin of 40% for the same period in 2022. The decrease in segment Adjusted EBITDA margin for the three months ended September 30, ~~2017 were~~2023 was primarily attributable to lower earnings from our equity affiliates and other income, higher production related fixed costs, and the ~~aforementioned volume increases, which were~~continued investment in R&D growth initiatives partially offset by ~~higher performance-related compensation, expenditures associated with Hurricane Harvey and capital-related expenses.~~ lower raw material costs experienced in the current quarter. The ~~increases~~increase in segment Adjusted EBITDA ~~and Adjusted EBITDA margin~~ for the nine months ended September 30, ~~2017 were~~2023 was primarily attributable to the aforementioned increase in sales volume ~~increases, which were~~and price, partially offset by higher raw material costs ~~associated with transformation activities~~ and lower earnings from our equity affiliates and other income. The decrease in Adjusted EBITDA margin during the nine months ended September 30, 2023 was primarily attributable to the aforementioned higher ~~performance-related compensation.~~raw material costs and lower earnings from our equity affiliates and other income.

~~Chemical Solutions~~

Three Months Ended September 30,

Nine Months Ended September 30,

(Dollars in millions)

2017

2016

2017

2016

Segment net sales

$
148

$
182

$
437

$
641

Adjusted EBITDA

18

9

37

30

Adjusted EBITDA margin

12
%

5
%

9
%

5
%

Change in segment net sales from prior period

Three Months Ended September 30, 2017

Nine Months Ended September 30, 2017

Price

—
%

1
%
Volume

5
%

5
%
Currency

—
%

—
%
Portfolio / other

(24
)%

(38
)%
Total change

(19
)%

(32
)%

The Chemours Company

~~Segment Net Sales~~

Advanced Performance Materials

~~Net~~

The following table sets forth the net sales, ~~decreased by 19%~~Adjusted EBITDA, and ~~32%~~Adjusted EBITDA margin amounts for our Advanced Performance Materials segment for the three and nine months ended September 30, ~~2017, respectively, when compared with~~2023 and 2022.


	Three Months Ended September 30,						Nine Months Ended September 30,
(Dollars in millions)	2023			2022			2023			2022
Segment net sales	$	343		$	450		$	1,118		$	1,236
Adjusted EBITDA		68			112			233			306
Adjusted EBITDA margin		20	%		25	%		21	%		25	%

The following table sets forth the ~~same periods in 2016. The decrease in~~impacts of price, volume, currency, and portfolio changes on our Advanced Performance Materials segment’s net sales for the three and nine months ended September 30, 2017 was primarily attributable to portfolio changes resulting from the sales of our aniline facility in Beaumont, Texas and our C&D and Sulfur businesses, as well as the production shutdown at our RMS facility in Niagara Falls, New York. Collectively, our portfolio changes represented a decrease in net sales of 24% and 38% when2023, compared with the ~~three and nine months ended September 30, 2016, respectively. The decrease~~same periods in 2022.


Change in segment net sales from prior period	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023
Price		2	%		6	%
Volume		(26	)%		(15	)%
Currency		—	%		(1	)%
Total change in segment net sales		(24	)%		(10	)%

Segment Net Sales

Our Advanced Performance Materials segment’s net sales ~~was partially offset~~decreased by ~~volume increases of 5%~~$107 million (or 24%) and ~~marginal price increases in the remaining segment~~$118 million (or 10%) to $343 million and $1.1 billion for the three and nine months ended September 30, ~~2017.~~

2023, respectively, compared with segment net sales of $450 million and $1.2 billion for the same period in 2022. The ~~Chemours Company~~

~~Adjusted EBITDA and Adjusted EBITDA Margin~~

~~Adjusted EBITDA increased by 100% and 23%~~decreases in segment net sales for the three and nine months ended September 30, ~~2017,~~2023 were primarily attributable to a decreases in volume of 26% and 15%, respectively, ~~when compared with~~partially offset by increases in price of 2% and 6%, respectively. Volumes decreased primarily due to demand softening in the ~~same periods~~Advanced Materials portfolio which serves more economically sensitive end-markets. Prices increased due to increasing sales in ~~2016.~~ high-value end-markets, including advanced electronics and clean energy, in the Performance Solutions portfolio, as well as pricing actions to offset higher raw material costs in our Advanced Materials portfolio. Unfavorable currency movements added a 1% headwind to the segment’s net sales during the nine months ended September 30, 2023.

Our ~~Adjusted EBITDA margin increased by 7%~~Performance Solutions portfolio’s net sales were $129 million and 4%$413 million for the three and nine months ended September 30, ~~2017,~~2023, respectively, ~~when compared with~~and $133 million and $373 million for the same ~~periods~~period in ~~2016. The increases in Adjusted EBITDA~~2022. Our Advanced Materials portfolio’s net sales were $214 million and ~~Adjusted EBITDA margin~~$705 million for the three and nine months ended September 30, ~~2017~~2023, respectively, and $317 million and $863 million for the same period in 2022.

Adjusted EBITDA and Adjusted EBITDA Margin

For the three months ended September 30, 2023, segment Adjusted EBITDA decreased by $44 million (or 39%) to $68 million and Adjusted EBITDA margin decreased by approximately 500 basis points to 20%, compared with segment Adjusted EBITDA of $112 million and Adjusted EBITDA margin of 25% for the same period in 2022. For the nine months ended September 30, 2023, segment Adjusted EBITDA decreased by $73 million (or 24%) to $233 million and Adjusted EBITDA margin decreased by approximately 400 basis points to 21%, compared with segment Adjusted EBITDA of $306 million and Adjusted EBITDA margin of 25% for the same period in 2022. The decreases in segment Adjusted EBITDA and Adjusted EBITDA margin for the three and nine months ended September 30, 2023 were primarily attributable to the aforementioned decreases in sales volume ~~increases~~driving lower fixed cost absorption, impact of higher raw material costs, and ~~cost reductions associated with portfolio changes and~~the continued effects of inflation on other ~~initiatives in the remaining segment.~~costs.

The Chemours Company

Corporate and Other

~~Corporate costs and certain legal and environmental expenses that are not allocated to the segments are reflected in~~

Corporate and ~~Other.~~Other costs increased by $3 million (or 6%) and decreased by $10 million (or 6%) to $54 million and $164 million for the three and nine months ended September 30, 2023, respectively, compared with Corporate and Other costs of $51 and $174 million for the same periods in 2022. The increase ~~of $16 million~~ in Corporate and Other costs for the three months ended September 30, ~~2017 when compared with the same period in 2016~~2023, was primarily attributable to ~~increased costs associated with~~higher legacy ~~environmental liabilities.~~related legal spend. The ~~increase of $31 million~~decrease in Corporate and Other costs for the nine months ended September 30, ~~2017 when compared with the same period in 2016~~2023, was primarily attributable to ~~increased costs associated with~~lower legacy environmental ~~liabilities, legal~~ costs and lower long-term performance-related ~~compensation.~~compensation partially offset by higher legacy related legal spend.

~~2017~~

2023 Outlook

~~For~~

Our 2023 results will be driven by the following expectations in each of our reportable segments:

•

Titanium Technologies – Fourth quarter demand is expected to be down sequentially consistent with normal seasonal patterns. Input costs are expected to improve inclusive of the benefits of the Kuan Yin plant closure;

•

Thermal & Specialized Solutions – Continued OpteonTM adoption in mobile and stationary applications ahead of the next EU and United States hydrofluorocarbons ("HFC") step-down in 2024, paired with uncertainty in the rate of automotive and construction end-market demand recovery. Expect typical seasonality in customer demand trends for the remainder of the ~~year, we continue to anticipate that~~year; and

•

Advanced Performance Materials – Anticipate weaker demand for products in the ~~Company’s revenue and earnings performance will remain strong.~~ Advanced Materials portfolio which serves economically sensitive end-markets, paired with continued elevated unit costs, partially offset by strong demand for high-value, differentiated products in the Performance Solutions portfolio.

We expect ~~to deliver full-year Adjusted EBITDA improvement,~~that our capital expenditures will be approximately $400 million, with ~~similar pre-tax income improvement, substantially in excess of our transformation goals. We are targeting additional structural cost savings of~~ approximately ~~$150~~$200 million for growth capital expenditures and ~~we continue to implement certain initiatives in order to realize our target cost savings, which are expected to be fully realized in 2018~~approximately $200 million for run and ~~beyond. We also expect to generate positive free cash flow for the full-year 2017, including payments relating to the PFOA MDL Settlement.~~ maintain, and sustainability.

Our outlook for 2023 reflects our current visibility and expectations based on market factors, such as currency movements, ~~TiO~~₂ ~~pricing,~~macro-economic factors, and end-market ~~demand~~demand. In particular, macro-economic factors may be impacted by factors beyond our control, including the ongoing Russia-Ukraine conflict. Our ability to meet our expectations are subject to numerous risks, including, but not limited to, those described in Item 1A – Risk Factors within our Annual Report on Form 10-K for the year ended December 31, 2022 and ~~seasonality.~~those updated in Item 1A – Risk Factors within this Quarterly Report on Form 10-Q for the period ended September 30, 2023.

Liquidity and Capital Resources

~~Chemours’~~

Our primary sources of liquidity are cash generated from operations and available cash, along with our receivables securitization and borrowings under our debt financing arrangements, which includes borrowing capacity under our revolving credit facility. Our operating cash flow generation is driven by, among other things, the general global economic conditions at any point in time and their resulting impacts on demand for our products, raw materials and energy prices, and industry-specific issues, such as production capacity and utilization. During the third quarter of 2023, we announced our Titanium Technologies Transformation Plan, that includes incremental efforts to streamline our workforce and improve other operational costs designed to yield cost savings and drive improved margins. We expect these transformation initiatives to deliver an earnings benefit of approximately $100 million in 2024. Despite the current challenging market conditions across the industry, we anticipate that through our cost efforts and growth initiatives, our operations will provide sufficient liquidity, together with the availability under our Revolving Credit Facility, to support the cash needs for the businesses. We have a historical pattern of seasonality, with working capital use of cash in the first half of the year, and a working capital source of cash in the second half of the year. We have generated strong operating cash flows through various past industry and economic cycles, evidencing the underlying operating strength of our businesses. The availability under our Revolving Credit Facility of $801 million as of September 30, 2023 is subject to the last 12 months of our consolidated EBITDA and senior secured net debt as defined under the Credit Agreement. Our debt financing arrangements are described in further detail in “Note 15 – Debt” to the Interim Consolidated Financial Statements in this Quarterly Report on Form 10-Q and “Note 20 – Debt” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2022.

The Chemours Company

Over the course of the next 12 months and beyond, we anticipate making significant cash payments for known contractual and other obligations, which we expect to fund through cash generated from operations, available cash, receivables securitization, and debt financing arrangements. Such obligations include principal and interest obligations on long-term debt, contractual obligations for operating and finance leases, purchase obligations, legal settlement agreements, and our expectations for capital expenditures, which, except as noted below, did not significantly change from what was previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022. Our contractual and other obligations also include:

•

Principal and interest obligations on long-term debt – In the third quarter of 2023, we entered into an amendment and restatement credit agreement, which amends and restates in its entirety the April 2018 Credit Agreement, that provides for New Term Loans, and a $900 million senior secured revolving credit facility. Proceeds from the New Term Loans were primarily used to prepay, in full, all outstanding amounts under the April 2018 Credit Agreement and fund our portion of the qualified settlement fund per the terms of the U.S. public water system settlement agreement. For a schedule of our debt principal maturities for the next five years and thereafter, refer to “Note 15 – Debt” to the Interim Consolidated Financial Statements.

•

Environmental remediation – We, due to the terms of our Separation-related agreements with EID, are subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances, which are attributable to EID’s activities before our spin-off. Much of this liability results from Comprehensive Environmental Response Compensation and Liability Act (“CERCLA”), Resource Conservation and Recovery Act (“RCRA”), and similar federal, state, local, and foreign laws. These laws may require us to undertake certain investigative, remediation, and restoration activities at sites where we conduct or EID once conducted operations or at sites where waste generated by us was disposed. At September 30, 2023, our consolidated balance sheets include $605 million for environmental remediation liabilities, of which $138 million was classified as current, and a portion is subject to recovery under the MOU. Of the current environmental liabilities of $138 million, $90 million relates to Fayetteville. Pursuant to the binding MOU that we entered into with DuPont, Corteva, and EID in January 2021, costs related to potential future legacy "PFAS" (perfluoroalkyl and polyfluoroalkyl substances) liabilities arising out of pre-July 1, 2015 conduct will be subject to the cost-sharing arrangement, where we bear half of the cost of such future potential legacy PFAS liabilities, and DuPont and Corteva will collectively bear the other half of the cost of such future potential legacy PFAS liabilities. Through September 30, 2023, aggregate Qualified Spend including settlements, by us, DuPont, and Corteva under the MOU amounted to $467 million. Refer to the “Environmental Matters” section within this MD&A for the anticipated environmental remediation payments over the next three years. Refer to “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements for further discussion of the MOU and Qualified Spend.

•

PFAS escrow funding requirements – In September 2023, we entered into a supplemental agreement to the binding MOU with DuPont, Corteva, and EID, whereby i) the parties agreed to release funds held in escrow to fund, in part, the qualified settlement fund per the terms of the U.S. public water system settlement agreement, ii) waive the escrow funding obligation of each party due no later than September 30, 2023 and iii) with respect to the escrow funding obligation due no later than September 30, 2024, will be waived by each of the parties under certain conditions as agreed to by the parties. The next escrow payment of $50 million is expected to be made on or before September 30, 2025 and on or before September 30 of each subsequent year through and including 2028. Refer to “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements for further discussion.

•

U.S Public Water District Settlement Agreement – In June 2023, we, Corteva/EID, and DuPont, together, entered into the U.S. public water system settlement agreement, under which the parties will collectively establish and contribute a total of $1.185 billion to the qualified settlement fund per the terms of the U.S. public water system settlement agreement. Contribution rates will be consistent with the binding MOU entered into among the parties in January 2021, with us contributing 50% (or approximately $592 million), and DuPont and Corteva collectively contributing the remaining 50%. The settlement amounts were to be funded by the parties in full and deposited into the qualified settlement fund within ten business days following preliminary approval of the settlement by the Court. Preliminary approval of the settlement by the Court was received on August 22, 2023, and on September 6, 2023, we funded $592 million into the qualified settlement fund, using a combination of proceeds from the issuance of the New Term Loans, funds available under the MOU escrow account, and available cash. The qualified settlement fund is recognized as restricted cash and restricted cash equivalents on our consolidated balance sheet at September 30, 2023. Refer to “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements for further discussion.

The Chemours Company

We continue to believe ~~these~~our sources of liquidity are sufficient to fund our planned operations and to meet our interest, dividend, and contractual ~~obligations.~~obligations, through at least October 2024. Our financial policy seeks ~~to (a)~~to: (i) selectively invest ~~for~~in organic and inorganic growth to enhance our portfolio, including certain strategic capital ~~investments, (b) return cash to shareholders through dividend payments and possible share repurchases in the future and (c)~~investments; (ii) maintain appropriate leverage by using free cash ~~flow~~flows to repay outstanding ~~borrowings.~~borrowings; and, (iii) return cash to shareholders through dividends and share repurchases. Specific to our objective to return cash to shareholders, in recent quarters, we have previously announced dividends of $0.25 per share, amounting to approximately $150 million per year, and, on October 26, 2023, we announced our quarterly cash dividend of $0.25 per share for the fourth quarter of 2023. Under our share repurchase program, as further discussed in Item 2 –Unregistered Sales of Equity Securities and Use of Proceeds in this Quarterly Report on Form 10-Q, we also have remaining authority to repurchase $441 million of our outstanding common stock. The share repurchase program may be suspended or discontinued at any time. Subject to approval by our board of directors, we may raise additional capital or borrowings from ~~time-to-time; however, there~~time to time, or seek to refinance our existing debt. There can be no ~~assurance~~assurances that future capital or borrowings will be available to us, and the cost and availability of new capital or borrowings could be materially impacted by market conditions.

~~We anticipate making significant payments for interest, capital expenditures, restructuring and dividends over~~ Further, the ~~next 12 months, which we expect~~decision to ~~fund through cash generated from operations, available cash and borrowings. We further anticipate that~~refinance our ~~operations and~~ existing debt ~~financing arrangements will provide sufficient liquidity for the Company over the next 12 months. The availability~~is based on a number of ~~funds under~~factors, including general market conditions and our ~~Revolving Credit Facility, which is discussed further~~ability to refinance on attractive terms at any given point in ~~the Credit Facilities and Notes section~~time. Any attempts to raise additional capital or borrowings or refinance our existing debt could cause us to incur significant charges. Such charges could have a material impact on our financial position, results of ~~this MD&A, is subject to the last 12 months of our consolidated EBITDA, as defined in the credit agreement.~~operations, or cash flows.

At September 30, ~~2017 and December 31, 2016,~~2023, we had ~~$1.0 billion and $678 million, respectively, of~~total cash and cash equivalents ~~on our consolidated balance sheets~~of $852 million, of which $526 million was held by our foreign subsidiaries. All cash and cash equivalents held by our foreign subsidiaries ~~all of which~~ is readily convertible into currencies used in our operations, including the U.S. ~~Dollar. Cash and earnings of our foreign subsidiaries are generally used to finance their operations and capital expenditures. At~~dollar. During the nine months ended September 30, ~~2017~~2023, we received approximately $210 million of net cash in the U.S. through intercompany dividends and loans. For further information related to our income tax positions, refer to “Note 9 – Income Taxes” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2016, management believed that sufficient liquidity was available in the U.S., and it is our intention to indefinitely reinvest undistributed earnings of our foreign subsidiaries outside of the U.S. From time to time, we evaluate opportunities to repatriate cash from foreign jurisdictions. Our current plans consider repatriating cash only at levels that would result in minimal or no net adverse tax consequences in the near term.2022.

No deferred tax liabilities have been recognized with regard to the $1.0 billion and $678 million of cash and cash equivalents held by our foreign subsidiaries at September 30, 2017 and December 31, 2016, respectively, or on our undistributed earnings. The potential tax implications of the repatriation of unremitted earnings are driven by facts at the time of distribution. Therefore, it is not practicable to estimate the income tax liabilities that might be incurred if such cash and earnings were repatriated to the U.S.

The Chemours Company

Cash Flows

The following table sets forth a summary of the net cash provided by (used for) our operating, investing, and financing ~~activities:~~

Nine Months Ended September 30,

(Dollars in millions)

2017

2016

Cash provided by operating activities

$
336

$
324

Cash (used for) provided by investing activities

(202
)

469

Cash provided by (used for) financing activities

468

(230
)

~~Operating Activities~~

~~Cash provided by operating~~ activities ~~was $336 million and $324 million~~ for the nine months ended September 30, ~~2017~~2023 and 2016, respectively. Increases resulting from net income of $519 million for the nine months ended September 30, 2017 when compared with $237 million for the nine months ended September 30, 2016 were offset by our payment of the PFOA MDL Settlement for $3352022.


	Nine Months Ended September 30,
(Dollars in millions)	2023			2022
Cash provided by operating activities	$	72		$	594
Cash used for investing activities		(99	)		(219	)
Cash provided by (used for) financing activities		179			(495	)

Operating Activities

We generated $72 million and ~~our full utilization of the $190~~$594 million ~~prepayment received~~in cash flows from ~~DuPont in 2016 during 2017, which negatively impacted~~ our operating ~~cash flows resulting from changes in working capital.~~

~~Investing Activities~~

~~Cash used for investing~~ activities was $202 million for the nine months ended September 30, 2017 compared with cash provided by investing activities of $469 million for the nine months ended September 30, 2016. Our capital expenditures for the nine months ended September 30, 2017 and 2016 remained consistent at $246 million and $235 million, respectively. In the nine months ended September 30, 2017, we sold our corporate headquarters building in Wilmington, Delaware and the land which formerly held our manufacturing facility in Edge Moor, Delaware for net proceeds of $29 million and $9 million, respectively. In the nine months ended September 30, 2016, we sold our aniline facility in Beaumont, Texas, land in Repauno, New Jersey, and our C&D and Sulfur businesses for net proceeds of $140 million, $22 million, $223 million and $321 million, respectively.

We expect our full year capital expenditures in 2017 to be between $400 million and $450 million, which exceeds our annual capital expenditures in 2016, primarily due to expenditures associated with our new Opteon^TM ~~plant under construction in Corpus Christi, Texas and our Mining Solutions expansion in Laguna, Mexico, which began in June 2017.~~

~~Financing Activities~~

Cash provided by financing activities was $468 million for the nine months ended September 30, 2017 compared with cash used for financing activities of $230 million for the nine months ended September 30, 2016. In May 2017, we issued a $500 million aggregate principal amount of 5.375% senior unsecured notes, which are due in May 2027. Proceeds from this offering were $489 million, which is net of an original issue discount of $5 million and underwriting fees and other related expenses of $6 million. We received $30 million from the exercise of employees’ stock options during 2017. Repayments on our senior secured term loans, payments for dividends and tax payments for withholdings on vested restricted stock units of $24 million, $16 million and $10 million, respectively, offset our financing cash inflows for the nine months ended September 30, 2017.

In the third quarter of 2016, we repurchased a portion of our senior secured term loans with an aggregate principal amount of $50 million for $49 million, a portion of our 2023 Notes with an aggregate principal amount of $116 million for $107 million and a portion of our Euro Notes with an aggregate principal amount of $42 million for $39 million. These repurchases were made in addition to our required quarterly repayments on our senior secured term loans throughout the year. We also paid dividends amounting to $16 million during the nine months ended September 30, ~~2016.~~2023 and 2022, respectively. The decrease in our operating cash inflows was primarily attributable to lower earnings, changes in net working capital, primarily due to higher payment of payables due to timing, inventory build and higher cost of raw materials, and higher spend at our Fayetteville site. These decreases were partially offset by lower incentive compensation payment in 2023 compared to 2022 and the one-time payment of the $25 million settlement with the State of Delaware in 2022 that did not recur in 2023.

~~Current Assets~~

(Dollars in millions)

September 30, 2017

December 31, 2016

Cash and cash equivalents

$
1,535

$
902

Accounts and notes receivable - trade, net

942

807

Inventories

877

767

Prepaid expenses and other

79

77

Total current assets

$
3,433

$
2,553

41Investing Activities

We used $99 million and $219 million in cash flows for our investing activities during the nine months ended September 30, 2023 and 2022, respectively which were primarily attributable to purchases of property, plant, and equipment amounting to $235 million and $240 million, respectively. Cash outflows from investing activities during the nine months ended September 30, 2023 were partially offset by $138 million of cash proceeds related to the Glycolic Acid Transaction. Cash outflows from investing activities during the nine months ended September 30, 2022 were partially offset by $17 million of cash proceeds related to the Beaumont Transaction and $16 million of cash proceeds related to the Pascagoula Transaction.

Financing Activities

We generated $179 million in cash flows for our financing activities during the nine months ended September 30, 2023 which were primarily attributable $367 million of net proceeds received in connection with the issuance of the New Term Loans. We also used cash for capital allocation activities, resulting in $69 million in purchases of our issued and outstanding common stock under our 2022 Share Repurchase Program and $112 million of cash dividends.

We used $495 million in cash flows for our financing activities during the nine months ended September 30, 2022 which were primarily attributable to our capital allocation activities, resulting in $351 million in purchases of our issued and outstanding common stock under our 2022 and 2018 Share Repurchase Programs, $117 million of cash dividends and $64 million in debt repayments, including open market repurchases, partially offset by $51 million in stock option exercises.

The Chemours Company

~~Accounts~~Current Assets

The following table sets forth the components of our current assets at September 30, 2023 and December 31, 2022.


(Dollars in millions)	September 30, 2023		December 31, 2022
Cash and cash equivalents	$	852	$	1,102
Restricted cash and restricted cash equivalents		595		—
Accounts and notes receivable, net		846		626
Inventories		1,314		1,404
Prepaid expenses and other		76		82
Total current assets	$	3,683	$	3,214

Restricted cash and restricted cash equivalents of $595 million represents cash and cash equivalents deposited in the Water District Settlement Fund, which was classified as a current asset at September 30, 2023 in line with the expected timing of the Final Judgment, as defined in the Settlement Agreement.

Our accounts and notes receivable, ~~- trade,~~net increased by $220 million (or 35%) to $846 million at September 30, 2023, compared with accounts and notes receivable, net of $626 million at December 31, 2022. This increase in our accounts and notes receivable, net at September 30, ~~2017 increased by $135 million when compared with December 31, 2016 due~~2023 was primarily attributable to the timing of collections from our customers and higher sales in the third quarter of ~~2017 over~~2023 (primarily in our Titanium Technologies and Thermal & Specialized Solutions businesses) driving higher receivables when compared to the fourth quarter of ~~2016 and a favorable currency translation impact~~2022, partially offset by the increased utilization of ~~$22 million.~~our Securitization Facility.

~~Inventories~~

Our inventories decreased by $90 million (or 6%) to $1.3 billion at September 30, ~~2017 increased by $110 million when~~2023, compared with inventories of $1.4 billion at December 31, ~~2016~~2022. The decrease in our inventories at September 30, 2023 was primarily attributable to efforts to optimize inventory levels to the current demand environment within our Titanium Technologies business and the write-off of $28 million of certain raw materials inventory from the Kuan Yin, Taiwan plant closure, partially offset by build-up of our finished product inventories within our Advanced Performance Materials business in anticipation of planned plant maintenance during the second half of 2023, a favorable foreign currency translation adjustment of approximately $21 million and an increase in the value of our raw material inventories due to ~~inventory build for increased sales demand~~higher raw material costs.

Our prepaid expenses and ~~a favorable currency translation impact~~other decreased by $6 million (or 7%) to $76 million at September 30, 2023, compared with prepaid expenses and other of ~~$17 million.~~$82 million at December 31, 2022. The decrease in our prepaid expenses and other was primarily due to decreases in prepaid income tax balances.

The Chemours Company

Current Liabilities

(Dollars in millions)

September 30, 2017

December 31, 2016

Accounts payable

$
1,010

$
884

Current maturities of long-term debt

14

15

Other accrued liabilities

546

872

Total current liabilities

$
1,570

$
1,771

~~Accounts~~

The following table sets forth the components of our current liabilities at September 30, 2023 and December 31, 2022.


(Dollars in millions)	September 30, 2023		December 31, 2022
Accounts payable	$	901	$	1,251
Compensation and other employee-related costs		94		121
Short-term and current maturities of long-term debt		23		25
Current environmental remediation		138		194
Other accrued liabilities		1,039		300
Total current liabilities	$	2,195	$	1,891

Our accounts payable decreased by $350 million (or 28%) to $901 million at September 30, 2023 compared with accounts payable of $1.3 billion at December 31, 2022. The decrease in our accounts payable at September 30, ~~2017~~2023 was primarily attributable to the timing of vendor payments and lower purchases due to lower demand (primarily in our Titanium Technologies business).

Our compensation and other employee-related costs decreased by $27 million (or 22%) to $94 million at September 30, 2023 compared with compensation and other employee-related costs of $121 million at December 31, 2022. The decrease in our compensation and other employee-related costs at September 30, 2023 was primarily attributable to decreased accruals for employee performance-based compensation following payout of 2022 employee performance-based compensation during the first quarter of 2023 and lower accruals in 2023 relative to prior year.

Our current environmental remediation decreased by $56 million (or 29%) to $138 million at September 30, 2023 compared with current environmental remediation of $194 million at December 31, 2022. The decrease in our current environmental remediation at September 30, 2023 was primarily attributable to the lower on-site accrual at Fayetteville following completion of the barrier wall and groundwater extraction and treatment systems to meet the requirements of the Consent Order (“CO”) from the North Carolina Department of Environmental Quality (the “NC DEQ”).

Our other accrued liabilities increased by ~~$126~~$739 million ~~when~~(or over 100%) to $1 billion at September 30, 2023 compared with other accrued liabilities of $300 million at December 31, ~~2016~~2022. The increase in our other accrued liabilities was primarily attributable to litigation and other legal accruals, including the $592 million accrual related to the U.S. public water system settlement agreement, along with increases in our accrued interest due to ~~higher inventories and~~the timing of ~~payments~~payment under our senior unsecured notes, accrued income taxes, and accrued severance primarily related to ~~vendors.~~

~~Other~~the Titanium Technologies Transformation Plan. The increase in our other accrued liabilities at September 30, ~~2017 decreased~~2023 was partially offset by ~~$326 million when compared with December 31, 2016 primarily due~~payments made for customer rebates during the first quarter of 2023. The litigation matters are further discussed in "Note 17 - Commitments and Contingent Liabilities" to ~~payment of~~ the ~~PFOA MDL Settlement for $335 million.~~Interim Consolidated Financial Statements in this Quarterly Report on Form 10-Q.

The Chemours Company

Credit Facilities and Notes

Our credit agreement, as amended, provides for seven-year senior secured term loans and a five-year, $750 million senior secured revolving credit facility (Revolving Credit Facility). The proceeds of any loans made under the Revolving Credit Facility can be used for capital expenditures, acquisitions, working capital needs and other general corporate purposes. Availability under the Revolving Credit Facility is subject

Refer to ~~certain covenant limitations. At September 30, 2017, the facility had a full borrowing capacity of $750 million, from which we had $102 million in letters of credit issued and outstanding.~~

On April 3, 2017, we completed an amendment (April 2017 Amendment) to our credit agreement which provides for a new class of term loans, denominated in Euros, in an aggregate principal amount of €400 million (Euro Term Loan), and a new class of term loans, denominated in U.S. Dollars, in an aggregate principal amount of $940 million (Dollar Term Loan, and, collectively with the Euro Term Loan, the New Term Loans). The New Term Loans replaced in full the prior term loan (Prior Term Loan) outstanding of $1.4 billion. The New Term Loans mature on May 12, 2022, which is the same maturity date of the Prior Term Loan. The Euro Term Loan bears a variable interest rate equal to EURIBOR plus 2.25%, subject to a EURIBOR floor of 0.75%, and the Dollar Term Loan bears a variable interest rate equal to LIBOR plus 2.50%, subject to a LIBOR floor of 0.00%. The April 2017 Amendment also modified certain provisions of the credit agreement, including increasing certain incurrence limits to allow further flexibility for the Company. All other provisions, including financial covenants, remained unchanged. No incremental debt was issued as a result of the April 2017 Amendment, although the Euro Term Loan is subject to remeasurement gains or losses. We recorded a $3 million loss on debt extinguishment and related amendment fees in the second quarter of 2017.

~~The credit agreement contains financial covenants which, solely with respect~~“Note 15 – Debt” to the ~~Revolving Credit Facility, as amended, require us not~~Interim Consolidated Financial Statements in this Quarterly Report on Form 10-Q and “Note 20 – Debt” to exceed a maximum senior secured net leverage ratio of: (a) 3.50 to 1.00 each quarter through December 31, 2016; (b) 3.00 to 1.00 through June 30, 2017; and (c) further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. We are also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict our and our subsidiaries’ ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. The senior secured credit facilities and the Notes (collectively, the 2023 Notes, the 2025 Notes, the Euro Notes and the 2027 Notes) contain events of default customary for these types of financings, including cross default and cross acceleration provisions to material indebtedness of Chemours. We wereConsolidated Financial Statements in ~~compliance with our debt covenants at September 30, 2017.~~

In the event of default under our Revolving Credit Facility, our lenders under the Revolving Credit Facility can terminate their commitments thereunder, cease making further revolving loans and accelerate any outstanding revolving loans. This would allow the lenders under the Revolving Credit Facility to declare the outstanding term loans to be immediately due and payable and to institute foreclosure proceedings against the collateral securing the credit facility, which could force us into bankruptcy or liquidation. Any event of default or declaration of acceleration under the credit agreement also may result in an event of default under the indentures governing the Notes. Any such default, event of default or declaration of acceleration could materially and adversely affect our results

~~The Chemours Company~~

~~of operations and financial condition. Please see the section titled Risks Related to Our Indebtedness of the Risk Factors section of~~ our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2022 for ~~additional detail.~~a discussion of our credit facilities and notes.

~~For the remainder~~

Guarantor Financial Information

The following disclosures set forth summarized financial information and alternative disclosures in accordance with Rule 13-01 of 2017, under the April 2017 Amendment, we are required to make principal payments related to the New Term Loans of $3 million and approximately $14 million in each year from 2018 to 2021. Debt maturities related to the New Term Loans and the Notes in 2022 and beyond will be $4,085 million. In addition, following the end of each fiscal year commencing on the year ended December 31, 2016, on an annual basis, we are also required to make additional principal repayments, depending on our leverage level as defined in the credit agreement, equivalent to up to 50% of excess cash flow based on certain leverage targets with stepdowns to 25% and 0% as actual leverage decreases to below a 3.00 to 1.00 leverage target at the end of each fiscal year. No principal repayments were required to beRegulation S-X (“Rule 13-01”). These disclosures have been made in ~~2017 based upon our December 31, 2016 excess cash flow determined under~~connection with certain subsidiaries' guarantees of the ~~credit agreement. See Note 12 to~~4.000% senior unsecured notes due May 2026, which are denominated in euros and the ~~Interim Consolidated Financial Statements included in this Quarterly Report on Form 10-Q for additional information related to our indebtedness.~~

~~On May 23, 2017, Chemours issued a $500 million aggregate principal amount of~~ 5.375% senior unsecured notes due May 2027 (2027 Notes). The 2027 Notes require payment of principal at maturity and interest semi-annually in cash and in arrears on May 15 and November 15 of each year. The Company received proceeds of $489 million, net of an original issue discount of $5 million and underwriting fees and other related expenses of $6 million,(collectively, the “Registered Notes”), which are ~~deferred and amortized to interest expense using~~registered under the ~~effective interest method over the term~~Securities Act of 1933, as amended. Each series of the ~~2027 Notes. A portion of the net proceeds from the 2027~~Registered Notes was ~~used to pay the $335 accrued for the global settlement of the PFOA MDL Settlement,~~issued by The Chemours Company (the “Parent Issuer”), and ~~the remainder is available for general corporate purposes.~~

~~The 2027 Notes are~~was fully and unconditionally guaranteed, jointly and severally, on a senior unsecured ~~unsubordinated~~ basis by ~~each of~~ the existing and future domestic subsidiaries that (a) incurs or guarantees indebtedness under the Senior Secured Credit Facilities or (b) guarantees other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $100 million. The guarantees of the ~~2027 Notes will rank equally with all other senior indebtedness~~Parent Issuer (together, the “Guarantor Subsidiaries”), subject to certain conditions, which are further discussed in “Note 20 – Debt” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2022. The assets, liabilities, and operations of the ~~guarantors.~~Guarantor Subsidiaries primarily consist of those attributable to The ~~2027 Notes rank equally~~Chemours Company FC, LLC, our primary operating subsidiary in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and are senior in right of payment to all of Chemours’ existing and future debt that is by its terms expressly subordinated in right of payment to the ~~2027 Notes. The 2027 Notes are subordinated to indebtedness under the Senior Secured Credit Facilities~~United States, as well as ~~any future secured debt~~certain U.S.-based subsidiaries included in Exhibit 22 to this Quarterly Report on Form 10-Q. Each of the Guarantor Subsidiaries is 100% owned by the Company. None of our other subsidiaries, either direct or indirect, guarantee the Registered Notes (together, the “Non-Guarantor Subsidiaries”). Pursuant to the ~~extent of~~indentures governing the ~~value of~~Registered Notes, the ~~assets securing such debt, and structurally subordinated to the liabilities of any non-guarantor subsidiaries.~~

Chemours may redeem the 2027 Notes, in whole or in part, at an amount equal to 100% of the aggregate principal amount plus a specified “make-whole” premium and accrued and unpaid interest, if any, to the date of purchase prior to February 15, 2027. Chemours may also redeem some or all of the 2027 Notes by means other than a redemption, including tender offer and open market repurchases. Chemours is obligated to offer to purchase the 2027 Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase,Guarantor Subsidiaries will be automatically released from those guarantees upon the occurrence of certain ~~change~~customary release provisions.

Our summarized financial information is presented on a combined basis, consisting of ~~control events.~~the Parent Issuer and Guarantor Subsidiaries (collectively, the “Obligor Group”), in accordance with the requirements under Rule 13-01, and is presented after the elimination of: (i) intercompany transactions and balances among the Parent Issuer and Guarantor Subsidiaries, and (ii) equity in earnings from and investments in the Non-Guarantor Subsidiaries.

~~Supplier Financing~~


(Dollars in millions)	Nine Months Ended September 30, 2023
Net sales	$	3,109
Gross profit		622
Loss before income taxes		(320	)
Net loss		(250	)
Net loss attributable to Chemours		(250	)

~~We maintain global paying services agreements with two financial institutions. Under these agreements,~~


(Dollars in millions)	September 30, 2023		December 31, 2022
Assets
Current assets (1,2,3)	$	2,129	$	1,553
Long-term assets (4)		3,250		3,485

Liabilities
Current liabilities (2)	$	1,928	$	1,554
Long-term liabilities		4,897		4,528

(1)

Current assets includes $325 million and $514 million of cash and cash equivalents at September 30, 2023 and December 31, 2022, respectively. Current assets at September 30, 2023 also includes $595 million of restricted cash and restricted cash equivalents related to qualified settlement funds under the ~~financial institutions act as~~U.S. public water system class action suit settlement.

(2)

Current assets includes $386 million and $326 million of intercompany accounts receivable from the ~~paying agents for Chemours with respect to~~Non-Guarantor Subsidiaries at September 30, 2023 and December 31, 2022, respectively. Current liabilities includes $230 million and $318 million of intercompany accounts payable ~~due~~ to ~~our suppliers who elect to participate in~~ the ~~program. The agreements allow our suppliers to sell their receivables to one of the participating financial institutions~~Non-Guarantor Subsidiaries at the discretion of both parties on terms that are negotiated between the supplier and the respective financial institution. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers’ decisions to sell their receivables under this program. At September 30, ~~2017, total payment instructions from Chemours amounted to $158 million. Pursuant to their agreement~~2023 and December 31, 2022, respectively.

(3)

As of September 30, 2023 and December 31, 2022, $126 million and $46 million of accounts receivable generated by the Obligor Group, respectively, remained outstanding with one of the Non-Guarantor Subsidiaries under the Securitization Facility.

(4)

Long-term assets includes $210 million and $303 million of intercompany notes receivable from the Non-Guarantor Subsidiaries at September 30, 2023 and December 31, 2022, respectively. Long-term assets at December 31, 2022 also includes $202 million of restricted cash and restricted cash equivalents related to an escrow account as per the terms of the MOU.

There are no significant restrictions that may affect the ability of the Guarantor Subsidiaries in guaranteeing the Parent Issuer’s obligations under our debt financing arrangements. While the Non-Guarantor Subsidiaries do not guarantee the Parent Issuer’s obligations under our debt financing arrangements, we may, from time to time, repatriate post-2017 earnings from certain of these subsidiaries to meet our financing obligations, as well.

The Chemours Company

Supplier Financing

We maintain supply chain finance programs with several financial ~~institutions, certain suppliers may elect to get paid early at their discretion.~~institutions. The available capacity under these programs can vary based on the number of investors and/or financial institutions participating in these programs at any point in time. See "Note 13 – Accounts Payable" to the Interim Consolidated Financial Statements for further details regarding supplier financing programs.

~~Contractual Obligations~~

~~During the quarter ended September 30, 2017,~~Off-Balance Sheet Arrangements

In March 2023, through a wholly-owned special purpose entity ("SPE"), we entered into ~~a raw materials supply contract with a third party supplier which resulted in an increase to our total purchase obligations for raw materials. This increase has been reflected in~~ the ~~table below, which shows the Company’s total purchase obligation-related contractual obligations.~~

Payments Due In

(Dollars in millions)

Total at
September 30, 2017

Remainder of 2017

2018 - 2019

2020 - 2021

2022 and
Beyond

Purchase obligations for raw materials

$
1,240

$
40

$
218

$
142

$
840

~~The Chemours Company~~

~~Off Balance Sheet Arrangements~~

~~Information with respect to Chemours’ guarantees is included in Note 20~~Third Amendment to the Purchase Agreement, as amended, under our Securitization Facility, which among other things, extends the term of the Purchase Agreement, increases the facility limit from $150 million to $175 million, replaces the interest rate benchmark from the London Interbank Offered Rate ("LIBOR") to the Secured Overnight Financing Rate ("SOFR"), and adds a conduit purchaser.

See "Note 15 – Debt" to the Interim Consolidated Financial Statements for further details regarding this off-balance sheet arrangement.

Historically, we have not made any payments to satisfy guarantee obligations; however, we believe we have the financial resources to satisfy these guarantees in the event required.

Critical Accounting Policies and Estimates

Our significant accounting policies are described in our MD&A and “Note 3 – Summary of Significant Accounting Policies” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2016. Historically, we have not made significant payments to satisfy guarantee obligations; however, we believe Chemours has the financial resources to satisfy these guarantees in the event required. Any remaining guarantees outstanding at September 30, 2017 were insignificant.

~~Critical Accounting Policies and Estimates~~

Chemours’ significant accounting policies are described in Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates and Note 3 to the Consolidated Financial Statements in our Annual Report on Form 10-K.2022. There have been no material changes to ~~our~~the critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~

~~Recent~~2022, except as described in “Note 2 – Summary of Significant Accounting ~~Pronouncements~~

~~See Note 2~~Policies” to the Interim Consolidated Financial Statements ~~included in Item 1~~.

Recent Accounting Pronouncements

See “Note 2 – Summary of ~~this Quarterly Report on Form 10-Q~~Significant Accounting Policies” to the Interim Consolidated Financial Statements for ~~discussions of~~a discussion about recent accounting pronouncements.

The Chemours Company

Environmental Matters

Consistent with ~~Chemours’~~our values and our Environment, Health, Safety, and ~~Safety Policy,~~Corporate Responsibility policy, we are committed to preventing releases to the environment at our manufacturing sites to keep our people and communities safe, and to be good stewards of the environment. ~~Chemours is~~We are also subject to environmental laws and regulations relating to the protection of the environment. We believe that, as a general matter, our policies, standards, and procedures are properly designed to prevent unreasonable risk of harm to people and the environment, and that our handling, manufacture, use, and disposal of hazardous substances are in accordance with applicable environmental laws and regulations.

Environmental Remediation

~~Mainly~~

In large part, because of past operations, operations of predecessor companies, or past disposal practices, we, like many other similar companies, have clean-up responsibilities and associated remediation costs, and are subject to claims by other parties, including claims for matters that are liabilities of ~~DuPont~~EID and its subsidiaries that ~~Chemours~~we may be required to indemnify pursuant to the ~~separation-related~~Separation-related agreements executed prior to ~~the separation.~~our separation from EID on July 1, 2015 (the “Separation”).

Our environmental ~~reserve includes~~liabilities include estimated costs, ~~related~~including certain accruable costs associated with on-site capital projects. The accruable costs relate to a number of sites for which it is probable that environmental remediation will be required, whether or not subject to enforcement activities, as well as those obligations that result from environmental laws such as ~~the Comprehensive Environmental Response Compensation and Liability Act (CERCLA, often referred to as Superfund), the Resource Conservation and Recovery Act (RCRA)~~CERCLA, RCRA, and similar federal, state, ~~federal~~local, and foreign laws. These laws may require certain investigative, remediation, and restoration activities at sites where ~~Chemours conducts~~we conduct or EID once conducted operations or at sites where ~~Chemours-generated~~our generated waste was disposed. AtOur consolidated balance sheets at September 30, ~~2017~~2023 and December 31, ~~2016, we recorded~~2022 include environmental remediation ~~accruals~~liabilities of ~~$268~~$605 million and ~~$278~~$668 million, respectively, relating to these matters, which, as discussed in ~~management’s opinion, is appropriate based on existing facts~~further detail below, include $399 million and ~~circumstances.~~$465 million, respectively, for Fayetteville.

~~Our remediation portfolio is relatively mature, with many of our sites under active clean-up moving towards final completion.~~

As remediation efforts progress, sites move from the investigation phase (“Investigation”) to the active clean-up phase (“Active Remediation”), and as construction is completed at ~~active clean-ups,~~Active Remediation sites, those sites move to the ~~ongoing~~operation, maintenance, and monitoring ~~(OM&M)~~(“OM&M”), or closure phase. As final ~~clean-ups~~clean-up activities for some significant sites are completed over the next several years, we expect our annual expenses related to these active sites to decline over time. The ~~time-frame~~time frame for a site to go through all phases of remediation ~~(investigation~~(Investigation and ~~active clean-up)~~Active Remediation) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, and diverse regulatory requirements, as well as the presence or absence of other ~~potentially responsible parties.~~Potentially Responsible Parties (“PRPs”). In addition, for claims that ~~Chemours~~we may be required to indemnify ~~DuPont~~EID pursuant to the ~~separation-related~~Separation-related agreements, ~~Chemours, through DuPont, has~~we and EID may have limited available information for certain sites or isare in the early stages of discussions with regulators. For these sites, ~~in particular,~~ there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs, and, under adverse changes in circumstances, ~~although deemed remote,~~we currently estimate the potential ~~liability~~liabilities may range up to ~~$510~~approximately $730 million above the amount accrued at September 30, ~~2017.~~ 2023. This estimate is not intended to reflect an assessment of our maximum potential liability. The estimated liabilities are determined based on existing remediation laws and technologies and our planned remedial responses, which are derived from environmental studies, sampling, testing, and analyses. Inherent uncertainties exist in such evaluations, primarily due to unknown environmental conditions, changing governmental regulations regarding liability, and emerging remediation technologies. We will continue to evaluate as new or additional information becomes available in the determination of our environmental remediation liability.

In general, uncertainty is greatest and the range of potential liability is widest in the ~~investigation~~Investigation phase, ~~and narrows~~narrowing over time as regulatory agencies approve site remedial ~~plans,~~plans. As a result, uncertainty is reduced,

~~The Chemours Company~~

and sites ultimately ~~sites~~ move into OM&M, ~~where~~as needed. As more sites advance from ~~investigation~~Investigation to ~~active clean-up~~Active Remediation to OM&M or closure, the upper end of the range of potential liability is expected to decrease over time.

Some remediation sites will achieve site closure and will require no further action to protect people and the environment and comply with laws and regulations. At certain sites, we expect that there will continue to be some level of remediation activity due to ongoing ~~monitoring and/or operations and maintenance~~OM&M of remedial systems. In addition, portfolio changes, such as an acquisition or divestiture, or notification as a ~~potentially responsible party~~PRP for a multi-party Superfund site, could result in additional remediation activity and potentially additional accrual.

Management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on our financial position ~~results of operations~~ or cash flows infor any given year, as such obligation can be satisfied or settled over many years. ~~For additional information, refer to the~~

The Chemours Company

Significant Environmental ~~Matters section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2016.~~Remediation Sites

While there are many remediation sites that contribute to ~~the~~our total accrued environmental remediation ~~accrual,~~liabilities at September 30, 2023 and December 31, 2022, the following table sets forth the liabilities of the five sites that are ~~among~~deemed the most ~~significant:~~significant, together with the aggregate liabilities for all other sites.

(Dollars in millions)

September 30, 2017

December 31, 2016

Beaumont, Texas

$
12

$
12

Chambers Works, New Jersey

21

24

East Chicago, Indiana

20

20

Pompton Lakes, New Jersey

64

77

USS Lead, East Chicago, Indiana

28

21

All other sites

123

124

Total accrued environmental remediation

$
268

$
278


(Dollars in millions)	September 30, 2023		December 31, 2022
Chambers Works, Deepwater, New Jersey	$	30	$	30
Fayetteville Works, Fayetteville, North Carolina		399		465
Pompton Lakes, New Jersey		41		41
USS Lead, East Chicago, Indiana		13		17
Washington Works, West Virginia		22		17
All other sites		100		98
Total environmental remediation	$	605	$	668

The five sites listed above represent ~~more than 50%~~83% and 85% of our ~~reserve~~total accrued environmental remediation liabilities at September 30, 2023 and December 31, 2022, respectively. For these five sites, we expect to spend, in the aggregate, ~~approximately $100~~$187 million over the next three years. For all other sites, we expect to spend ~~approximately $80~~$63 million over the next three years.

~~Beaumont Works, Beaumont, Texas~~

Beaumont Works began operations in 1954 in Beaumont, Jefferson County, Texas. Over the years, Beaumont Works has produced a number of basic chemicals and elastomer products including acrylonitrile, ammonia, methanol, methyl methacrylate, caprolactam, Hypalon® synthetic rubber, Nordel® hydrocarbon rubber and blended tetraethyl lead with halo-carbon solvent/stabilizers. As of June 30, 2017, with our sale of the aniline production unit to Dow in 2016, Chemours has no ongoing manufacturing operations on the site. Dow and Lucite remain as long-term manufacturing tenants.

As site owner, Chemours remains responsible for remediation of historical chemical releases from past operations and is conducting this work under a RCRA hazardous waste post-closure permit and Compliance Plan (CP) issued by the State of Texas. The hazardous waste permit includes provisions to manage wastes and to investigate and mitigate releases. The CP is a component of the permit and includes mitigation and monitoring requirements, including a groundwater remediation system that was installed in 1991 to control chemical migration and protect adjacent water bodies. In addition, several solid waste management unit closures have been conducted and areas of past release addressed through interim measures to protect people and the environment. Over the years, extensive site studies have been completed and a final investigation report (Affected Property Assessment Report, or APAR, under the Texas Risk Reduction Program) for the entire site was approved by the state in 2014. Chemours has recently completed a remedial action plan (RAP), currently under agency review, to address all remaining historical solid waste management units and areas of concern identified in these studies, and expects to have this RAP approved in 2018.

The remediation accrual for Beaumont addresses remaining work identified in the RAP under review by the state as well as post-closure care and monitoring and ongoing operation of the groundwater remediation system. A portion of the accrual also addresses an outstanding Natural Resource Damage claim by state and federal trustees directed to impacts on marshlands within the plant property.

~~The Chemours Company~~

Chambers Works, Deepwater, New Jersey (“Chambers Works”)

The Chambers Works complex is located on the eastern shore of the Delaware River in Deepwater, Salem County, New Jersey. The site comprises the former Carneys Point Works in the northern area and the Chambers Works manufacturing area in the southern area. Site operations began in 1892 when the former Carneys Point smokeless gunpowder plant was constructed at the northern end of Carneys Point. Site operations began in the manufacturing area around 1914 and included the manufacture of dyes, aromatics, elastomers, chlorofluorocarbons, and tetraethyl lead. ~~Chemours continues~~We continue to manufacture a variety of ~~fluorochemicals~~fluoropolymers and finished products at Chambers Works. In addition, ~~three~~two tenants operate processes at Chambers ~~Works including steam/electricity generation, industrial gas production and the manufacture of intermediate chemicals.~~Works. As a result of over 100 years of continuous industrial activity, site soils and groundwater have been impacted by chemical releases.

In response to identified groundwater contamination, a groundwater interceptor well system ~~(IWS)~~(“IWS”) was installed in 1970, which was designed to contain contaminated groundwater and restrict off-site migration. Additional remediation is being completed under a ~~Federal~~federal RCRA Corrective Action ~~Permit.~~permit. The site has been studied extensively over the years, and more than 25 remedial actions have been completed to date and engineering and institutional controls put in place to ensure protection of people and the environment. In 2017, a site perimeter sheet pile barrier intended to more efficiently contain groundwater was completed.

Remaining work beyond continued operation of the IWS and groundwater monitoring includes completion of ~~a site perimeter sheet pile barrier intended to more efficiently contain groundwater, completion of~~ various targeted studies ~~onsite~~on site and in adjacent water bodies to close investigation data gaps, ~~and~~as well as selection and implementation of final remedies under RCRA Corrective Action for various solid waste management units and areas of concern not yet addressed through interim measures. Discussions are ongoing with the U.S. Environmental Protection Agency (the “EPA”) and the New Jersey Department of Environmental Protection (the “NJ DEP”) relating to such remaining work as well as the scope of remedial programs and investigation relating to the Chambers Works site historic industrial activity as well as ongoing remedial programs.

~~East Chicago, Indiana~~

~~East Chicago~~

The Chemours Company

Fayetteville Works, Fayetteville, North Carolina

Fayetteville is ~~a former manufacturing~~located southeast of the City of Fayetteville in Cumberland and Bladen counties, North Carolina. The facility ~~owned~~encompasses approximately 2,200 acres, which were purchased by ~~Chemours~~EID in ~~East Chicago, Lake County, Indiana. The approximate 440-acre site is~~1970, and are bounded to the ~~south~~east by the ~~East Branch of the Grand Calumet~~Cape Fear River ~~to the east and north by residential and commercial areas~~ and to the west by ~~industrial areas, including a~~North Carolina Highway 87. Currently, we manufacture fluorinated monomers, fluorinated vinyl ethers, NafionTM membranes and dispersions, and polymerization aids at the site. A former ~~lead processing facility. The inorganic chemicals unit on site~~manufacturing area, which was sold in 1992, produced ~~various chloride, ammonia~~nylon strapping and ~~zinc products~~elastomeric tape. EID sold its Butacite® and ~~inorganic agricultural chemicals beginning~~SentryGlas® manufacturing units to Kuraray America, Inc. in ~~1892 until 1986. Organic chemical manufacturing began in 1944, consisting primarily of chlorofluorocarbons production. Current operations, including support activities, now cover 28 acres~~September 2014. In July 2015, upon our Separation from EID, we became the owner of the ~~site. The remaining business was sold~~Fayetteville land assets along with fluoromonomers, NafionTM membranes, and the related polymerization aid manufacturing units. A polyvinyl fluoride resin manufacturing unit remained with EID.

Beginning in 1996, several stages of site investigation were conducted under oversight by NC DEQ, as required by the facility's hazardous waste permit. In addition, the site has voluntarily agreed to ~~W.R. Grace Company (Grace) in early 2000, and Grace operates the unit as a tenant. Approximately 172 acres~~agency requests for additional investigations of the ~~site were never developed~~potential release of PFAS beginning with “PFOA” (collectively, perfluorooctanoic acids and ~~are managed~~its salts, including the ammonium salt) in 2006. As a result of detection of GenX in on-site groundwater wells during our investigations in 2017, NC DEQ issued a Notice of Violation (“NOV”) in September 2017 alleging violations of North Carolina water quality statutes and requiring further response. Since that time, and in response to three additional NOVs issued by ~~The Nature Conservancy for habitat preservation.~~NC DEQ and pursuant to the Consent Order (as discussed below), we have worked cooperatively with the agency to investigate and address releases of PFAS to on-site and off-site groundwater and surface water.

~~A comprehensive evaluation of soil~~

As discussed in “Note 17 – Commitments and ~~groundwater conditions~~Contingent Liabilities” to the InterimConsolidated Financial Statements, we, along with NC DEQ and Cape Fear River Watch (“CFRW”), a non-profit organization, have filed a final CO that comprehensively addressed various issues, NOVs, and court filings made by NC DEQ regarding Fayetteville and resolved litigations filed by NC DEQ and CFRW. In connection with the CO, a thermal oxidizer became fully operational at the site ~~was performed as part~~in December 2019 to reduce aerial PFAS emissions from Fayetteville. The CO requires us to provide permanent replacement drinking water supplies, via connection to public water supply, whole building filtration units and/or reverse osmosis units, to qualifying surrounding residents, businesses, schools, and public buildings with private drinking water wells.

In 2020, we, along with NC DEQ and CFRW, reached agreement on the terms of an addendum to the CO (the “Addendum”). The Addendum establishes the procedure to implement specified remedial measures for reducing PFAS loadings from Fayetteville to the Cape Fear River, including construction of a barrier wall with groundwater extraction system to be completed by March 15, 2023, or an extended date in accordance with the Addendum. In June 2023, we completed the construction of the ~~RCRA corrective action process. Studies of historical site impacts began~~barrier wall with a groundwater extraction and treatment system in ~~1983 in response to preliminary CERCLA actions undertaken by~~accordance with the U.S. Environmental Protection Agency (EPA). The EPA eventually issued an Administrative Order on Consent for the site in 1997. The order specified that remediation work be performed under RCRA Corrective Action authority. Work has proceededrequirements under the ~~RCRA Corrective Action process since that time.~~CO, subject to receipt of final quality assurance samples, engineers certification and NC DEQ’s review.

~~Subsequent investigations~~

Further discussion related to Fayetteville is included under the ~~preparation of initial environmental site assessments~~heading “Fayetteville Works, Fayetteville, North Carolina” in “Note 17 – Commitments and ~~multiple phases of investigation. In 2002, as an interim remedial measure, two 2,000-foot-long permeable reactive barrier treatment walls were installed along~~Contingent Liabilities” to the northern property boundary to address migration of chemicals in groundwater. Since that time, the investigation process has been completed and approved by the EPA and work is in progress to define the final remedy for the site.Interim Consolidated Financial Statements.

Pompton Lakes, New Jersey

During the 20th century, blasting caps, fuses, and related materials were manufactured at Pompton Lakes, Passaic County, New Jersey. Operating activities at the site were ceased in the mid-1990s. ~~Primary~~The primary contaminants in the soil and sediments are lead and mercury. ~~Ground water~~Groundwater contaminants include volatile organic compounds. Under the authority of ~~the~~ EPA and ~~the New Jersey Department of Environmental Protection,~~NJ DEP, remedial actions at the site are focused on investigating and ~~cleaning up~~cleaning-up the area. ~~Ground water~~Groundwater monitoring at the site is ongoing, and ~~Chemours has~~we have installed and ~~continues~~continue to install vapor mitigation systems at residences within the ~~ground water~~groundwater plume. In addition, ~~Chemours is~~we are further assessing ~~ground water~~groundwater conditions. In ~~June~~September 2015, ~~the~~ EPA issued a modification to the site’s RCRA permit that requires ~~Chemours~~us to dredge mercury contamination from a 36-acre area of the lake and remove sediment from two other areas of the lake near the shoreline. The remediation activities commenced when permits and implementation plans were approved in May 2016, and work on the lake dredging project is ~~expected~~now complete. In April 2019, we submitted a revised Corrective Measures Study (“CMS”) proposing actions to ~~be complete~~address on-site soils impacted from past operations that exceed applicable clean-up criteria. We received comments on the CMS from EPA and NJ DEP in ~~2018.~~March 2020, and we responded to their comments in June 2020 and continue to seek resolution with EPA.

The Chemours Company

U.S. Smelter and Lead Refinery, Inc., East Chicago, Indiana

The U.S. Smelter and Lead Refinery, Inc. ~~(USS Lead)~~(“USS Lead”) Superfund ~~Site~~site is located in the Calumet neighborhood of East Chicago, Lake County, Indiana. The site includes the former USS Lead facility along with nearby commercial, municipal, and residential areas. The primary compounds of interest are lead and arsenic which may be found in soils within the impacted area. The EPA is directing and organizing remediation on this site, and ~~Chemours is~~we are one of a number of parties working cooperatively with ~~the~~ EPA on the safe and timely completion of this work. ~~DuPont’s~~EID’s former East Chicago manufacturing facility was located adjacent to the site, and ~~DuPont~~EID assigned responsibility for the site to ~~Chemours~~us in the ~~2015 separation agreement.~~Separation Agreement.

The USS Lead Superfund site was listed on the National Priorities List in 2009. To facilitate negotiations with ~~potentially responsible parties, the~~PRPs, EPA divided the residential part of the USS Lead Superfund ~~Site~~site into three zones, referred to as Zone 1, Zone 2, and Zone 3. The division into three zones resulted in Atlantic Richfield Co. (“Atlantic Richfield”) and ~~DuPont~~EID entering into an agreement in 2014 with ~~the~~ EPA and the State of Indiana to reimburse ~~the~~ EPA’s costs to implement ~~cleanup~~clean-up in Zone 1 and Zone 3. ~~More recently in~~In March 2017, ~~Chemours~~we and three other parties ~~(Atlantic~~– Atlantic Richfield, ~~Co., DuPont~~EID, and the U.S. Metals Refining Co. (“U.S. Metals”) – entered into an administrative order on consent to reimburse ~~the~~ EPA’s costs to ~~clean up~~clean-up a portion of Zone 2. ~~The~~In March 2018, EPA ~~is continuing its efforts to identify additional potentially responsible parties (PRPs)~~issued a Unilateral Administrative Order for the USS Lead site cleanup, including the remainder of Zone 2. The EPA has scheduled negotiations with some of these parties. The EPA has stated its intention to issue a unilateral order to potentially responsible parties to complete the Zone 2 work. There is uncertainty as to whether the parties who receive the unilateral order will be able to reach an allocation and agree to comply with it.

The environmental accrual for USS Lead is based on the Record of Decision (ROD) and Statement of Work currently in place for Zones 1 and 3, as well as the current estimate of Chemours’ share of the EPA’s Zone 2 cleanup cost. The EPA has announced its intent to reconsider the ROD for Zone 1 and the result of that review could increase or decrease Chemours’ future obligations. In response to the latest cost information received from the EPA for Zone 3 work, as well as the EPA’s stated objective to order Chemours and other PRPs to complete the remainder of the Zone 2 work ~~Chemours increased its~~to five parties, including us, Atlantic Richfield, EID, U.S. Metals, and USS Lead Muller Group, and these parties entered into an interim allocation agreement to perform that work. As of the end of 2019, the required work in Zone 3 had been completed, and Zone 2 was nearly complete by the end of 2020. The determination of a final allocation for Zone 2 and/or the other Zones is ongoing, and additional PRPs may be identified.

The environmental accrual for USS Lead includes completion of the remaining obligations under the 2012 Record of Decision (“ROD”) and Statement of Work, which principally encompasses completion of Zone 1. The EPA released a proposed amendment to the 2012 ROD (the “ROD Amendment”) for a portion of Zone 1 in December 2018 (following its August 2018 Feasibility Study Addendum), with its recommended option based on future residential use. The EPA’s ROD Amendment for modified Zone 1 was released in March 2020, and selects as the preferred remedy one which requires a clean-up to residential standards based on the current applicable residential zoning. The ROD Amendment for modified Zone 1 also sets forth a selected contingent remedy which requires clean-up to commercial/industrial standards if the future land use becomes commercial/industrial. In November 2019, a Letter of Intent was executed by ~~$8 million~~the City of East Chicago, Indiana and Industrial Development Advantage, LLC ("IDA"), relating to modified Zone 1 development, and EPA has indicated that it is “more likely” that future land use in this area will be commercial/industrial and not residential.

In 2021, we resolved the claims asserted by EPA related to past indirect costs associated with the 2012 ROD as amended, and the 2014 agreement entered into with EPA and the State of Indiana. In September 2022, EPA confirmed the selection of remedial actions for modified Zone 1 and provided notice to all relevant parties, including IDA, to cause the agreements between EPA, DOJ, the State of Indiana, us and other PRPs to become effective. We expect that our future costs relating to the USS Lead site will be contingent on implementation of these agreements, resolution of EPA’s costs as well as any final allocation between PRPs.

The Chemours Company

Washington Works, Parkersburg, West Virginia (“Washington Works”)

The Washington Works complex is located on the eastern shore of the Ohio River south of Parkersburg, West Virginia. The facility encompasses approximately 400 acres, which were purchased by EID in the ~~third quarter~~late 1940’s. Other nearby land parcels purchased by EID included Blennerhassett Island, and three separate properties where West Virginia Department of ~~2017.~~Environmental Protection ("WV DEP") permitted landfills were operated. Site operations began in 1948 and included the manufacture of nylon, filaments, and acrylics. In 1949, fluoropolymer manufacturing began, and in 1959, Delrin production was started. Landfill operations occurred from the 1960’s through the early 2000’s when all three were closed according to WV DEP approved closure plans. Beginning in 2014, EID no longer used PFOA as a polymerization aid to manufacture some fluoropolymer resins at Washington Works.

~~PFOA~~

~~See discussion~~In July 2015, upon our separation from EID, we became the owner of the Washington Works complex. The site has implemented environmental investigations, including Verification Investigation in 1992 and RCRA Facility Investigation ("RFI") in 1999 pursuant to corrective action requirements of its RCRA Part B and HSWA Permit under ~~PFOA~~EPA and the West Virginia Department of Natural Resources oversight. The RFI was approved in ~~Note 13~~2012 and a CMS was completed in 2015 that recommended certain remedial actions, including capping of the former on-site landfill and ponds, which had already been completed, sitewide groundwater hydraulic control, drinking water supply well treatment via granular activated carbon, and long-term groundwater monitoring. These actions were memorialized in a RCRA final remedy implementation plan approved by the agencies in 2018 and integrated into the updated RCRA permit in August 2020.

The remedial actions required by the RCRA final remedy implementation plan have been completed or are part of routine operations, maintenance and monitoring. Landfill post closure care includes systems to treat surface water, leachate or groundwater, landfill cover or cap maintenance, monitoring and reporting. Additionally, upgrades to the Local landfill cover are being developed. Accruals related to these remedial actions were $22 million and $17 million as of September 30, 2023 and December 31, 2022, respectively.

Chemours Washington Works discharges, through outfalls at the site, wastewater and stormwater pursuant to a National Pollutant Discharge Elimination System ("NPDES") permit issued by the WV DEP. In connection with actions being taken by us to comply with certain NPDES effluent limits, including for PFOA and hexafluoropropylene oxide dimer acid, we submitted a permit modification to WV DEP relating to groundwater abatement for certain process water used at the facility, a temperature reduction project and realigning discharge flows to certain outfalls. In July 2021, EPA provided a specific objection to the draft modification based on Clean Water Act (“CWA”) regulations and requirements. In August 2021, WV DEP issued a NPDES permit modification to provide for the start-up of an abatement unit at the facility and to extend compliance dates for certain limits to December 2021 due to delays from the COVID-19 pandemic. In September 2021, WV DEP issued a further NPDES modification, including for the operation of an abatement unit from the site’s Ranney Well, and the site is taking additional actions to reduce PFAS discharges associated with wet weather flows and continuing to assess future stormwater discharges and permitting. In April 2023, we agreed to an Administrative Order on Consent with EPA that includes additional sampling as well as a compliance analysis and implementation of actions to address PFOA and hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid”) discharge exceedances that occurred following the outfall limits for these compounds coming into effect in January 2022. We expect to make future capital and other operating related expenditures at Washington Works in connection with this Consent Order.

Pursuant to an Order on Consent ("OC"), entered into by EID with EPA since 2006, we provide alternate drinking water supplies, via granular activated carbon ("GAC") treatment or other approved supply, to residential well owners and local public drinking water systems near the Washington Works complex whose PFOA concentration exceeds 70 parts per trillion. We also provide regular sampling and GAC change outs activities as per OC requirements. Accruals related to this matter were $16 million and $15 million as of September 30, 2023 and December 31, 2022, respectively, and were included in Accrued Litigation liability in “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements.

New Jersey Department of Environmental Protection Directives and Litigation

In March 2019, NJ DEP issued two Directives, one being a state-wide PFAS Directive, and filed four lawsuits against us and other defendants, including allegations relating to clean-up and removal costs at four sites including Chambers Works. In December 2021, a consolidated order was entered in the lawsuits granting, in part, and denying, in part a motion to dismiss or strike parts of the Second Amended Complaints. In January 2022, NJ DEP filed a motion for a preliminary injunction requiring EID and us to establish a remediation funding source (“RFS”) in the amount of $943 million for Chambers Works, the majority of which is for non-PFAS remediation items. Further discussion related to these matters is included in ~~this Quarterly Report~~“Note 17 – Commitments and Contingent Liabilities” to the InterimConsolidated Financial Statements.

The Chemours Company

Climate Change

Central to our commitment to sustainability are our ten CRC goals that we aim to achieve by 2030. These goals map to the United Nations Sustainable Development Goals. We recognize that our responsibility to all stakeholders goes well beyond our CRC goals, and our commitment to sustainability cannot be separated from our growth strategy or our vision. As a result, in 2023 we are aligning our sustainability focus and actions to the four key strategic pillars that support our Chemours vision: Innovation and Sustainable Solutions, Environmental Leadership, Community Impact, and Greatest Place to Work for All.

The Environmental Leadership pillar underlines our commitment to deliver essential solutions responsibly, without causing harm to the Earth. With a focus on ~~Form 10‑Q.~~the responsible treatment of climate, water, and waste, our Environmental Leadership 2030 goals are comprised of the following:

•

60% reduction in Scope 1 and Scope 2 absolute GHG emissions;

•

99% or more reduction of air and water process emissions of fluorinated organic chemicals ("FOCs"); and,

•

70% reduction in landfill volume intensity.

~~Fayetteville, North Carolina~~In 2021, we announced an update to our climate goals to better align our climate commitment with the Paris Accord and set us on a path to achieve net zero greenhouse gas emissions from our operations by 2050. In 2022, we announced our signed commitment with the Science Based Targets initiative (“SBTi”) to establish science-based targets for scopes 1, 2, and 3 GHG emissions.

As part of the Innovation and Sustainable Solutions pillar, we are reimagining our portfolio to offer solutions that are also safer, healthier, and more resilient for a world that demands more. We believe that climate change is an important global issue that presents both opportunities and challenges for our company, our partners, our customers, and our communities. Climate change matters for our company are likely to be driven by changes in physical and transition risk, such as regulations and/or public policy, and changes in technology and product demand. Our operations and business results are increasingly subject to evolving climate-related legislation and regulations, inclusive of restrictions on GHG emissions, cap and trade emissions trading systems, and taxes on GHG emissions, fuel, and energy, among other provisions. Such regulatory matters have led, and are expected to continue to lead, to subsequent developments in product technology and demand. This helps guide our investment decisions and drive growth in demand for low-carbon and energy-efficient products, manufacturing technologies, and services that facilitate adaptation to a changing climate. Our business segments conduct market trend impact assessments, continuously evaluate opportunities for existing and new products and are well-positioned to take advantage of opportunities that may arise from increased consumer demand for and/or legislation mandating or incentivizing the use of products and technologies necessary to achieve a low-carbon economy.

In our Thermal & Specialized Solutions segment, global regulations driving the phase-down of hydrofluorocarbons ("HFCs"), including the EU’s F-Gas Directive, the EU’s Mobile Air Conditioning Directive, and the recently enacted U.S. American Innovation and Manufacturing Act (“AIM”), promote the adoption and sale of our high performing Opteon™ products, which have lower global warming potential (“GWP”) and zero ozone-depletion footprint. Our Opteon™ portfolio has been developed to meet global regulations while maintaining or improving performance compared to the products they replace in refrigeration and cooling applications, such as food transportation, food and pharmaceutical/medical storage, food manufacturing and retail, automotive air conditioning, and residential and commercial building air conditioning. By the year 2025, we estimate that our low GWP products will eliminate an estimated 325 million tons of carbon dioxide equivalents on a global basis.

We are a proponent of the recently passed bipartisan AIM Act, that went into effect in 2022, and will begin the national phase-down of hydrofluorocarbons. We successfully completed an improvement project to significantly reduce emissions of HFC-23 at our Louisville, Kentucky manufacturing site. The project includes the design, custom-build and installation of proprietary technology to capture at least 99% of HFC-23 process emissions from the site. This project was operational as of October 2022 and we are completing compliance validation of the system under an extension granted by the EPA.

In our Advanced Performance Materials segment, our growth prospects in fluoropolymers are also enhanced by regulation driving the increasing demand for electric vehicles and high-performance, low-emission vehicles. Our fluoropolymers are critical to delivering high performance over a wide range of harsh operating conditions, enhancing passenger safety, improving emission controls and fuel economy, and enabling vehicle electrification and the shift to hydrogen-powered vehicles. We expect the use of our fluoropolymers in vehicles to increase, driven by the automotive industry’s trends toward energy efficiency and clean energy due to evolving emissions performance regulations and increasing adoption of electric vehicles. Our fluoropolymer technology supports growing market demand for clean hydrogen generation using water electrolyzers, energy storage in flow batteries, and hydrogen conversion to power fuel cell vehicles.

The Chemours Company

In our Titanium Technologies business, we recently unveiled our new Ti-Pure™ Sustainability ("TS") product series, designed to advance our customers’ and company’s sustainability goals through TiO2 innovation. The product series includes enhanced product sustainability designations—including climate impact, circularity, resource efficiency, and health and wellness. The business is aligning its new product development pipeline to the same categories, ensuring all innovations align with critical customer and societal challenges, enable at-a-glance product sustainability comparisons, and ultimately help customers advance their sustainability goals. New TS innovations will be launched across market segments in 2023.

As an energy and emissions intensive company, our costs of complying with complex environmental laws and regulations, as well as internal and external voluntary programs, are significant and will continue to be significant for the foreseeable future. These laws and regulations may change and could become more stringent over time, which could result in significant additional compliance costs, increased costs of purchased energy or other raw materials, increased transportation costs, investments in, or restrictions on, our operations, installation or modification of GHG-emitting equipment, or additional costs associated with GHG emissions. Additionally, significant regional or national differences in approaches to the imposition of such regulations and restrictions could present competitive challenges or opportunities in a global marketplace. Currently, most of our global operating facilities are required to monitor and report their GHG emissions but may or may not be subject to programs requiring trading or emission controls. The EU Emission Trading System applies to our operating sites in that region. Furthermore, U.S. political administration could lead to additional federal regulation with respect to GHG emissions limits and/or other legislation that could impact our operations. By tracking and taking action to reduce our GHG emissions footprint through energy efficiency programs, increased use of renewable energy and focused GHG emissions reduction programs, we can decrease the potential future impact of these regulatory matters.

PFOA

See our discussion under ~~Fayetteville, North Carolina~~the heading “PFOA” in ~~Note 13~~“Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements ~~included~~.

GenX

In June 2019, the Member States Committee of the European Chemicals Agency (“ECHA”) voted to list HFPO Dimer Acid as a Substance of Very High Concern. The vote was based on Article 57(f) – equivalent level of concern having probable serious effects to the environment. This identification does not impose immediate regulatory restriction or obligations, but may lead to a future authorization or restriction of the substance. On September 24, 2019, we filed an application with the EU Court of Justice for the annulment of the decision of ECHA to list HFPO Dimer Acid as a Substance of Very High Concern. In February 2022, the General Court dismissed the annulment action and we have appealed such decision.

PFAS

Refer to our discussion in “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements.

In May 2020, ECHA announced that five Member States (Germany, the Netherlands, Norway, Sweden, and Denmark) launched a call for evidence to inform a PFAS restriction proposal to restrict the manufacture, placing on the market and use of PFAS in the EU. In this ~~Quarterly Report~~regulatory process, more than 4,000 substances, including F-gases and fluoropolymers are being considered as part of this broad regulatory action. Companies producing or using PFAS, as well as selling mixture or products containing PFAS, were invited to provide input. This call for evidence closed July 31, 2020. Thousands of substances meet the definition of PFAS as outlined in the call for evidence. This very broad definition covers substances with a variety of physical and chemical properties, health and environmental profiles, uses, and benefits. We submitted information on ~~Form 10‑Q.~~the substances covered by the call for evidence to the Member State competent authority for Germany, which is the Federal Institute for Occupational Safety and Health (“BAuA”). On July 15, 2021, the countries submitted their restriction proposal, which informs ECHA of the intent to prepare a PFAS restriction dossier for fluorinated substances within a defined structural formula scope, including branched fluoroalkyl groups and substances containing ether linkages, fluoropolymers and side chain fluorinated polymers. The restriction dossier was submitted to ECHA in January 2023, and in February 2023 ECHA published a report and supporting annexes on the restriction proposal, which includes identified concerns for in-scope PFAS and their degradation products and the proposed restriction of a full ban with certain use-specific time-limited derogation periods. The restriction dossier will be reviewed by the ECHA Risk Assessment Committee ("RAC") and Socio-economic Analysis Committee (“SEAC”) and proposals submitted to the EU Commission in 2023. The estimated earliest entry into force of restrictions is 2025, contingent upon timely completion of the remaining steps in the EU Registration, Evaluation, Authorization, and Restriction of Chemicals (“REACH”) restriction process.

The Chemours Company

Non-GAAP Financial Measures

We prepare our interim consolidated financial statements in accordance with generally accepted accounting principles in the U.S. ~~(U.S. GAAP)~~(“GAAP”). To supplement our financial information presented in accordance with ~~U.S.~~ GAAP, we provide the following non-GAAP financial measures – Adjusted EBITDA, Adjusted Net Income, ~~and~~Adjusted Earnings per Share (“EPS”), Free Cash ~~Flow,~~Flows (“FCF”), Adjusted FCF, Return on Invested Capital (“ROIC”), and Net Leverage Ratio – in order to clarify and provide investors with a better understanding of ~~the Company’s~~our performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational ~~decision making.~~decision-making. We utilize Adjusted EBITDA as the primary measure of segment profitability used by our ~~Chief Operating Decision Maker.~~CODM.

Adjusted EBITDA is defined as income (loss) before income taxes, excluding the following:

•

interest expense, depreciation, and amortization;

•

costs;

•

exchange (gains) losses included in other income (expense), net;

•

restructuring, asset-related, ~~charges~~ and other ~~charges, net;~~

charges;

•

~~asset impairments;~~

(gains) losses on ~~sale~~sales of ~~business or assets;~~assets and

business; and,

•

other items not considered indicative of our ongoing operational performance and expected to occur ~~infrequently.~~

infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA.

Adjusted ~~net income~~Net Income is defined as our net income ~~attributable to Chemours~~(loss), adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, ~~and~~ amortization, and certain provision for (benefit from) income ~~taxes. Free Cash Flow~~tax amounts. Adjusted EPS is calculated by dividing Adjusted Net Income by the weighted-average number of our common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of our stock-based compensation awards, which includes unvested restricted shares. FCF is defined as

~~The Chemours Company~~

our cash flows provided by (used for) operating activities, less ~~cash used for~~ purchases of property, plant, and equipment as ~~disclosed~~shown in ~~the~~our consolidated statements of cash flows. ROIC is defined as Adjusted Earnings before Interest and Taxes (“Adjusted EBIT”), divided by the average of our invested capital, which amounts to our net debt, or debt less cash and cash equivalents, plus equity. Net Leverage Ratio is defined as our total debt principal outstanding less cash and cash equivalents, divided by Adjusted EBITDA.

Beginning in the third quarter of 2023, we added a new non-GAAP liquidity measure of Adjusted FCF to exclude the impact of cash inflows/outflows that are significant, unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of our business nor reflect the ongoing operational performance and underlying cash generation of our businesses. The change was driven by certain PFAS related settlements and legal fees that we believe were unusual in nature or infrequent in occurrence that neither related to the Company’s ordinary course of business nor ongoing operational performance and underlying cash generation of our businesses. We believe that excluding items of this nature provides the Company’s investors with better understanding of, and enables them to compare, the underlying cash generation of our businesses from period to period. Prior year measures have been presented to conform with the current measure of Adjusted FCF for the nine months ended September 30, 2022.

We believe the presentation of these non-GAAP financial measures, when used in conjunction with ~~U.S.~~ GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing ~~the Company’s~~our operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under ~~U.S.~~ GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, FCF, Adjusted FCF, ROIC, and ~~Free Cash Flow~~Net Leverage Ratio should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. Additionally, FCF or Adjusted FCF should not be used in a manner that inappropriately implies that the measure represents the residual cash flow available for discretionary expenditures, since mandatory debt service requirements or other non-discretionary expenditures are not deducted from these measures. The non-GAAP financial measures we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provided in this Quarterly Report on Form 10-Q, should be read in conjunction with the ~~Company’s interim consolidated financial statements~~Interim Consolidated Financial Statements and notes thereto included in this ~~Quarterly Report on Form 10-Q,~~report, as well as the ~~Company's consolidated financial statements~~Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2022.

The Chemours Company

The following table ~~reconciles~~sets forth a reconciliation of our net income (loss) attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS for the three and nine months ended September 30, 2023 and 2022.


	Three Months Ended September 30,						Nine Months Ended September 30,
(Dollars in millions, except per share amounts)	2023			2022			2023			2022
Net income (loss) attributable to Chemours	$	20		$	240		$	(212	)	$	675
Non-operating pension and other post-retirement employee benefit cost (income)		1			(1	)		1			(4	)
Exchange losses (gains), net		9			(13	)		21			(11	)
Restructuring, asset-related, and other charges (1)		153			(2	)		168			14
Loss (gain) on extinguishment of debt		1			(7	)		1			(7	)
Gain on sales of assets and businesses (2)		(106	)		—			(106	)		(27	)
Transaction costs (3)		7			—			7			—
Qualified spend recovery (4)		(11	)		(14	)		(43	)		(41	)
Litigation-related charges (5)		31			(23	)		675			(15	)
Environmental charges (6)		8			11			9			182
Adjustments made to income taxes (7)		(1	)		(3	)		(5	)		(9	)
(Benefit from) provision for income taxes relating to reconciling items (8)		(16	)		8			(107	)		(20	)
Adjusted Net Income		96			196			409			737
Net income attributable to non-controlling interests		—			—			1			—
Interest expense, net		55			41			145			123
Depreciation and amortization		76			72			233			217
All remaining provision for income taxes		20			54			86			164
Adjusted EBITDA	$	247		$	363		$	874		$	1,241

Weighted-average number of common shares outstanding - basic		148,623,633			155,376,422			148,929,580			157,149,738
Dilutive effect of our employee compensation plans (9)		1,562,005			2,473,700			1,753,788			3,199,339
Weighted-average number of common shares outstanding - diluted		150,185,638			157,850,122			150,683,368			160,349,077

Per share data
Basic earnings (loss) per share of common stock (10)	$	0.13		$	1.54		$	(1.42	)	$	4.30
Diluted earnings (loss) per share of common stock (9) (10)		0.13			1.52			(1.42	)		4.21
Adjusted basic earnings per share of common stock (9)		0.64			1.26			2.75			4.69
Adjusted diluted earnings per share of common stock (9)		0.63			1.24			2.71			4.60

(1)

Refer to "Note 5 – Restructuring, Asset-related, and Other Charges" to the Interim Consolidated Financial Statements for further details. In addition, the periods ended in September 30, 2023 include $28 million related to the write-off of certain raw materials inventory from the Kuan Yin, Taiwan plant closure. In 2022, includes asset charges and write-offs resulting from the conflict between Russia and Ukraine and our decision to suspend our business with Russian entities.

(2)

Refer to “Note 6 – Other Income (Expense), Net” to the Interim Consolidated Financial Statements for further details.

(3)

Includes costs associated with the New Senior Secured Credit Facilities entered into during the third quarter of 2023 which is discussed in further detail in "Note 15 – Debt" to the Interim Consolidated Financial Statements.

(4)

Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements.

(5)

(6)

Environmental charges pertains to management’s assessment of estimated liabilities associated with certain non-recurring environmental remediation expenses at various sites. In 2022, environmental charges include $175 million primarily related to an update to the off-site drinking water programs at Fayetteville and changes in estimates related to the barrier wall constructions. Refer to “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements for further details.

(7)

Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.

(8)

The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

(9)

In periods where we incur a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the nine months ended September 30, 2023. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three and nine months ended September 30, 2023, as Adjusted Net Income ~~discussed above~~was in a net income position.

(10)

Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers.

The Chemours Company

The following table sets forth a reconciliation of our cash flows provided by (used for) operating activities to FCF and Adjusted FCF for the nine months ended September 30, 2023 and 2022.


	Nine Months Ended September 30,
(Dollars in millions)	2023			2022
Cash provided by operating activities	$	72		$	594
Less: Purchases of property, plant, and equipment		(235	)		(240	)
Free Cash Flows		(163	)		354
PFAS Litigation Settlements (1)		37			25
Adjusted Free Cash Flows	$	(126	)	$	379

(1)

Represents litigation settlements and fees related to PFAS and PFOA matters.

The following table sets forth a reconciliation of Adjusted EBIT and average invested capital, and their nearest respective GAAP measures, to ROIC for the periods presented.


	Twelve Months Ended September 30,
(Dollars in millions)	2023			2022
Adjusted EBITDA (1)	$	995		$	1,548
Less: Depreciation and amortization (1)		(307	)		(294	)
Adjusted EBIT	$	688		$	1,254

	As of September 30,
(Dollars in millions)	2023			2022
Total debt, net (2)	$	3,967		$	3,534
Total equity		757			1,285
Less: Cash and cash equivalents		(852	)		(1,167	)
Invested capital, net	$	3,872		$	3,652
Average invested capital (3)	$	3,776		$	3,648

Return on Invested Capital		18	%		34	%

(1)

Reconciliations of net income (loss) attributable to Chemours to Adjusted EBITDA are provided on a quarterly basis. Refer to the preceding table for the ~~periods presented:~~

Three Months Ended September 30,

Nine Months Ended September 30,

(Dollars in millions)

2017

2016

2017

2016

Net income attributable to Chemours

$
207

$
204

$
518

$
237

Non-operating pension and other post-retirement
employee benefit income

(7
)

(5
)

(24
)

(19
)
Exchange losses (gains)

4

17

(3
)

37

Restructuring charges

8

14

31

41

Asset-related charges

1

46

3

109

Gain on sale of assets or businesses

—

(169
)

(14
)

(258
)
Transaction costs ¹

1

2

3

18

Legal and other charges ²

7

5

18

24

Benefit from income taxes relating to reconciling items ³

(7
)

(2
)

(10
)

(16
)
Adjusted Net Income

214

112

522

173

Net income attributable to non-controlling interests

—

—

1

—

Interest expense, net

55

51

161

157

Depreciation and amortization

62

73

204

212

All remaining provision for income taxes ³

50

32

140

41

Adjusted EBITDA

$
381

$
268

$
1,028

$
583

reconciliation of net income (loss) attributable to Chemours to Adjusted EBITDA for the nine months ended September 30, 2023 and 2022.

(2)

Total debt principal minus unamortized issue discounts of $26 million and $4 million and debt issuance costs of $22 million and $24 million at September 30, 2023 and 2022, respectively.

(3)

Average invested capital is based on a five-quarter trailing average of invested capital, net.

The following table sets forth a reconciliation of our total debt principal, cash and cash equivalents, and Adjusted EBITDA to Net Leverage Ratio.


	As of September 30,
(Dollars in millions)	2023			2022
Total debt principal	$	4,015		$	3,562
Less: Cash and cash equivalents		(852	)		(1,167	)
Total debt principal, net	$	3,163		$	2,395

	Twelve Months Ended September 30,
(Dollars in millions)	2023			2022
Adjusted EBITDA (1)	$	995		$	1,548

Net Leverage Ratio	3.2x			1.5x

(1)

Reconciliations of net income (loss) attributable to Chemours to Adjusted EBITDA are provided on a quarterly basis. Refer to the preceding table for the reconciliation of net income (loss) attributable to Chemours to Adjusted EBITDA for the nine months ended September 30, 2023 and 2022.

The Chemours Company

¹	~~Includes accounting, legal and bankers’ transaction fees incurred related to the Company’s strategic initiatives.~~

²	~~Includes litigation settlements, water treatment accruals related to PFOA, employee separation costs and lease termination charges.~~

³	Total of (benefit from) provision for income taxes reconciles to the amount reported in the Interim Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities, and cash flows denominated in a variety of foreign currencies. We also have variable rate indebtedness, which subjects us to interest rate risk. Additionally, we are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices may have an impact on our future cash ~~flow~~flows and earnings. We manage these risks through our normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.

~~Chemours enters into foreign currency forward contracts~~

By using derivative financial instruments, we are subject to ~~minimize volatility in earnings related to~~credit and market risk. The fair values of the ~~foreign exchange gains~~derivative financial instruments are determined by using valuation models whose inputs are derived using market observable inputs, and ~~losses resulting from remeasuring monetary assets and liabilities that Chemours holds which are denominated in non-functional currencies. These derivatives are stand-alone and have not been designated~~reflect the asset or liability position as ~~a hedge. As~~ of ~~September 30, 2017, we had open foreign exchange forward contracts with an aggregate notional U.S. Dollar equivalent~~the end of ~~$619 million,~~each reporting period. When the fair value of ~~which amounted~~a derivative contract is positive, the counterparty owes us, thus creating a receivable risk for us. We are exposed to ~~approximately $1 million of net unrealized loss.~~

~~In a hypothetical adverse change~~counterparty credit risk in the ~~market prices or rates that existed at September 30, 2017, a 10% appreciation~~event of ~~the U.S. Dollar against~~non-performance by counterparties to our ~~outstanding hedged contracts on foreign currencies, such as the Euro and Chinese Yuan, at the currency exchange~~derivative agreements. We minimize counterparty credit (or repayment) risk by entering into transactions with major financial institutions of investment grade credit ratings.

~~The Chemours Company~~

rates as of September 30, 2017 would decrease our net income by approximately $10 million, while a 10% depreciation of the U.S. Dollar against the same hedged currencies would increase our net income by approximately $10 million.

Chemours hedges its net investment in certain European operations. Changes in the fair value of the hedge in the net investment of certain European operations are recorded in accumulated other comprehensive income (loss). For the three and nine months ended September 30, 2017, Chemours did not record any ineffectiveness and recognized pre-tax losses of $26 million and $76 million, respectively, on its net investment hedges within accumulated other comprehensive income (loss).

~~Chemours’~~Our risk management programs and the underlying ~~exposure~~exposures are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by the ~~change~~changes in the value of the underlying ~~exposure. See Note 14~~exposures. Refer to “Note 21 – Financial Instruments” to the Interim Consolidated Financial Statements ~~in Item 1~~ for further information.

~~Additional Information~~

~~See Part II, Item 7A, Quantitative~~

Foreign Currency Risks

We enter into foreign currency forward contracts to minimize the volatility in our earnings related to foreign exchange gains and ~~Qualitative Disclosures About Market Risk,~~losses resulting from remeasuring our monetary assets and liabilities that are denominated in non-functional currencies, and any gains and losses from the foreign currency forward contracts are intended to be offset by any gains or losses from the remeasurement of the underlying monetary assets and liabilities. These derivatives are stand-alone and, except as described below, have not been designated as a hedge. At September 30, 2023, we had 11 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of $268 million, the fair value of which amounted to a net of zero. At December 31, 2022, we had 9 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of $180 million, the fair value of which amounted to negative $1 million. We recognized net losses of $1 million and $8 million for the three and nine months ended September 30, 2023, respectively, and net gains of $3 million for the three and nine months ended September 30, 2022, respectively, within other income (expense), net related to our non-designated foreign currency forward contracts.

We enter into certain qualifying foreign currency forward contracts under a cash flow hedge program to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of our ~~Annual Report on Form 10-K~~international subsidiaries that use the euro as their functional currency. At September 30, 2023, we had 157 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of $193 million, the fair value of which amounted to $6 million. At December 31, 2022, we had 153 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of $180 million, the fair value of which amounted to negative $2 million. We recognized pre-tax gains of $7 million and $5 million for the ~~year~~three and nine months ended ~~December 31, 2016~~September 30, 2023, respectively, and a pre-tax gains of $18 million and $30 million for ~~additional information on~~ the ~~Company’s utilization~~three and nine months ended September 30, 2022, respectively, within accumulated other comprehensive loss. For the three and nine months ended September 30, 2023, $1 million of ~~financial instruments~~loss and ~~an analysis~~$5 million of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively. For the three and nine months ended September 30, 2022, $5 million and $11 million of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively.

We designated our euro-denominated debt as a hedge of our net investment in certain of our international subsidiaries that use the euro as their functional currency in order to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates of the ~~sensitivity~~euro with respect to the U.S. dollar. We recognized pre-tax gains of ~~these instruments. There have been no material changes in the market risks previously disclosed in the Company’s Annual Report on Form 10-K~~$35 million and $13 million for the ~~year~~three and nine months ended ~~December 31, 2016.~~September 30, 2023, respectively, and pre-tax gains of $81 million and $139 million for the three and nine months ended September 30, 2022, respectively, on our net investment hedge within accumulated other comprehensive loss.

The Chemours Company


Item 4.	CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

~~The Company maintains~~

We maintain disclosure controls and procedures designed to provide reasonable assurance that the information required to be disclosed in ~~the Company’s~~our reports filed or submitted under the Securities Exchange Act of 1934 ~~(Exchange Act)~~(“Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the U.S. Securities and Exchange ~~Commission.~~Commission (“SEC”). These controls and procedures also provide reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management, including ~~its~~our Chief Executive Officer ~~(CEO)~~(“CEO”) and Chief Financial Officer ~~(CFO)~~(“CFO”), to allow timely decisions regarding required disclosures.

As of September 30, ~~2017, the Company’s~~2023, our CEO and CFO, together with management, conducted an evaluation of the effectiveness of ~~the Company’s~~our disclosure controls and procedures as defined in ~~Rules~~Rule 13a-15(e) ~~and 15d-15(e)~~ under the Exchange Act. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no changes in ~~the Company's~~our internal control over financial reporting that occurred during the quarter ended September 30, ~~2017~~2023 that have materially affected, or are reasonably likely to materially affect, ~~the Company’s~~our internal control over financial reporting.

The Chemours Company

PART II. OTHER INFORMATION


Item 1.	LEGAL PROCEEDINGS

~~The Company is~~

Legal Proceedings

We are subject to various legal proceedings, including, but not limited to, product liability, ~~patent infringement, antitrust claims~~intellectual property, personal injury, commercial, contractual, employment, governmental, environmental and ~~claims for property damage~~regulatory, anti-trust, and other such matters that arise in the ordinary course of business. In addition, we, by virtue of our status as a subsidiary of EID prior to the Separation, are subject to or ~~personal injury.~~required under the Separation-related agreements executed prior to the Separation to indemnify EID against various pending legal proceedings. Information regarding certain of these matters is set forth below and in ~~Note 13~~“Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements. In the foregoing, we have excluded matters that we expect to result in ~~Part I, Item 1, which is incorporated by reference herein.~~sanctions of less than $1 million, if any.

~~Litigation~~

~~PFOA:~~

Litigation

PFOA and PFAS: Environmental and Litigation Proceedings

For purposes of this report, the term ~~PFOA~~“PFOA” means, collectively, perfluorooctanoic acid and its salts, including the ammonium salt, and does not distinguish between the two forms. The term “PFAS” means per- and polyfluoroalkyl substances. Information related to ~~this~~these and other litigation matters is included in ~~Note 13~~“Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements ~~in Part I, Item 1, which is incorporated by reference herein.~~.

~~The Chemours Company~~

Fayetteville, North Carolina

~~The following actions~~

Actions related to Fayetteville, other than those by the State of North Carolina, as discussed in ~~Note 13~~“Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements ~~in Part I, Item 1,~~, are ~~filed in~~shown below.

In the U.S. District Court for the Eastern District of North ~~Carolina, Southern Division:~~Carolina:

•

Carey et al. vs. E. I. ~~du Pont~~DuPont de Nemours and Company (7:17-cv-00189-D; 7:17-cv-00197-D; and, 7:17-cv-00201-D);

•

Cape Fear Public Utility Authority vs. The Chemours Company FC, LLC et al. and Brunswick County v. DowDuPont et al.(7:~~17-cv-00195-D)~~17-cv-00195-D and 7:17-cv-00209-D);

~~Nix~~

•

Dew et al. vs. E. I. DuPont de Nemours and Company et al. (17:18-cv-00030-D);

•

O’Brien et al. vs. E. I. DuPont de Nemours and Company et al. (5:20-cv-00208-D); and,

•

Priselac vs. The Chemours Company ~~FC, LLC (2:17-cv-0046-D);~~et al. (20-CVS-499).

~~Morton~~In Bladen County, North Carolina:

•

Kinlaw et al. vs. The Chemours Company ~~FC, LLC (7:17-cv-00197-FL)~~et al. (20-CVS-497); and,

~~Brunswick County~~

•

Lohr et al. vs. The Chemours Company ~~(7:17-cv-00209-BO)~~et al. (20-CVS-498).

The Chemours Company

Environmental Proceedings

~~LaPorte Plant, LaPorte, Texas~~

~~The EPA conducted a multimedia inspection at~~Dordrecht, Netherlands

In May 2020, we were notified of an alleged criminal offense related to the ~~DuPont LaPorte, Texas facility in January 2008. DuPont, the EPA~~Netherlands’ Environmental Management Act and the ~~Department~~Working Conditions Decree, regarding the use of ~~Justice began discussions~~PFOA during the pre-spin time period of June 1, 2008 to December 31, 2012. The investigation was initiated in the ~~fall~~first quarter of 2011 relating to the management of certain materials in the facility's waste water treatment system, hazardous waste management, flare and air emissions. These negotiations continue. Chemours operates a fluoroproducts production facility at this site.

~~PFOA: Dordrecht, Netherlands~~

The Company has received requests from the Labor Inspectorate (ISZW), the local environmental agency (OZHZ) and the National Institute for Public Health and the Environment (RIVM) in the Netherlands for information and documents regarding the Dordrecht site's operations. The Company has complied with the requests, and no further documents have been requested of the Company since the publication of the reports in May 2017 (RIVM) and July 2017 (ISZW). The agencies will decide whether additional investigation is warranted. We understand that some of the requests from OZHZ are part of a preliminary investigation initiated2016 by a public ~~prosecutor, although~~prosecutor. We believe that we have complied with all relevant laws, and we are in contact with the prosecutor.

In addition, in March 2022, the public prosecutor in The Netherlands has raised a matter related to an alleged infraction of Regulation (EU) 517/2014. Due to a reporting error, our Dordrecht Works facility exceeded its allocated or transferred quota of hydrofluorocarbons within the European market over several years. We implemented improvements to our reporting procedures and operated within the allocated quota. We paid a fine in the fourth quarter of 2022 and are in contact with the prosecutor regarding the matter.

Fayetteville, North Carolina

In February 2019, we received a Notice of Violation (“NOV”) from EPA, alleging certain Toxic Substances Control Act (“TSCA”) violations at Fayetteville. Matters raised in the NOV could have the potential to affect operations at Fayetteville. For this NOV, we responded to EPA in March 2019 and at this time management does not believe that a loss is probable related to this NOV. We have also received ~~notice~~NOVs from the NC DEQ following entry of the CO, including in April 2020, January 2021, and August 2021, alleging violations relating to Fayetteville. We have responded to these matters and in April 2022 entered into a settlement agreement with NC DEQ with respect to the August 2021 NOV. We do not believe that ~~it intends~~a loss is probable related to ~~pursue such action.~~the matters in the other NOVs. Further discussion related to these matters is included under the heading “Fayetteville Works, Fayetteville, North Carolina” in “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements.

~~Item 1A.~~R~~ISK FACTORS~~

Item 1A. RISK FACTORS

Except for the ~~Risk Factors~~updated risk factors set forth below, ~~which have been amended and restated in their entirety,~~ there have been no material changes to the ~~Risk Factors~~risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~2016.~~2022.

~~Risks Related to Our Business~~

Market conditions and global and regional economic downturns, as well as changes in regulatory requirements (including environmental standards), that adversely affect the demand for the end-use products that contain titanium dioxide, fluoroproducts or our other products, could adversely affect the profitability of our operations and the prices at which we can sell our products, negatively impacting our financial results.

~~Our revenue and profitability is largely dependent on the titanium dioxide (TiO~~₂~~) industry and the industries that are end users of our fluoroproducts. TiO~~₂ and our fluoroproducts, such as refrigerants and resins, are used in many “quality of life” products for which demand historically has been linked to global, regional and local gross domestic product and discretionary spending, which can be negatively impacted by regional and world events or economic conditions. Such events are likely to cause a decrease in demand for our products and, as a result, may have an adverse effect on our results of operations and financial condition. The future profitability of our operations, and cash flows generated by those operations, will also be affected by the available supply of our products in the market. In addition, because demand for our fluorochemicals is driven in part by industry needs to comply with certain mandated environmental regulations (such as markets for refrigerants and foams with low global warming potential), changes in or elimination of such environmental regulations in the U.S. or other jurisdictions also can negatively impact demand for such products and, as a result, our results of operations and financial condition.

~~Our results of operations could be adversely affected by litigation and other commitments and contingencies.~~

We face risks arising from various unasserted and asserted legal claims, investigation and litigation matters, such as product liability, patent infringement, antitrust claims and claims for third party property damage or personal injury stemming from alleged

~~The Chemours Company~~

environmental actions (which may concern regulated or unregulated substances) or other torts, including, as discussed below, litigation related to the production and use of PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) by DuPont prior to the separation. We have also received inquiries, investigations and litigation related to HFPO Dimer Acid (sometimes referred to as GenX or C3 Dimer) and other compounds. We have noted a nationwide trend in purported class actions against chemical manufacturers generally seeking relief such as medical monitoring, property damages, off-site remediation and punitive damages arising from alleged environmental actions (which may concern regulated or unregulated substances) or other torts without claiming present personal injuries. We also have noted a trend in public and private nuisance suits being filed on behalf of states, counties, cities and utilities alleging harm to the general public. Various factors or developments can lead to changes in current estimates of liabilities such as a final adverse judgment, significant settlement or changes in applicable law. A future adverse ruling or unfavorable development could result in future charges that could have a material adverse effect on us. An adverse outcome in any one or more of these matters could be material to our financial results and could adversely impact the value of any of our brands that are associated with any such matters. As discussed in more detail in Note 13 to the Interim Consolidated Financial Statements in Part I, Item 1, although the 2017 MDL settlement resolved almost all of the approximately 3,500 personal injury lawsuits against DuPont alleging that the respective plaintiffs were exposed to PFOA in drinking water as a result of DuPont’s use of PFOA at the Washington Works plant in Parkersburg, West Virginia, there are risks of additional lawsuits arising out of DuPont’s use of PFOA, its manufacture of PFOA or its customers’ use of DuPont products that may not be within the scope of the MDL Settlement. A number of additional PFOA lawsuits have been filed since the MDL Settlement. In addition, as discussed in more detail in Note 13 to the Interim Consolidated Financial Statements in Part I, Item 1, the Company has received governmental inquiries, and the Company and DuPont have been named in multiple lawsuits, relating to HFPO Dimer Acid and/or other perfluorinated or polyfluorinated compounds, and there are risks that additional lawsuits could be filed. The existing lawsuits and inquiries, and any such additional litigation, relating to PFOA, HFPO Dimer Acid or these other compounds could result in us incurring additional costs and liabilities, which may be material to our financial results.

In the ordinary course of business, we may make certain commitments, including representations, warranties and indemnities relating to current and past operations, including those related to divested businesses, and issue guarantees of third party obligations. Additionally, we are required to indemnify DuPont with regard to liabilities allocated to, or assumed by us under each of the separation agreement, the employee matters agreement, the tax matters agreement and the intellectual property cross-license agreement that were executed prior to the spin-off. These indemnification obligations to date have included defense costs associated with certain litigation matters as well as certain damages awards, settlements and penalties. In connection with the MDL Settlement entered above, as detailed in Note 13 to the Interim Consolidated Financial Statements in Part I, Item 1, DuPont and Chemours entered into an amendment to the separation agreement concerning PFOA costs. As we are required to make payments, such payments could be significant and could exceed the amounts we have accrued with respect thereto, adversely affecting our results of operations. In addition, in the event that DuPont seeks indemnification for adverse trial rulings or outcomes, these indemnification claims could materially adversely affect our financial condition. Disputes between Chemours and DuPont many also arise with respect to indemnification matters including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect us.

For further information about the Company’s litigation and other commitments and contingencies, see Note 13 to the Interim Consolidated Financial Statements in Part I, Item 1 or Legal Proceedings in Part II, Item 1 of this Quarterly Report on Form 10-Q.

We are subject to extensive environmental and health and safety laws and regulations that may result in unanticipated loss or liability related to our current and past operations, and that may result in significant additional compliance costs or obligations, which in either case, could reduce our ~~profitability.~~profitability or liquidity.

Our operations and production facilities are dependent upon attainment and renewal of requisite operating permits and are subject to extensive environmental and health and safety laws, regulations, and ~~regulations~~enforcements, proceedings or other actions at national, international, and local levels in numerous jurisdictions, relating to pollution, protection of the environment, climate change, transporting and storing raw materials and finished products, ~~and~~ storing and disposing of hazardous ~~wastes.~~wastes, and product content and other safety or human rights concerns. Such laws include, ~~in the U.S.,~~but are not limited to:

•

U.S.-based regulations, such as the Comprehensive Environmental Response, Compensation, and Liability Act ~~(often~~(“CERCLA”, often referred to as ~~Superfund)~~“Superfund”), the Resource Conservation and Recovery Act (“RCRA”) and similar state and global laws for management and remediation of hazardous materials, the Clean Air Act (“CAA”) and ~~the~~ Clean Water Act (“CWA”) and similar state and global laws for the protection of air and water resources, and the Toxic Substances Control Act ~~and in the European Union (EU),~~(“TSCA”);

•

Foreign-based chemical control regulations, such as the Registration, Evaluation, Authorization, and Restriction of Chemicals ~~(REACH),~~(“REACH”) in the EU, the Chemical Substances Control Law (“CSCL”) in Japan, MEP Order No. 7 in China, and the Toxic Chemical Substance Control Act (“TCSCA”) in Taiwan for ~~regulation~~the production and distribution of chemicals in commerce and reporting of potential ~~known~~ adverse ~~effects~~effects;

•

The EU Emissions Trading System and ~~numerous~~similar local and global laws for regulating GHG emissions; and,

•

Numerous local, state, federal, and foreign laws, regulations, and ~~regulations~~enforcements governing materials transport and packaging.

The Chemours Company

If we are found to be in violation of these laws, regulations, or ~~regulations,~~enforcements, which may be subject to change based on legislative, scientific, or other factors, we may incur substantial costs, including fines, damages, criminal or civil sanctions, remediation costs, reputational harm, loss of sales or market access, or experience interruptions in our operations. WeOur operations and production may also ~~may~~ be subject to changes ~~in our operations and production~~ based on increased regulation or other changes to, or restrictions imposed by, any such additional regulations. Any operational interruptions or plant shutdowns may result in delays in production or may cause us to incur additional costs to develop redundancies in order to avoid interruptions in our production cycles. In addition, the manner in which adopted regulations (including environmental and safety regulations) are ultimately implemented may affect our products, the demand for and public perception of our products, the reputation of our brands, our market access, and our results of operations. In the event of a catastrophic incident involving any of the raw materials we use or

~~The Chemours Company~~

chemicals we produce, we could incur material costs ~~as a result of addressing~~to address the consequences of such event and future reputational costs associated with any such event.

~~As a result of our operations, including the operations of divested businesses and certain discontinued operations, we could incur substantial~~

Our costs ~~including remediation and restoration costs. The costs of complying~~to comply with complex environmental laws and regulations, as well as internal and external voluntary programs, are significant and will continue to be significant for the foreseeable future. ~~This includes~~These laws and regulations may change and could become more stringent over time, which could result in significant additional compliance costs, increased costs of purchased energy or other raw materials, increased transportation costs, investments in, or restrictions on, our operations, installation or modification of emission control equipment, or additional costs associated with emissions control equipment. As a result of our current and historic operations, including the operations of divested businesses and certain discontinued operations, we also expect to continue to incur costs for environmental investigation and remediation activities at a number of our current or former sites and ~~third party~~third-party disposal locations. However, the ultimate costs under environmental laws and the timing of these costs are difficult to accurately predict. While we establish accruals in accordance with U.S. generally accepted accounting principles (“GAAP”), the ultimate actual costs and liabilities may vary from the accruals because the estimates on which the accruals are based depend on a number of factors (many of which are outside of our control), including the nature of the matter and any associated ~~third party~~third-party claims, the complexity of the site, site geology, the nature and extent of contamination, the type of remedy, the outcome of discussions with regulatory agencies and other Potentially Responsible Parties ~~(PRPs)~~(“PRPs”) at multi-party sites, and the number and financial viability of other PRPs. ~~For further information about~~We also could incur significant additional costs as a result of additional contamination that is discovered or remedial obligations imposed in the ~~Company’s environmental matters and other commitments and contingencies, see Note 13~~future. Refer to ~~the Interim Consolidated Financial Statements in Part I, Item 1, Environmental Matters~~“Environmental Matters” within ~~Part I,~~ Item 2 – Management’s Discussion and Analysis of Financial ~~Conditions~~Condition and Results of Operations ~~or Legal Proceedings~~ and “Note 17 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements for further information.

As discussed in ~~Part II, Item 1~~“Note 17 – Commitments and Contingent Liabilities” to the InterimConsolidated Financial Statements, we continue to have active dialogue with the North Carolina Department of ~~this Quarterly Report on Form 10-Q.~~Environmental Quality (“NC DEQ”) and other stakeholders regarding potential remedies that are both economically and technologically feasible to achieve the objectives of the Consent Order (“CO”) and Addendum (“Addendum”) related to the discharge of HFPO Dimer Acid and PFAS from Fayetteville into the Cape Fear River, site surface water, groundwater, and air emissions. The Addendum establishes the procedure to implement specified remedial measures for reducing PFAS loadings from Fayetteville to the Cape Fear River, including construction of a barrier wall with a groundwater extraction system. The estimated liabilities of achieving the CO and Addendum objectives consist of several components, each of which may vary significantly and may exceed the recorded reserve estimates, which could be material.

There is also a risk that one or more of our manufacturing processes, key raw materials, or ~~one or more of our~~ products may be found to have, or be characterized or perceived as having, a toxicological or health-related impact on the environment or on our customers or employees or unregulated emissions, which could potentially result in us incurring liability in connection with such characterization and the associated effects of any toxicological or health-related impact. If such a discovery or characterization occurs, we may incur increased costs in order to comply with new regulatory requirements or as a result of litigation. In addition, the relevant materials or products, including products of our customers incorporating our materials or products, may be recalled, phased-out, or banned. Changes in laws, science, or regulations, or their ~~interpretation,~~interpretations, and our customers’ perception of such changes or interpretations may also affect the marketability of certain of our products.

In ~~May 2016,~~June 2019, the Member States Committee of the European Chemicals Agency ~~(ECHA) accepted a proposal from France’s competent authority under REACH that would classify TiO~~₂("ECHA") also voted to list HFPO Dimer Acid as a ~~carcinogen~~Substance of Very High Concern. The vote was based on Article 57(f) – equivalent level of concern having probable serious effects to the environment. This identification does not impose immediate regulatory restriction or obligations, but may lead to a future authorization or restriction of the substance. In September 2019, we filed an application with the EU Court of Justice for ~~humans by inhalation, starting an~~the annulment of the decision of ECHA ~~Committee for Risk Action (RAC) process~~ to review and decide on this proposal. In June 2017, ECHA’s RAC announced its preliminary conclusion that the evidence meets the criteria under the EU’s Classification, Labeling and Packaging Regulation to classify TiO₂list HFPO Dimer Acid as a ~~Category 2 Carcinogen (suspected human carcinogen)~~Substance of Very High Concern. In February 2022, the General Court dismissed the annulment action and we have appealed such decision.

The Chemours Company

In May 2020, five European countries began an initiative to restrict the manufacture, placing on the market, and use of PFAS in the EU. In this regulatory process, more than 4,000 substances, including F-gases and fluoropolymers are being considered for potential broad regulatory action. On July 15, 2021, the countries submitted their restriction proposal, which informed ECHA of the intent to prepare a PFAS restriction dossier for fluorinated substances within a defined structural formula scope, including branched fluoroalkyl groups and substances containing ether linkages, fluoropolymers and side chain fluorinated polymers. The restriction dossier was submitted to ECHA in January 2023, and in February 2023 ECHA published a report and supporting annexes on the restriction proposal, which includes identified concerns for in-scope PFAS and their degradation products and the proposed restriction of a full ban with certain use-specific time-limited derogation periods. The restriction dossier will be reviewed by ~~inhalation.~~the ECHA Risk Assessment Committee ("RAC") and Socio-economic Analysis Committee (“SEAC”) and proposals submitted to the EU Commission in 2023. The estimated earliest entry into force of restrictions is 2025, contingent upon timely completion of the remaining steps in the EU REACH restriction process.

In the first quarter of 2023, the European Commission, ~~(EC) will evaluate~~ the ~~RAC’s formal recommendation~~Parliament, and the Council, each proposed a regulation supporting the phase down of hydrofluorocarbons (“HFC”) by 2050 and multiple bans on HFCs and hydrofluoroolefin (“HFO”) in ~~determining whether any~~various applications. The proposed regulation was subject to negotiations and discussions amongst the European Commission, the Parliament, and the Council, that was completed in October 2023. These provisional bans are subject to European Commission review, to be carried out before January 2030. The proposed regulation is subject to final approval from the European Parliament and Council and is expected to be completed in the first quarter of 2024.

The impacts of these various restrictions and regulatory measures ~~should be taken. If~~in the ~~EC were~~EU as noted above, individually and in the aggregate, could lead to ~~adopt~~material adverse effects on our results of operations, financial condition, and cash flows.

In October 2021, EPA released its PFAS Strategic Roadmap, identifying a comprehensive approach to addressing PFAS. The PFAS Strategic Roadmap sets timelines by which EPA plans to take specific actions through 2024, including establishing a national primary drinking water regulation ("NPDWR") for PFOA and perfluorooctanesulfonic acid (“PFOS”) and taking Effluent Limitations Guidelines actions to regulate PFAS discharges from industrial categories among other actions. As provided under its roadmap, EPA also released its National PFAS Testing Strategy, under which the ~~regulatory measures that classify TiO~~₂ ~~as a suspected carcinogen, it could increase our TiO~~₂ ~~manufacturing~~agency will identify and ~~handling processes and costs.~~

~~In connection with our separation, we were required to assume, and indemnify DuPont for,~~select certain liabilities. As we are required to make payments pursuant to these indemnities to DuPont, we may need to divert cash to meet those obligations and our financial results could be negatively affected. In addition, DuPont’s obligation to indemnify us for certain liabilities may not be sufficient to insure us against the full amount of liabilitiesPFAS compounds for which it will ~~be allocated responsibility, and DuPont may not be able~~require manufacturers to ~~satisfy its indemnification obligations in the future.~~

~~Pursuant~~conduct testing pursuant to the ~~separation agreement,~~Toxic Substances Control Act (TSCA) section 4. Chemours has received various test orders and has formed consortia to jointly manage compliance with the ~~employee matters agreement,~~test order requirements. Chemours expects to receive future test orders, however the ~~tax matters agreement and~~timing of the intellectual property cross-license agreement we entered into with DuPont prior to the spin-off, we were required to assume, and indemnify DuPont for, certain liabilities. These indemnification obligations to date have included, among other items, defenseremaining test orders is not determinable at this time. Additional costs ~~associated with certain litigation matters as well as certain damages awards, settlement amounts and penalties. In~~could be incurred in connection with ~~MDL Settlement described above under~~ ~~Our~~EPA's actions, which could be material.

Also in October 2021, EPA published a final toxicity assessment for GenX compounds that decreased the draft reference dose for GenX compounds based on EPA’s review of new studies and analyses. On March 18, 2022, we filed a petition to EPA requesting to withdraw and correct its toxicity assessment for GenX compounds, and this petition was denied by EPA on June 14, 2022. The next day, on June 15, 2022, EPA released health advisories for four PFAS, including interim updated lifetime drinking water health advisories for PFOA and PFOS, and final health advisories for GenX compounds, including HFPO Dimer Acid and another PFAS compound (PFBS). On July 13, 2022, we filed a Petition for Review of the GenX compounds health advisory. On March 13, 2023, EPA proposed a NPDWR to establish Maximum Contaminant Levels (MCL’s) for six PFAS, with PFOA and PFOS having MCLs as individual compounds (each proposed as 4 parts per trillion) and four other PFAS compounds, including HFPO Dimer Acid, having a hazard index approach limit on any mixture containing one or more of the compounds. The proposed PFAS NPDWR is subject to public comment until May 30, 2023, and is expected to be finalized in late 2023 or early 2024. No action is required on the proposed NPDWR until it is final. Depending on the ultimate outcome of EPA’s actions, our estimated environmental remediation liabilities and accrued litigation could increase to meet any new drinking water standards, which could have a material adverse effect on our results of operations, ~~could be adversely affected by litigation~~financial condition, and ~~other commitments and contingencies~~, DuPont and Chemours entered into an amendment to the separation agreement concerning PFOA costs, the terms of which are described in Note 13 to the Interim Consolidated Financial Statements in Part I, Item 1. Payments pursuant to these indemnities, whether relating to PFOA costs or otherwise, may be significant and could negatively impact our business, particularly indemnities relating to our actions that could impact the tax-free nature of the distribution. In addition, in the event that DuPont seeks indemnification for adverse trial rulings or outcomes, these indemnification claims could materially adversely affect our financial condition. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matter of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect us.cash flows.

Third parties could also seek to hold us responsible for any of the liabilities of the DuPont businesses. DuPont has agreed to indemnify us for such liabilities, but such indemnity from DuPont may not be sufficient to protect us against the full amount of such liabilities, and DuPont may not be able to fully satisfy its indemnification obligations. Moreover, even if we ultimately succeed in recovering from DuPont any amounts for which we are held liable, we may be temporarily required to bear these losses ourselves. Each of these

The Chemours Company

~~risks~~Adverse developments affecting the financial markets, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could ~~negatively~~adversely affect our business, financial condition, or results of operations.

Certain U.S. and non-U.S. financial institutions experienced crisis in the first quarter of 2023, resulting in disruption in the financial markets. While we do not foresee any concerns around our liquidity, events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or the financial services industry generally, or concerns about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance our current and future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.

In addition, investor, regulatory, or other concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations or result in breaches of our contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, results of operations, financial condition, and cash flows. ~~See Note 13 to the Interim Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information.~~


Item 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

2022 Share Repurchase Program

On April 27, 2022, our board of directors approved a share repurchase program authorizing the purchase of shares of our issued and outstanding common stock in an aggregate amount not to exceed $750 million, plus any associated fees or costs in connection with our share repurchase activity (the “2022 Share Repurchase Program”). Under the 2022 Share Repurchase Program, shares of our common stock can be purchased in the open market from time to time, subject to management’s discretion, as well as general business and market conditions. Our 2022 Share Repurchase Program became effective on April 27, 2022 and is scheduled to continue through the earlier of its expiration on December 31, 2025 or the completion of repurchases up to the approved amount. The program may be suspended or discontinued at any time.

The following table sets forth the purchases of our issued and outstanding common stock under the programs for the three months ended September 30, 2023.


(Dollars in millions, except per share amounts)							Approximate
					Total Number		Dollar Value of
					of Shares		Shares That May
	Total Number				Purchased as Part		Yet be Purchased
	of Shares		Average Price		of Publicly		Under the Plans
	Purchased		Paid per Share		Announced		or Programs
Period	(1)		(2)		Plans or Programs		(2)
Month ended July 31, 2023		376,396	$	37.77		376,396	$	444
Month ended August 31, 2023		74,271		36.76		74,271		441
Month ended September 30, 2023		-		-		-		441
Total		450,667	$	37.60		450,667	$	441

(1)

The total number of shares purchased under the share repurchase program is determined using trade dates for the related transactions.

(2)

The average price paid per share and approximate dollar value of shares that may yet be purchased under the share repurchase program exclude fees, taxes, commissions, and other charges for the related transactions.

~~None.~~

Through September 30, 2023, we purchased a cumulative 10,342,722 shares of our issued and outstanding common stock under the 2022 Share Repurchase Program, which amounted to $309 million at an average share price of $29.90 per share. The aggregate amount of our common stock that remained available for purchase under the 2022 Share Repurchase Program at September 30, 2023 was $441 million.

The Chemours Company


Item 3.	DEFAULTS UPON SENIOR SECURITIES

None.


Item 4.	MINE SAFETY DISCLOSURES

Information regarding mine safety and other regulatory actions at ~~the Company’s~~our surface ~~mine~~mines and/or mineral sands separation facilities in Starke, Florida, isJesup, Georgia, Nahunta, Georgia, and Offerman, Georgia, are included in Exhibit 95 to ~~this report.~~

~~Item 5.~~

~~OTHER INFORMATION~~

~~None.~~

~~Item 6.~~

~~EXHIBITS~~

~~See the Exhibit Index for the exhibits filed with~~ this Quarterly Report on Form ~~10-Q or incorporated by reference.~~10-Q.

Item 5. OTHER INFORMATION

None of the Company's directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended September 30, 2023.

5383

The Chemours Company

Item 6. EXHIBITS

~~EXHIBIT INDEX~~


Exhibit Number		Description
~~2.1(1)~~3.1		Amendment No. 1, dated August 24, 2017, to the Separation Agreement, dated as of July 1, 2015, by and between E. I. du Pont de Nemours and Company and The Chemours Company (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on August 25, 2017).

~~3.1~~		Company’s Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 1, 2015).

3.2		Company’s Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 1, 2015).

~~31.1~~10.1		Amendment and Restatement Agreement, dated as of August 18, 2023, among The Chemours Company, the Lenders and Issuing Banks party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent. (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on August 23, 2023).

22		List of Guarantor Subsidiaries.

31.1		Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Executive Officer.

31.2		Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Financial Officer.

32.1		Section 1350 Certification of the Company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
32.2		Section 1350 Certification of the Company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.

95		Mine Safety ~~Disclosures~~Disclosures.

~~101.INS~~101		~~XBRL Instance Document~~The following financial statements from the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023 have been formatted in Inline XBRL: (i) the Interim Consolidated Statements of Operations (Unaudited); (ii) the Interim Consolidated Statements of Comprehensive Income (Unaudited); (iii) the Interim Consolidated Balance Sheets (Unaudited); (iv) the Interim Consolidated Statements of Stockholders’ Equity (Unaudited); (v) the Interim Consolidated Statements of Cash Flows (Unaudited); and, (vi) the Notes to the Interim Consolidated Financial Statements (Unaudited). These financial statements have been tagged as blocks of text and include detailed tags.

~~101.SCH~~104		The cover page from the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, which has been formatted in Inline XBRL ~~Taxonomy Extension Schema Document~~and included within Exhibit 101.

The Chemours Company


~~101.CAL~~		~~XBRL Taxonomy Extension Calculation Linkbase Document~~

~~101.DEF~~		~~XBRL Taxonomy Extension Definition Linkbase Document~~

~~101.LAB~~		~~XBRL Taxonomy Extension Label Linkbase Document~~

~~101.PRE~~		~~XBRL Taxonomy Extension Presentation Linkbase Document~~SIGNATURE

~~The Chemours Company~~

~~SIGNATURE~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	THE CHEMOURS COMPANY
	(Registrant)

~~Date:~~	~~November 3, 2017~~Date:	October 27, 2023


~~By:~~	By:	/s/ ~~Mark E. Newman~~Jonathan Lock

	~~Mark E. Newman~~	Jonathan Lock
		Senior Vice President, ~~and~~Chief Financial Officer
	~~Chief Financial Officer~~
	(As Duly Authorized Officer and Principal Financial Officer)

5585


Title of Each Class	Trading Symbol(s)	Name of Exchange on Which Registered
Common Stock ($0.01 par value)	CC	New York Stock Exchange


Large Accelerated Filer☒	Accelerated Filer ☐
Non-Accelerated Filer ☐	Smaller reporting company ☐
	Emerging growth company ☐

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Numerator:
Net income attributable to Chemours	$	207	$	204	$	518	$	237
Denominator:
Weighted-average number of common shares outstanding - basic		185,431,036		181,596,161		184,641,599		181,452,194
Dilutive effect of the Company’s employee compensation plans ¹		6,206,778		1,932,395		5,909,015		1,089,738
Weighted-average number of common shares outstanding - diluted ¹		191,637,814		183,528,556		190,550,614		182,541,932


	September 30, 2023			December 31, 2022
Finished products	$	853		$	910
Semi-finished products		234			218
Raw materials, stores, and supplies		604			654
Inventories before LIFO adjustment		1,691			1,782
Less: Adjustment of inventories to LIFO basis		(377	)		(378	)
Total inventories	$	1,314		$	1,404


	September 30, 2023			December 31, 2022
Equipment	$	7,578		$	7,745
Buildings		1,160			1,180
Construction-in-progress		376			324
Land		93			102
Mineral rights		36			36
Property, plant, and equipment		9,243			9,387
Less: Accumulated depreciation		(6,124	)		(6,216	)
Total property, plant, and equipment, net	$	3,119		$	3,171


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


~~Page~~TABLE OF CONTENTS
~~Part I~~			~~Financial Information~~
~~Item 1.~~		Page
Part I	Financial Information
Item 1.	Interim Consolidated Financial Statements	2
	Interim Consolidated Statements of Operations (Unaudited)	2
	Interim Consolidated Statements of Comprehensive (Loss) Income (Unaudited)	3
	Interim Consolidated Balance Sheets (Unaudited)	4
	Interim Consolidated Statements of Stockholders’ Equity (Unaudited)	5
	Interim Consolidated Statements of Cash Flows (Unaudited)	6
	Notes to the Interim Consolidated Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3449
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4876
Item 4.	Controls and Procedures	4977

Part II	Other Information
Item 1.	Legal Proceedings	4978
Item 1A.	Risk Factors	5079
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	5382
Item 3.	Defaults Upon Senior Securities	5383
Item 4.	Mine Safety Disclosures	5383
Item 5.	Other Information	5383
Item 6.	Exhibits	5384
~~Exhibit Index~~Signature		85 54

	(Unaudited)
	September 30,			December 31,
	2017			2016			September 30, 2023			December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	1,535		$	902		$	852		$	1,102
Accounts and notes receivable - trade, net		942			807
Restricted cash and restricted cash equivalents								595			—
Accounts and notes receivable, net								846			626
Inventories		877			767			1,314			1,404
Prepaid expenses and other		79			77			76			82
Total current assets		3,433			2,553			3,683			3,214
Property, plant and equipment		8,412			7,997
Property, plant, and equipment								9,243			9,387
Less: Accumulated depreciation		(5,462	)		(5,213	)		(6,124	)		(6,216	)
Property, plant and equipment, net		2,950			2,784
Goodwill and other intangible assets, net		167			170
Property, plant, and equipment, net								3,119			3,171
Operating lease right-of-use assets								258			240
Goodwill								102			102
Other intangible assets, net								5			13
Investments in affiliates		166			136			192			175
Restricted cash and restricted cash equivalents								—			202
Other assets		404			417			589			523
Total assets	$	7,120		$	6,060		$	7,948		$	7,640
Liabilities and equity
Liabilities
Current liabilities:
Accounts payable	$	1,010		$	884		$	901		$	1,251
Current maturities of long-term debt		14			15
Compensation and other employee-related cost								94			121
Short-term and current maturities of long-term debt								23			25
Current environmental remediation								138			194
Other accrued liabilities		546			872			1,039			300
Total current liabilities		1,570			1,771			2,195			1,891
Long-term debt, net		4,081			3,529			3,944			3,590
Operating lease liabilities								207			198
Long-term environmental remediation								467			474
Deferred income taxes		175			132			54			61
Other liabilities		489			524			324			319
Total liabilities		6,315			5,956			7,191			6,533
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 185,092,058 and 182,600,533 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively)		2			2
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 197,344,369 shares issued and 148,364,181 shares outstanding at September 30, 2023; 195,375,810 shares issued and 148,504,030 shares outstanding at December 31, 2022)								2			2
Treasury stock, at cost (48,980,188 shares at September 30, 2023; 46,871,780 shares at December 31, 2022)								(1,807	)		(1,738	)
Additional paid-in capital		830			789			1,030			1,016
Retained earnings (accumulated deficit)		388			(114	)
Retained earnings								1,845			2,170
Accumulated other comprehensive loss		(420	)		(577	)		(315	)		(343	)
Total Chemours stockholders’ equity		800			100			755			1,107
Non-controlling interests		5			4			2			—
Total equity		805			104			757			1,107
Total liabilities and equity	$	7,120		$	6,060		$	7,948		$	7,640

	Common Stock				Additional Paid-In			(Accumulated Deficit) Retained			Accumulated Other Comprehensive			Non-controlling
	Shares		Amount		Capital			Earnings			(Loss) Income			Interests		Total			Common Stock					Treasury Stock					Additional Paid-in			Retained			Accumulated Other Comprehensive			Non-controlling
Balance at January 1, 2016		181,069,751	$	2	$	775		$	(115	)	$	(536	)	$	4	$	130
																			Shares			Amount		Shares		Amount			Capital			Earnings			(Loss) Income			Interests		Total Equity
Balance at July 1, 2022																				194,761,628		$	2	$	39,188,959	$	(1,517	)	$	1,005		$	2,102		$	(378	)	$	1	$	1,215
Common stock issued - compensation plans																				2,439			—		—		—			—			—			—			—		—
Exercise of stock options, net																				414,511			—		—		—			3			—			—			—		3
Purchases of treasury stock, at cost																				—			—		2,910,688		(87	)		—			—			—			—		(87	)
Stock-based compensation expense																				—			—		—		—			7			—			—			—		7
Net income		—		—		—			237			—			—		237			—			—		—		—			—			240			—			—		240
Dividends declared on common shares ($0.25 per share)																				—			—		—		—			—			(38	)		—			—		(38	)
Other comprehensive loss																				—			—		—		—			—			—			(55	)		—		(55	)
Balance at September 30, 2022																				195,178,578		$	2		42,099,647	$	(1,604	)	$	1,015		$	2,304		$	(433	)	$	1	$	1,285

Balance at July 1, 2023																				196,759,211		$	2		48,529,521	$	(1,790	)	$	1,014		$	1,864		$	(282	)	$	2	$	810
Common stock issued - compensation plans		650,971		—		—			—			—			—		—			(16,576	)		—		—		—			1			(1	)		—			—		—
Dividends		—		—		(11	)		(5	)		—			—		(16	)
Other comprehensive income		—		—		—			—			13			—		13
Exercise of stock options, net																				601,734			—		—		—			9			—			—			—		9
Purchases of treasury stock, at cost																				—			—		450,667		(17	)		—			—			—			—		(17	)
Stock-based compensation expense		—		—		17			—			—			—		17			—			—		—		—			6			—			—			—		6
Balance at September 30, 2016		181,720,722	$	2	$	781		$	117		$	(523	)	$	4	$	381
Net income																				—			—		—		—			—			20			—			—		20
Dividends declared on common shares ($0.25 per share)																				—			—		—		—			—			(38	)		—			—		(38	)
Other comprehensive loss																				—			—		—		—			—			—			(33	)		—		(33	)
Balance at September 30, 2023																				197,344,369		$	2		48,980,188	$	(1,807	)	$	1,030		$	1,845		$	(315	)	$	2	$	757

Balance at January 1, 2017		182,600,533	$	2	$	789		$	(114	)	$	(577	)	$	4	$	104
Net income		—		—		—			518			—			1		519


																			Common Stock					Treasury Stock					Additional Paid-in			Retained			Accumulated Other Comprehensive			Non-controlling
																			Shares			Amount		Shares		Amount			Capital			Earnings			(Loss) Income			Interests		Total Equity
Balance at January 1, 2022																				191,860,159		$	2		30,813,427	$	(1,247	)	$	944		$	1,746		$	(364	)	$	1	$	1,082
Common stock issued - compensation plans		504,098		—		—			—			—			—		—			295,736			—		—		—			—			—			—			—		—
Dividends		—		—		—			(16	)		—			—		(16	)
Other comprehensive income		—		—		—			—			157			—		157
Exercise of stock options																				3,022,683			—		—		—			51			—			—			—		51
Purchases of treasury stock, at cost																				—			—		11,286,220		(357	)		—			—			—			—		(357	)
Stock-based compensation expense		—		—		21			—			—			—		21			—			—		—		—			24			—			—			—		24
Cancellation of unissued stock awards withheld to cover taxes		—		—		(10	)		—			—			—		(10	)		—			—		—		—			(4	)		—			—			—		(4	)
Exercise of stock options, net		1,987,427		—		30			—			—			—		30
Balance at September 30, 2017		185,092,058	$	2	$	830		$	388		$	(420	)	$	5	$	805
Net income																				—			—		—		—			—			675			—			—		675
Dividends declared on common shares ($0.75 per share)																				—			—		—		—			—			(117	)		—			—		(117	)
Other comprehensive loss																				—			—		—		—			—			—			(69	)		—		(69	)
Balance at September 30, 2022																				195,178,578		$	2		42,099,647	$	(1,604	)	$	1,015		$	2,304		$	(433	)	$	1	$	1,285

Balance at January 1, 2023																				195,375,810		$	2		46,871,780	$	(1,738	)	$	1,016		$	2,170		$	(343	)	$	—	$	1,107
Common stock issued - compensation plans																				836,031			—		—		—			1			(1	)		—			—		—
Exercise of stock options																				1,132,528			—		—		—			18			—			—			—		18
Purchases of treasury stock, at cost																				—			—		2,108,408		(69	)		—			—			—			—		(69	)
Stock-based compensation expense																				—			—		—		—			13			—			—			—		13
Cancellation of unissued stock awards withheld to cover taxes																				—			—		—		—			(18	)		—			—			—		(18	)
Net (loss) income																				—			—		—		—			—			(212	)		—			1		(211	)
Dividends declared on common shares ($0.75 per share)																				—			—		—		—			—			(112	)		—			—		(112	)
Contributions by non-controlling interests																				—			—		—		—			—			—			—			1		1
Other comprehensive income																				—			—		—		—			—			—			28			—		28
Balance at September 30, 2023																				197,344,369		$	2		48,980,188	$	(1,807	)	$	1,030		$	1,845		$	(315	)	$	2	$	757


	September 30, 2023		December 31, 2022
Contract assets:
Accounts receivable - trade, net (Note 8)	$	753	$	509
Contract liabilities:
Deferred revenue	$	5	$	5
Customer rebates (Note 14)		72		90


	2022 Restructuring Programs			ERP Implementation Abandonment		Titanium Technologies Transformation Plan		2023 Restructuring Program		Total
Balance at December 31, 2022	$	6		$	—	$	—	$	—	$	6
(Credits) charges to income		(2	)		1		20		6		25
Payments		(3	)		—		—		—		(3	)
Balance at September 30, 2023	$	1		$	1	$	20	$	6	$	28

	Titanium Technologies Site Closures			Fluoro- Products Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring			2017 Restructuring Program		Total
Balance at December 31, 2016	$	4		$	1		$	8		$	21		$	—	$	34
Charges to income		—			—			—			—			5		5
Payments		(3	)		(1	)		(4	)		(19	)		—		(27	)
Net currency translation and other adjustments ¹		—			—			—			1			—		1
Balance at September 30, 2017	$	1		$	—		$	4		$	3		$	5	$	13


	September 30, 2023		December 31, 2022
Accounts receivable - trade, net (1)	$	753	$	509
VAT, GST, and other taxes (2)		72		88
Other receivables (3)		21		29
Total accounts and notes receivable, net	$	846	$	626


	September 30, 2017		December 31, 2016
Accounts receivable - trade, net ¹	$	872	$	742
VAT, GST and other taxes ²		49		46
Other receivables ³		21		19
Total accounts and notes receivable - trade, net	$	942	$	807


	September 30, 2023		December 31, 2022
Capitalized repair and maintenance costs	$	172	$	240
Pension assets (1)		53		50
Deferred income taxes		277		152
Miscellaneous (2)		87		81
Total other assets	$	589	$	523


	September 30, 2023		December 31, 2022
Trade payables	$	878	$	1,228
VAT and other payables		23		23
Total accounts payable	$	901	$	1,251

	Nine Months Ended September 30, 2017
Risk-free interest rate		2.14	%
Expected term (years)		6.00
Volatility		44.49	%
Dividend yield		0.35	%
Fair value per stock option	$	15.21

	Number of Shares (in thousands)			Weighted-Average Exercise Price (per share)		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2016		7,969		$	13.72		5.08	$	66,668
Granted		878			34.84
Exercised		(1,987	)		14.41
Forfeited		(40	)		19.10
Expired		(28	)		12.00
Outstanding, September 30, 2017		6,792		$	15.69		5.27	$	237,179
Exercisable, September 30, 2017		3,814		$	14.03		3.63	$	139,523

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value (per share)
Non-vested, December 31, 2016		2,316		$	11.23
Granted		211			36.42
Vested		(1,275	)		11.09
Forfeited		(39	)		15.10
Non-vested, September 30, 2017		1,213		$	15.46

Three Months Ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2017
Net sales to external customers	$	799	$	637	$	148	$	—		$	1,584
Adjusted EBITDA		249		158		18		(44	)		381
Depreciation and amortization		24		28		4		6			62

2016
Net sales to external customers	$	625	$	591	$	182	$	—		$	1,398
Adjusted EBITDA		144		143		9		(28	)		268
Depreciation and amortization		32		26		6		9			73

Nine Months Ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2017
Net sales to external customers	$	2,173	$	1,998	$	437	$	—		$	4,608
Adjusted EBITDA		601		510		37		(120	)		1,028
Depreciation and amortization		89		81		13		21			204

2016
Net sales to external customers	$	1,742	$	1,695	$	641	$	—		$	4,078
Adjusted EBITDA		309		333		30		(89	)		583
Depreciation and amortization		87		75		24		26			212

	Three Months Ended September 30, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	960	$	1,053		$	(429	)	$	1,584
Cost of goods sold		—			773		753			(409	)		1,117
Gross profit		—			187		300			(20	)		467
Selling, general and administrative expense		7			105		43			(7	)		148
Research and development expense		—			19		1			—			20
Restructuring and asset-related charges, net		—			8		—			—			8
Total expenses		7			132		44			(7	)		176
Equity in earnings of affiliates		—			—		9			—			9
Equity in earnings of subsidiaries		233			—		—			(233	)		—
Interest (expense) income, net		(57	)		2		—			—			(55	)
Intercompany interest income (expense), net		16			—		(16	)		—			—
Other income (expense), net		6			22		(17	)		(6	)		5
Income before income taxes		191			79		232			(252	)		250
(Benefit from) provision for income taxes		(16	)		18		42			(1	)		43
Net income		207			61		190			(251	)		207
Less: Net income attributable to non-controlling interests		—			—		—			—			—
Net income attributable to Chemours	$	207		$	61	$	190		$	(251	)	$	207
Comprehensive income attributable to Chemours	$	228		$	63	$	225		$	(288	)	$	228

	Three Months Ended September 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	961		$	847		$	(410	)	$	1,398
Cost of goods sold		—			791			656			(391	)		1,056
Gross profit		—			170			191			(19	)		342
Selling, general and administrative expense		5			115			34			(6	)		148
Research and development expense		—			19			—			—			19
Restructuring and asset-related charges, net		—			60			—			—			60
Total expenses		5			194			34			(6	)		227
Equity in earnings of affiliates		—			1			8			—			9
Equity in earnings of subsidiaries		226			—			—			(226	)		—
Interest expense, net		(50	)		(1	)		—			—			(51	)
Intercompany interest income (expense), net		15			1			(16	)		—			—
Other income, net		5			70			94			(8	)		161
Income before income taxes		191			47			243			(247	)		234
(Benefit from) provision for income taxes		(13	)		29			29			(15	)		30
Net income		204			18			214			(232	)		204
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income attributable to Chemours	$	204		$	18		$	214		$	(232	)	$	204
Comprehensive income attributable to Chemours	$	210		$	18		$	226		$	(244	)	$	210

	Nine Months Ended September 30, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	2,898		$	2,367		$	(1,187	)	$	4,078
Cost of goods sold		—			2,506			1,921			(1,160	)		3,267
Gross profit		—			392			446			(27	)		811
Selling, general and administrative expense		17			350			103			(16	)		454
Research and development expense		—			58			2			—			60
Restructuring and asset-related charges (credits), net		—			147			(2	)		—			145
Total expenses		17			555			103			(16	)		659
Equity in (loss) earnings of affiliates		—			(2	)		19			—			17
Equity in earnings of subsidiaries		307			—			—			(307	)		—
Interest expense, net		(155	)		(2	)		—			—			(157	)
Intercompany interest income (expense), net		44			4			(48	)		—			—
Other income, net		15			178			72			(15	)		250
Income before income taxes		194			15			386			(333	)		262
(Benefit from) provision for income taxes		(43	)		25			53			(10	)		25
Net income (loss)		237			(10	)		333			(323	)		237
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	237		$	(10	)	$	333		$	(323	)	$	237
Comprehensive income (loss) attributable to Chemours	$	250		$	(10	)	$	355		$	(345	)	$	250